Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),[ml] / [kg·min],4.0,268,DB00201,Caffeine
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),,4.2,269,DB00201,Caffeine
,8135041,clearance,The clearance of TH determined from the concentration of TH in a single plasma sample obtained 6 h after TH administration was significantly reduced (p < 0.05) by fever but not malaria (4.0 +/- 0.7 ml/min/kg in controls; 4.2 +/- 0.5 in malaria; 2.4 +/- 0.4 in fever).,Metabolism of caffeine and theophylline in rats with malaria and endotoxin-induced fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135041/),,2.4,270,DB00201,Caffeine
,23777257,Km,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,33,1718,DB00201,Caffeine
,23777257,Vmax,"2. Diclofenac was converted to 4'-hydroxydiclofenac by recombinantly expressed human P450 1A2 with Km and Vmax values of 33 µM and 0.20 min(-1), respectively.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),1/[min],0.20,1719,DB00201,Caffeine
,23777257,inhibition constant,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,37,1720,DB00201,Caffeine
,23777257,maximum plasma concentration,"Using the inhibition constant (37 µM) of diclofenac on caffeine 3-N-demethylation and the reported 95th percentiles of maximum plasma concentration (10.5 µM) after an oral dose of diclofenac, the in vivo estimated increase in area under the plasma concentration-time curve was 29%.",Drug interactions of diclofenac and its oxidative metabolite with human liver microsomal cytochrome P450 1A2-dependent drug oxidation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23777257/),μM,10.5,1721,DB00201,Caffeine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.875,3863,DB00201,Caffeine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.358,3864,DB00201,Caffeine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.829,3865,DB00201,Caffeine
,1352225,M/S ratios,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.412,3866,DB00201,Caffeine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.875,3867,DB00201,Caffeine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.358,3868,DB00201,Caffeine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.829,3869,DB00201,Caffeine
,1352225,M/Sobs,M/S ratios were determined in vivo (M/Sobs; caffeine = 0.875 +/- 0.052; paraxanthine = 0.358 +/- 0.019; theobromine = 0.829 +/- 0.038; and theophylline = 0.412 +/- 0.054) under single dose conditions using area under the milk and serum concentration-time profiles.,Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),,0.412,3870,DB00201,Caffeine
,1352225,systemic clearance,"The mean systemic clearance of total caffeine (CIs) in the adults and the pups was 3.83 +/- 1.94 and 1.14 +/- 0.80 ml/min/kg, respectively.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],3.83,3871,DB00201,Caffeine
,1352225,systemic clearance,"The mean systemic clearance of total caffeine (CIs) in the adults and the pups was 3.83 +/- 1.94 and 1.14 +/- 0.80 ml/min/kg, respectively.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],1.14,3872,DB00201,Caffeine
,1352225,"unbound systemic clearance (CIs,u)","The mean unbound systemic clearance (CIs,u) for caffeine was 5.09 +/- 2.60 ml/min/kg in the adults and 1.41 +/- 0.71 ml/min/kg in the pups.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],5.09,3873,DB00201,Caffeine
,1352225,"unbound systemic clearance (CIs,u)","The mean unbound systemic clearance (CIs,u) for caffeine was 5.09 +/- 2.60 ml/min/kg in the adults and 1.41 +/- 0.71 ml/min/kg in the pups.",Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352225/),[ml] / [kg·min],1.41,3874,DB00201,Caffeine
,23184666,Time to maximum (peak) plasma concentration (C(max)),Time to maximum (peak) plasma concentration (C(max)) of anagrelide was 4.0 h in the fed and 1.5 h in the fasted group (p < 0.05); similar results were observed for 3-hydroxyanagrelide.,Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184666/),h,4.0,6106,DB00201,Caffeine
,23184666,Time to maximum (peak) plasma concentration (C(max)),Time to maximum (peak) plasma concentration (C(max)) of anagrelide was 4.0 h in the fed and 1.5 h in the fasted group (p < 0.05); similar results were observed for 3-hydroxyanagrelide.,Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184666/),h,1.5,6107,DB00201,Caffeine
,23184666,C(max),"The mean C(max) of anagrelide was 4.45 ± 2.32 ng/mL and 5.08 ± 2.99 ng/mL in the fed/caffeine and fasted groups, respectively; peak concentrations were higher for 3-hydroxyanagrelide in both the fed/caffeine and fasted groups.",Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184666/),[ng] / [ml],4.45,6108,DB00201,Caffeine
,23184666,C(max),"The mean C(max) of anagrelide was 4.45 ± 2.32 ng/mL and 5.08 ± 2.99 ng/mL in the fed/caffeine and fasted groups, respectively; peak concentrations were higher for 3-hydroxyanagrelide in both the fed/caffeine and fasted groups.",Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184666/),[ng] / [ml],5.08,6109,DB00201,Caffeine
,23184666,heart rate,There was a trend towards a greater heart rate increase in subjects reporting palpitations than in those without (mean heart rate ± SD at 1 h: 10.1 ± 6.4 vs.,Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23184666/),,10.1,6110,DB00201,Caffeine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],2.07,6247,DB00201,Caffeine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],2.20,6248,DB00201,Caffeine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],0.93,6249,DB00201,Caffeine
,3756065,total plasma clearances,"The total plasma clearances of CA and PX were similar in value (2.07 and 2.20 ml min-1 kg-1, respectively) as were those for TP and TB (0.93 and 1.20 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.20,6250,DB00201,Caffeine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],3.11,6251,DB00201,Caffeine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],4.14,6252,DB00201,Caffeine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.61,6253,DB00201,Caffeine
,3756065,unbound plasma clearances,"The unbound plasma clearances of CA and PX were also similar in magnitude (3.11 and 4.14 ml min-1 kg-1, respectively) as were those of TP and TB (1.61 and 1.39 ml min-1 kg-1, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[ml] / [kg·min],1.39,6254,DB00201,Caffeine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,6.2,6255,DB00201,Caffeine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,7.2,6256,DB00201,Caffeine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,4.1,6257,DB00201,Caffeine
,3756065,half-lives,"The half-lives of TP and TB (6.2 and 7.2 h, respectively) were significantly longer than those of CA and PX (4.1 and 3.1 h, respectively).","Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),h,3.1,6258,DB00201,Caffeine
,3756065,volume of distribution at steady state,The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.44,6259,DB00201,Caffeine
,3756065,volume of distribution at steady state,The volume of distribution at steady state of TP (0.44 l kg-1) was lower than that of the other methylxanthines (0.63-0.72 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.63-0.72,6260,DB00201,Caffeine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.77,6261,DB00201,Caffeine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],0.79,6262,DB00201,Caffeine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],1.18,6263,DB00201,Caffeine
,3756065,unbound volume of distribution,The unbound volume of distribution of TP (0.77 l kg-1) was however the same as that of TB (0.79 l kg-1) whereas the unbound volume of distribution of PX (1.18 l kg-1) was similar to that of CA (1.06 l kg-1).,"Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756065/),[l] / [kg],1.06,6264,DB00201,Caffeine
,4007312,half-life,"After withdrawal of caffeine, plasma caffeine levels decreased to almost zero in the first 24 hr with a half-life of 5.5 hr, and plasma theophylline levels declined with a half-life of 12.7 hr.",The fate of chronically consumed caffeine in the monkey (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007312/),h,5.5,7301,DB00201,Caffeine
,4007312,half-life,"After withdrawal of caffeine, plasma caffeine levels decreased to almost zero in the first 24 hr with a half-life of 5.5 hr, and plasma theophylline levels declined with a half-life of 12.7 hr.",The fate of chronically consumed caffeine in the monkey (Macaca fascicularis). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4007312/),h,12.7,7302,DB00201,Caffeine
,23982107,half-life times,Trigonelline appeared early but persisted with calculated half-life times ~5 h.,Bioappearance and pharmacokinetics of bioactives upon coffee consumption. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23982107/),h,5,11710,DB00201,Caffeine
,3371873,clearance,"In an intraindividual experiment in smoking health probands, caffeine clearance decreased from 118 +/- 33 to 77 +/- 22 ml per min (p less than 0.05) after abstaining cigarette smoking for 3 weeks.",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),[ml] / [min],118,12370,DB00201,Caffeine
,3371873,clearance,"In an intraindividual experiment in smoking health probands, caffeine clearance decreased from 118 +/- 33 to 77 +/- 22 ml per min (p less than 0.05) after abstaining cigarette smoking for 3 weeks.",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),[ml] / [min],77,12371,DB00201,Caffeine
,3371873,clearance,"In a control group without liver disease (8 smokers, 15 nonsmokers), we found a caffeine clearance of 114 +/- 40 ml per min in smokers and 64 +/- 20 in nonsmokers (p less than 0.05).",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),[ml] / [min],114,12372,DB00201,Caffeine
,3371873,clearance,"In a control group without liver disease (8 smokers, 15 nonsmokers), we found a caffeine clearance of 114 +/- 40 ml per min in smokers and 64 +/- 20 in nonsmokers (p less than 0.05).",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),,64,12373,DB00201,Caffeine
,3371873,clearance,"However, caffeine clearance was 63 +/- 63 ml per min in smoking patients compared to 34 +/- 49 ml per min in nonsmokers (p less than 0.05).",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),[ml] / [min],63,12374,DB00201,Caffeine
,3371873,clearance,"However, caffeine clearance was 63 +/- 63 ml per min in smoking patients compared to 34 +/- 49 ml per min in nonsmokers (p less than 0.05).",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),[ml] / [min],34,12375,DB00201,Caffeine
,3371873,Fasting plasma concentrations,"Fasting plasma concentrations of caffeine were higher in nonsmokers (5.1 +/- 6.2 micrograms per ml) than in smokers (2.1 +/- 4.5 micrograms per ml, p less than 0.05).",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),[μg] / [ml],5.1,12376,DB00201,Caffeine
,3371873,Fasting plasma concentrations,"Fasting plasma concentrations of caffeine were higher in nonsmokers (5.1 +/- 6.2 micrograms per ml) than in smokers (2.1 +/- 4.5 micrograms per ml, p less than 0.05).",Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371873/),μg,2.1,12377,DB00201,Caffeine
,1943489,peak extracellular levels,The peak extracellular levels were in the range of 20 - 80 microM.,Drug distribution studies with microdialysis. III: Extracellular concentration of caffeine in adipose tissue in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1943489/),μM,20 - 80,12596,DB00201,Caffeine
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),hg·mm,11.7,14939,DB00201,Caffeine
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),[beats] / [min],5.9,14940,DB00201,Caffeine
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,9.7,14941,DB00201,Caffeine
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,5.0,14942,DB00201,Caffeine
,11839447,Tmax,Mean Tmax for the gum groups ranged from 44.2 to 80.4 min as compared with 84.0-120.0 min for the capsule groups.,The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),min,44.2 to 80.4,16626,DB00201,Caffeine
,11839447,Tmax,Mean Tmax for the gum groups ranged from 44.2 to 80.4 min as compared with 84.0-120.0 min for the capsule groups.,The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),min,84.0-120.0,16627,DB00201,Caffeine
,11839447,ka,The mean ka values for the gum group ranged from 3.21 to 3.96 h-1 and for the capsule groups ranged from 1.29 to 2.36 h-1.,The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),1/[h],3.21 to 3.96,16628,DB00201,Caffeine
,11839447,ka,The mean ka values for the gum group ranged from 3.21 to 3.96 h-1 and for the capsule groups ranged from 1.29 to 2.36 h-1.,The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),1/[h],1.29 to 2.36,16629,DB00201,Caffeine
,11839447,Relative bioavailability,"Relative bioavailability of the gum formulation after the 50, 100 and 200 mg dose was 64, 74 and 77%, respectively.",The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),%,64,16630,DB00201,Caffeine
,11839447,Relative bioavailability,"Relative bioavailability of the gum formulation after the 50, 100 and 200 mg dose was 64, 74 and 77%, respectively.",The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),%,74,16631,DB00201,Caffeine
,11839447,Relative bioavailability,"Relative bioavailability of the gum formulation after the 50, 100 and 200 mg dose was 64, 74 and 77%, respectively.",The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),%,77,16632,DB00201,Caffeine
,11839447,relative bioavailability,"When normalized to the total drug released from the gum (85%), the relative bioavailability of the 50, 100 and 200 mg dose were 75, 87, and 90%, respectively.",The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),%,75,16633,DB00201,Caffeine
,11839447,relative bioavailability,"When normalized to the total drug released from the gum (85%), the relative bioavailability of the 50, 100 and 200 mg dose were 75, 87, and 90%, respectively.",The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),%,87,16634,DB00201,Caffeine
,11839447,relative bioavailability,"When normalized to the total drug released from the gum (85%), the relative bioavailability of the 50, 100 and 200 mg dose were 75, 87, and 90%, respectively.",The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11839447/),%,90,16635,DB00201,Caffeine
,28758694,peak plasma concentration,"Caffeine disposition was similar after caffeine administration by the AeroShot device and energy drink: peak plasma concentration 1790 and 1939 ng ml-1 , and area under the concentration-time curve (AUC) 15 579 and 17 569 ng ml-1 × h, respectively, but they were not bioequivalent: AeroShot AUC of 80.3% (confidence interval 71.2-104.7%) and peak plasma concentration of 86.3% (confidence interval 62.8-102.8%) compared to the energy drink.",Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28758694/),[ng] / [ml],1790,17008,DB00201,Caffeine
,28758694,peak plasma concentration,"Caffeine disposition was similar after caffeine administration by the AeroShot device and energy drink: peak plasma concentration 1790 and 1939 ng ml-1 , and area under the concentration-time curve (AUC) 15 579 and 17 569 ng ml-1 × h, respectively, but they were not bioequivalent: AeroShot AUC of 80.3% (confidence interval 71.2-104.7%) and peak plasma concentration of 86.3% (confidence interval 62.8-102.8%) compared to the energy drink.",Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28758694/),[ng] / [ml],1939,17009,DB00201,Caffeine
,28758694,area under the concentration-time curve (AUC),"Caffeine disposition was similar after caffeine administration by the AeroShot device and energy drink: peak plasma concentration 1790 and 1939 ng ml-1 , and area under the concentration-time curve (AUC) 15 579 and 17 569 ng ml-1 × h, respectively, but they were not bioequivalent: AeroShot AUC of 80.3% (confidence interval 71.2-104.7%) and peak plasma concentration of 86.3% (confidence interval 62.8-102.8%) compared to the energy drink.",Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28758694/),[h·ng] / [ml],15 579,17010,DB00201,Caffeine
,28758694,area under the concentration-time curve (AUC),"Caffeine disposition was similar after caffeine administration by the AeroShot device and energy drink: peak plasma concentration 1790 and 1939 ng ml-1 , and area under the concentration-time curve (AUC) 15 579 and 17 569 ng ml-1 × h, respectively, but they were not bioequivalent: AeroShot AUC of 80.3% (confidence interval 71.2-104.7%) and peak plasma concentration of 86.3% (confidence interval 62.8-102.8%) compared to the energy drink.",Comparison of caffeine disposition following administration by oral solution (energy drink) and inspired powder (AeroShot) in human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28758694/),[h·ng] / [ml],17 569,17011,DB00201,Caffeine
,22824731,runtime,The plasma samples were extracted by liquid-liquid extraction with ethyl acetate and separated on Shim-pack XR-ODS II column by a gradient elution within a runtime of 8.0 min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),min,8.0,17333,DB00201,Caffeine
,22824731,flow rate,The mobile phase consisted of A (0.1% formic acid in acetonitrile) and B (0.1% formic acid in water) at a flow rate of 0.4 ml/min.,Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ml] / [min],0.4,17334,DB00201,Caffeine
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],"10-10,000",17335,DB00201,Caffeine
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],2.0-2000,17336,DB00201,Caffeine
,22824731,linear,"The linear range was 10-10,000 ng/ml for caffeine, 2.0-2000 ng/ml for theobromine and 1.0-1000 ng/ml for theophylline, respectively.",Identification and dynamic analysis of the purine alkaloids in rat plasma after oral administration of green tea by liquid chromatography hybrid ion trap time-of-flight mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22824731/),[ng] / [ml],1.0-1000,17337,DB00201,Caffeine
,22822712,CL,There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹ kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹ kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h).,Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822712/),h⁻¹·kg⁻¹·ml,7.3,17703,DB00201,Caffeine
,22822712,V,There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹ kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹ kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h).,Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822712/),kg⁻¹·ml,593,17704,DB00201,Caffeine
,22822712,t(½),There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹ kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹ kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h).,Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822712/),h,57,17705,DB00201,Caffeine
,22822712,CL,There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹ kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹ kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h).,Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822712/),h⁻¹·kg⁻¹·ml,4.9-7.9,17706,DB00201,Caffeine
,22822712,V,There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹ kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹ kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h).,Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822712/),kg⁻¹·ml,640-970,17707,DB00201,Caffeine
,22822712,t(½),There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹ kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹ kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h).,Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22822712/),h,101-144,17708,DB00201,Caffeine
,15618679,T(i),"Patch preparations had a T(i) value of 2.33+/-0.33 h and showed significantly longer MRT-T(i), 3.87+/-0.21 h, as compared to the control preparation (MRT-T(i)=1.04+/-0.38 h) under fasting condition (p<0.05).",Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,2.33,18011,DB00201,Caffeine
,15618679,MRT-T(i),"Patch preparations had a T(i) value of 2.33+/-0.33 h and showed significantly longer MRT-T(i), 3.87+/-0.21 h, as compared to the control preparation (MRT-T(i)=1.04+/-0.38 h) under fasting condition (p<0.05).",Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,3.87,18012,DB00201,Caffeine
,15618679,MRT-T(i),"Patch preparations had a T(i) value of 2.33+/-0.33 h and showed significantly longer MRT-T(i), 3.87+/-0.21 h, as compared to the control preparation (MRT-T(i)=1.04+/-0.38 h) under fasting condition (p<0.05).",Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,1.04,18013,DB00201,Caffeine
,15618679,T(i),Food intake prolonged the gastric emptying time (GET) of the preparations with T(i) values of 5.00+/-1.15 h for control preparation and 4.67+/-1.20 h for patch preparation.,Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,5.00,18014,DB00201,Caffeine
,15618679,T(i),Food intake prolonged the gastric emptying time (GET) of the preparations with T(i) values of 5.00+/-1.15 h for control preparation and 4.67+/-1.20 h for patch preparation.,Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,4.67,18015,DB00201,Caffeine
,15618679,MRT-T(i),The MRT-T(i) values were 0.62+/-0.20 h (control) and 2.45+/-0.73 h (patch).,Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,0.62,18016,DB00201,Caffeine
,15618679,MRT-T(i),The MRT-T(i) values were 0.62+/-0.20 h (control) and 2.45+/-0.73 h (patch).,Evaluation of gastrointestinal transit characteristics of oral patch preparation using caffeine as a model drug in human volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618679/),h,2.45,18017,DB00201,Caffeine
,6470942,recoveries,"Mean recoveries of 98% with a coefficient of variation of 3% were obtained for plasma standards, in which concentrations ranged from 0.1 to 8 micrograms/mL.",Rapid quantitative liquid chromatographic determination of caffeine levels in plasma after oral dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470942/),%,98,18278,DB00201,Caffeine
,6715563,tmax,"Caffeine was rapidly absorbed (mean tmax = 0.76 +/- 0.12 hour), with an average maximum concentration in the blood of 7.4 micrograms/ml for the 400-mg dose and 3.4 micrograms/ml for the 200-mg dose.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),h,0.76,18832,DB00201,Caffeine
,6715563,maximum concentration in the blood,"Caffeine was rapidly absorbed (mean tmax = 0.76 +/- 0.12 hour), with an average maximum concentration in the blood of 7.4 micrograms/ml for the 400-mg dose and 3.4 micrograms/ml for the 200-mg dose.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),[μg] / [ml],7.4,18833,DB00201,Caffeine
,6715563,maximum concentration in the blood,"Caffeine was rapidly absorbed (mean tmax = 0.76 +/- 0.12 hour), with an average maximum concentration in the blood of 7.4 micrograms/ml for the 400-mg dose and 3.4 micrograms/ml for the 200-mg dose.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),[μg] / [ml],3.4,18834,DB00201,Caffeine
,6715563,clearance,"The mean clearance of caffeine was 161 and 156 ml/min, while the mean volume of distribution was 50 and 47 liters for the 400- and 200-mg doses, respectively.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),[ml] / [min],161,18835,DB00201,Caffeine
,6715563,clearance,"The mean clearance of caffeine was 161 and 156 ml/min, while the mean volume of distribution was 50 and 47 liters for the 400- and 200-mg doses, respectively.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),[ml] / [min],156,18836,DB00201,Caffeine
,6715563,volume of distribution,"The mean clearance of caffeine was 161 and 156 ml/min, while the mean volume of distribution was 50 and 47 liters for the 400- and 200-mg doses, respectively.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),l,50,18837,DB00201,Caffeine
,6715563,volume of distribution,"The mean clearance of caffeine was 161 and 156 ml/min, while the mean volume of distribution was 50 and 47 liters for the 400- and 200-mg doses, respectively.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),l,47,18838,DB00201,Caffeine
,6715563,half-life,"The mean half-life of caffeine in the blood and semen was 3.7 and 3.6 hours, respectively, indicating that the decline of caffeine in the blood is very similar to that in semen.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),h,3.7,18839,DB00201,Caffeine
,6715563,half-life,"The mean half-life of caffeine in the blood and semen was 3.7 and 3.6 hours, respectively, indicating that the decline of caffeine in the blood is very similar to that in semen.",The excretion of caffeine in the semen of men: pharmacokinetics and comparison of the concentrations in blood and semen. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6715563/),h,3.6,18840,DB00201,Caffeine
,16620293,VO(2),"3. Caffeine, CN100, CN200 did not alter VO(2) or VO(2) area under the curve (137 301 +/- 8318, 139 729 +/- 9300, 134 297 +/- 8318, mL/480 min).","Naringin does not alter caffeine pharmacokinetics, energy expenditure, or cardiovascular haemodynamics in humans following caffeine consumption. ",V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620293/),[ml] / [480·min],137 301,19394,DB00201,Caffeine
,16620293,VO,"3. Caffeine, CN100, CN200 did not alter VO(2) or VO(2) area under the curve (137 301 +/- 8318, 139 729 +/- 9300, 134 297 +/- 8318, mL/480 min).","Naringin does not alter caffeine pharmacokinetics, energy expenditure, or cardiovascular haemodynamics in humans following caffeine consumption. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620293/),[ml] / [480·min],137 301,19395,DB00201,Caffeine
,16620293,area under the curve,"3. Caffeine, CN100, CN200 did not alter VO(2) or VO(2) area under the curve (137 301 +/- 8318, 139 729 +/- 9300, 134 297 +/- 8318, mL/480 min).","Naringin does not alter caffeine pharmacokinetics, energy expenditure, or cardiovascular haemodynamics in humans following caffeine consumption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620293/),[ml] / [480·min],139 729,19396,DB00201,Caffeine
,16620293,area under the curve,"3. Caffeine, CN100, CN200 did not alter VO(2) or VO(2) area under the curve (137 301 +/- 8318, 139 729 +/- 9300, 134 297 +/- 8318, mL/480 min).","Naringin does not alter caffeine pharmacokinetics, energy expenditure, or cardiovascular haemodynamics in humans following caffeine consumption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620293/),[ml] / [480·min],134,19397,DB00201,Caffeine
,16620293,area under the curve,"3. Caffeine, CN100, CN200 did not alter VO(2) or VO(2) area under the curve (137 301 +/- 8318, 139 729 +/- 9300, 134 297 +/- 8318, mL/480 min).","Naringin does not alter caffeine pharmacokinetics, energy expenditure, or cardiovascular haemodynamics in humans following caffeine consumption. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16620293/),[ml] / [480·min],297,19398,DB00201,Caffeine
,7229951,half-life,"After rapid intravenous doses of aminophylline, the theophylline half-life was 5-7 hr, which decreased slightly when the drug was administered concomitantly with caffeine during steady state of caffeine.",Effect of caffeine on circulating theophylline levels in beagle dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229951/),h,5-7,20051,DB00201,Caffeine
,7229951,volume of distribution,The theophylline volume of distribution (0.75 liter/kg) was unaffected by caffeine.,Effect of caffeine on circulating theophylline levels in beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7229951/),[l] / [kg],0.75,20052,DB00201,Caffeine
,2867172,volume of distribution of the central compartment (V1),"Caffeine increased the volume of distribution of the central compartment (V1) for ceftriaxone significantly from 49 +/- 38 ml kg-1 (mean +/- s.d., n = 6) to 97 +/- 33 ml kg-1 (caffeine 5 mg kg-1, P less than 0.05), and 94 +/- 8 ml kg-1 (caffeine 10 mg kg-1, P less than 0.05) and decreased the volume of distribution of the peripheral compartment (V2) from 145 +/- 106 ml kg-1 (mean +/- s.d., n = 6) to 31 +/- 18 ml kg-1 (caffeine 5 mg kg-1, P less than 0.5) and 36 +/- 31 ml kg-1 (caffeine 10 mg kg-1, P less than 0.1).",Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867172/),[ml] / [kg],49,21487,DB00201,Caffeine
,2867172,volume of distribution of the central compartment (V1),"Caffeine increased the volume of distribution of the central compartment (V1) for ceftriaxone significantly from 49 +/- 38 ml kg-1 (mean +/- s.d., n = 6) to 97 +/- 33 ml kg-1 (caffeine 5 mg kg-1, P less than 0.05), and 94 +/- 8 ml kg-1 (caffeine 10 mg kg-1, P less than 0.05) and decreased the volume of distribution of the peripheral compartment (V2) from 145 +/- 106 ml kg-1 (mean +/- s.d., n = 6) to 31 +/- 18 ml kg-1 (caffeine 5 mg kg-1, P less than 0.5) and 36 +/- 31 ml kg-1 (caffeine 10 mg kg-1, P less than 0.1).",Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867172/),[ml] / [kg],97,21488,DB00201,Caffeine
,2867172,volume of distribution of the central compartment (V1),"Caffeine increased the volume of distribution of the central compartment (V1) for ceftriaxone significantly from 49 +/- 38 ml kg-1 (mean +/- s.d., n = 6) to 97 +/- 33 ml kg-1 (caffeine 5 mg kg-1, P less than 0.05), and 94 +/- 8 ml kg-1 (caffeine 10 mg kg-1, P less than 0.05) and decreased the volume of distribution of the peripheral compartment (V2) from 145 +/- 106 ml kg-1 (mean +/- s.d., n = 6) to 31 +/- 18 ml kg-1 (caffeine 5 mg kg-1, P less than 0.5) and 36 +/- 31 ml kg-1 (caffeine 10 mg kg-1, P less than 0.1).",Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867172/),[ml] / [kg],94,21489,DB00201,Caffeine
,2867172,volume of distribution of the peripheral compartment (V2),"Caffeine increased the volume of distribution of the central compartment (V1) for ceftriaxone significantly from 49 +/- 38 ml kg-1 (mean +/- s.d., n = 6) to 97 +/- 33 ml kg-1 (caffeine 5 mg kg-1, P less than 0.05), and 94 +/- 8 ml kg-1 (caffeine 10 mg kg-1, P less than 0.05) and decreased the volume of distribution of the peripheral compartment (V2) from 145 +/- 106 ml kg-1 (mean +/- s.d., n = 6) to 31 +/- 18 ml kg-1 (caffeine 5 mg kg-1, P less than 0.5) and 36 +/- 31 ml kg-1 (caffeine 10 mg kg-1, P less than 0.1).",Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867172/),[ml] / [kg],145,21490,DB00201,Caffeine
,2867172,volume of distribution of the peripheral compartment (V2),"Caffeine increased the volume of distribution of the central compartment (V1) for ceftriaxone significantly from 49 +/- 38 ml kg-1 (mean +/- s.d., n = 6) to 97 +/- 33 ml kg-1 (caffeine 5 mg kg-1, P less than 0.05), and 94 +/- 8 ml kg-1 (caffeine 10 mg kg-1, P less than 0.05) and decreased the volume of distribution of the peripheral compartment (V2) from 145 +/- 106 ml kg-1 (mean +/- s.d., n = 6) to 31 +/- 18 ml kg-1 (caffeine 5 mg kg-1, P less than 0.5) and 36 +/- 31 ml kg-1 (caffeine 10 mg kg-1, P less than 0.1).",Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867172/),[ml] / [kg],31,21491,DB00201,Caffeine
,2867172,volume of distribution of the peripheral compartment (V2),"Caffeine increased the volume of distribution of the central compartment (V1) for ceftriaxone significantly from 49 +/- 38 ml kg-1 (mean +/- s.d., n = 6) to 97 +/- 33 ml kg-1 (caffeine 5 mg kg-1, P less than 0.05), and 94 +/- 8 ml kg-1 (caffeine 10 mg kg-1, P less than 0.05) and decreased the volume of distribution of the peripheral compartment (V2) from 145 +/- 106 ml kg-1 (mean +/- s.d., n = 6) to 31 +/- 18 ml kg-1 (caffeine 5 mg kg-1, P less than 0.5) and 36 +/- 31 ml kg-1 (caffeine 10 mg kg-1, P less than 0.1).",Effect of caffeine on the plasma protein binding and the disposition of ceftriaxone. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867172/),[ml] / [kg],36,21492,DB00201,Caffeine
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,121.8,21797,DB00201,Caffeine
,11673747,oral clearance,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,254.5,21798,DB00201,Caffeine
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.28,21799,DB00201,Caffeine
,11673747,oral bioavailability,Long-term St John's wort administration caused a significant (P <.05) increase in oral clearance of midazolam from 121.8 +/- 70.7 to 254.5 +/- 127.8 and a corresponding significant decline in oral bioavailability from 0.28 +/- 0.15 to 0.17 +/- 0.06.,The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11673747/),,0.17,21800,DB00201,Caffeine
,1763520,whole-body,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,10.2,21980,DB00201,Caffeine
,1763520,whole-body,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,1.2,21981,DB00201,Caffeine
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,10.2,21982,DB00201,Caffeine
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,1.2,21983,DB00201,Caffeine
,1763520,half-life,"3. The whole-body half-life of caffeine (1 mg) in mice was 10.2, 1.2, and 0.37 h following 8-MOP (50 mg/kg per day) x 1, vehicle, and 8-MOP x 3 respectively.",Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1763520/),h,0.37,21984,DB00201,Caffeine
,22595262,flow rate,"The separation was performed on LichroCART RP-18e with particle size of 5 µm (250 × 4.6 mm) with mobile phase acetonitrile-50 mM KH(2)PO(4) buffer, pH 7.1, using a gradient mode with a 1.0 mL/min flow rate.",New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),[ml] / [min],1.0,24703,DB00201,Caffeine
,22595262,Recovery,Recovery values for the substances ranged between 59 and 83%.,New HPLC method to detect individual opioids (heroin and tramadol) and their metabolites in the blood of rats on combination treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595262/),%,59 and 83,24704,DB00201,Caffeine
,11483122,Maximum serum concentrations,Maximum serum concentrations ranged from 55 to 123 mg/L.,Theophylline toxicokinetics in premature newborns. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),[mg] / [l],55 to 123,26529,DB00201,Caffeine
,11483122,half-lives,"In contrast to older children and adults, in whom theophylline disposition follows zero-order kinetics at high concentrations, a monoexponential function best described theophylline elimination in the premature newborn, with half-lives ranging from 24.7 to 36.5 hours and estimated clearance from 0.02 to 0.05 L/kg per hour.",Theophylline toxicokinetics in premature newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),h,24.7 to 36.5,26530,DB00201,Caffeine
,11483122,clearance,"In contrast to older children and adults, in whom theophylline disposition follows zero-order kinetics at high concentrations, a monoexponential function best described theophylline elimination in the premature newborn, with half-lives ranging from 24.7 to 36.5 hours and estimated clearance from 0.02 to 0.05 L/kg per hour.",Theophylline toxicokinetics in premature newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11483122/),[l] / [h·kg],0.02 to 0.05,26531,DB00201,Caffeine
,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,∼100,27489,DB00201,Caffeine
<,26114209,Bioavailabilities,"3. Bioavailabilities were ∼100% for caffeine and warfarin, but <25% for omeprazole and metoprolol.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,25,27490,DB00201,Caffeine
,26114209,Bioavailability,"Bioavailability of midazolam was 4% in marmosets, presumably because of contribution of marmoset P450 3A4 expressed in small intestine and liver, with a high catalytic efficiency for midazolam 1'-hydroxylation as evident in the recombinant system.","Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol and midazolam, in common marmosets (Callithrix jacchus). ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114209/),%,4,27491,DB00201,Caffeine
,10499237,distribution half-lives (t1/2 alpha),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,1.37,31527,DB00201,Caffeine
,10499237,distribution half-lives (t1/2 alpha),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,2.66,31528,DB00201,Caffeine
,10499237,elimination half-lives (t1/2 beta),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,11.8,31529,DB00201,Caffeine
,10499237,elimination half-lives (t1/2 beta),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),h,10.4,31530,DB00201,Caffeine
,10499237,steady state volumes of distribution (Vss),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.88,31531,DB00201,Caffeine
,10499237,steady state volumes of distribution (Vss),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.76,31532,DB00201,Caffeine
,10499237,volumes of the central compartment (Vc),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.41,31533,DB00201,Caffeine
,10499237,volumes of the central compartment (Vc),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[l] / [kg],0.51,31534,DB00201,Caffeine
,10499237,total body clearances (Clt),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[ml] / [h·kg],62.3,31535,DB00201,Caffeine
,10499237,total body clearances (Clt),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[ml] / [h·kg],50.2,31536,DB00201,Caffeine
,10499237,renal clearance (Vr),"The data obtained (median and range) for the low and high dose, respectively, were as follows: the distribution half-lives (t1/2 alpha) were 1.37 (0.64-3.25) and 2.66 (0.83-3.5) h, the elimination half-lives (t1/2 beta) were 11.8 (8.25-14.9) and 10.4 (10.0-13.5) h, the steady state volumes of distribution (Vss) were 0.88 (0.62-1.54) and 0.76 (0.63-0.76) L/kg, volumes of the central compartment (Vc) were 0.41 (0.35-0.63) and 0.51 (0.36-0.52) L/kg, total body clearances (Clt) were 62.3 (39.4-97.0) and 50.2 (47.7-67.4) mL/h.kg body weight and renal clearance (Vr) for the low dose was 0.6 (0.42-0.96) mL/h.kg body weight.",The disposition of theophylline in camels after intravenous administration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[ml] / [h·kg],0.6,31537,DB00201,Caffeine
,10499237,protein binding,Theophylline protein binding at a concentration of 5 micrograms/mL was 32.2 +/- 3.3%.,The disposition of theophylline in camels after intravenous administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),%,32.2,31538,DB00201,Caffeine
,10499237,steady state serum concentration,This dosing regimen should achieve an average steady state serum concentration of 10 micrograms/mL with peak serum concentration not exceeding 15 micrograms/mL.,The disposition of theophylline in camels after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[μg] / [ml],10,31539,DB00201,Caffeine
not exceeding,10499237,peak serum concentration,This dosing regimen should achieve an average steady state serum concentration of 10 micrograms/mL with peak serum concentration not exceeding 15 micrograms/mL.,The disposition of theophylline in camels after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499237/),[μg] / [ml],15,31540,DB00201,Caffeine
,25700100,clearance,Caffeine clearance was 0.95±0.14 mL·min(-1)·kg(-1) while the elimination half-life of caffeine was 17.63±8.06 h.,The Effect of Caffeine Ingestion during Evening Exercise on Subsequent Sleep Quality in Females. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700100/),[ml] / [kg·min],0.95,32052,DB00201,Caffeine
,25700100,elimination half-life,Caffeine clearance was 0.95±0.14 mL·min(-1)·kg(-1) while the elimination half-life of caffeine was 17.63±8.06 h.,The Effect of Caffeine Ingestion during Evening Exercise on Subsequent Sleep Quality in Females. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700100/),h,17.63,32053,DB00201,Caffeine
,15257070,terminal elimination half-life,The terminal elimination half-life of the compound was (mean +/- SD) 5.0 +/- 2.8 hours.,A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257070/),h,5.0,32239,DB00201,Caffeine
,15257070,apparent volume of distribution (Vss/F),The apparent volume of distribution (Vss/F) was calculated to be 122.1 +/- 39.7 L.,A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257070/),l,122.1,32240,DB00201,Caffeine
,16740103,elimination half-life,"Median elimination half-life was 11 hours (range, 9.3 to 29.8 hours) in alpacas and 16 hours (range, 5.4 to 17 hours) in llamas.",Pharmacokinetics of intravenously administered caffeine in healthy alpacas (Lama pacos) and llamas (Lama glama). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740103/),h,11,32576,DB00201,Caffeine
,16740103,elimination half-life,"Median elimination half-life was 11 hours (range, 9.3 to 29.8 hours) in alpacas and 16 hours (range, 5.4 to 17 hours) in llamas.",Pharmacokinetics of intravenously administered caffeine in healthy alpacas (Lama pacos) and llamas (Lama glama). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740103/),h,16,32577,DB00201,Caffeine
,16740103,volume of distribution at steady state,"The volume of distribution at steady state was 0.60 L/kg (range, 0.45 to 0.93 L/kg) in alpacas and 0.75 L/kg (range, 0.68 to 1.15 L/kg) in llamas.",Pharmacokinetics of intravenously administered caffeine in healthy alpacas (Lama pacos) and llamas (Lama glama). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740103/),[l] / [kg],0.60,32578,DB00201,Caffeine
,16740103,volume of distribution at steady state,"The volume of distribution at steady state was 0.60 L/kg (range, 0.45 to 0.93 L/kg) in alpacas and 0.75 L/kg (range, 0.68 to 1.15 L/kg) in llamas.",Pharmacokinetics of intravenously administered caffeine in healthy alpacas (Lama pacos) and llamas (Lama glama). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740103/),[l] / [kg],0.75,32579,DB00201,Caffeine
,16740103,Total plasma clearance,"Total plasma clearance was 44 mL/h/kg (range, 24 to 56 mL/h/kg) in alpacas and 42 mL/h/kg (range, 30 to 109 mL/h/kg) in llamas.",Pharmacokinetics of intravenously administered caffeine in healthy alpacas (Lama pacos) and llamas (Lama glama). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740103/),[ml] / [h·kg],44,32580,DB00201,Caffeine
,16740103,Total plasma clearance,"Total plasma clearance was 44 mL/h/kg (range, 24 to 56 mL/h/kg) in alpacas and 42 mL/h/kg (range, 30 to 109 mL/h/kg) in llamas.",Pharmacokinetics of intravenously administered caffeine in healthy alpacas (Lama pacos) and llamas (Lama glama). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16740103/),[ml] / [h·kg],42,32581,DB00201,Caffeine
,15289794,initial,"On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1).",Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],2.47,33852,DB00201,Caffeine
,15289794,clearance,"On cessation of smoking, initial caffeine clearance (estimated geometric means and 95% confidence intervals) decreased significantly (P <.01), by 36.1% (30.9%-42.2%), from 2.47 mL. min(-1).",Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],2.47,33853,DB00201,Caffeine
,15289794,new steady state,kg(-1) body weight) to a new steady state of 1.53 mL. min(-1).,Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),[ml] / [min],1.53,33854,DB00201,Caffeine
,15289794,apparent half-life,The apparent half-life of CYP1A2 activity decrease was 38.6 hours (27.4-54.4 hours).,Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15289794/),h,38.6,33855,DB00201,Caffeine
,7359014,t1/2 (beta),The t1/2 (beta) was significantly prolonged in women on OCS (10.7 +/- 3.0 hr vs. 6.2 +/- 1.6) (p less than 0.001) as compared to women taking no OCS.,Impaired elimination of caffeine by oral contraceptive steroids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359014/),h,10.7,33990,DB00201,Caffeine
,7359014,t1/2 (beta),The t1/2 (beta) was significantly prolonged in women on OCS (10.7 +/- 3.0 hr vs. 6.2 +/- 1.6) (p less than 0.001) as compared to women taking no OCS.,Impaired elimination of caffeine by oral contraceptive steroids. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359014/),,6.2,33991,DB00201,Caffeine
,7359014,total plasma clearance,Women on OCS had a significantly lower total plasma clearance (0.79 +/- 0.21 ml/min/kg vs. 1.3 +/- 0.35) and free clearance (1.12 +/- 0.28 ml/min/kg vs. 1.97 +/- 0.57) that women not taking OCS.,Impaired elimination of caffeine by oral contraceptive steroids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359014/),[ml] / [kg·min],0.79,33992,DB00201,Caffeine
,7359014,total plasma clearance,Women on OCS had a significantly lower total plasma clearance (0.79 +/- 0.21 ml/min/kg vs. 1.3 +/- 0.35) and free clearance (1.12 +/- 0.28 ml/min/kg vs. 1.97 +/- 0.57) that women not taking OCS.,Impaired elimination of caffeine by oral contraceptive steroids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359014/),,1.3,33993,DB00201,Caffeine
,7359014,free clearance,Women on OCS had a significantly lower total plasma clearance (0.79 +/- 0.21 ml/min/kg vs. 1.3 +/- 0.35) and free clearance (1.12 +/- 0.28 ml/min/kg vs. 1.97 +/- 0.57) that women not taking OCS.,Impaired elimination of caffeine by oral contraceptive steroids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359014/),[ml] / [kg·min],1.12,33994,DB00201,Caffeine
,7359014,free clearance,Women on OCS had a significantly lower total plasma clearance (0.79 +/- 0.21 ml/min/kg vs. 1.3 +/- 0.35) and free clearance (1.12 +/- 0.28 ml/min/kg vs. 1.97 +/- 0.57) that women not taking OCS.,Impaired elimination of caffeine by oral contraceptive steroids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7359014/),,1.97,33995,DB00201,Caffeine
,21439120,extraction recovery,"Mean extraction recovery from human plasma of caffeine and the IS was 91% and 86%, respectively.",Validated HPLC method for determination of caffeine level in human plasma using synthetic plasma: application to bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21439120/),%,91,34304,DB00201,Caffeine
,21439120,extraction recovery,"Mean extraction recovery from human plasma of caffeine and the IS was 91% and 86%, respectively.",Validated HPLC method for determination of caffeine level in human plasma using synthetic plasma: application to bioavailability studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21439120/),%,86,34305,DB00201,Caffeine
,32285669,area under the time-concentration curves,"The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·μg/L pre-hop and 521.9 ± 36.1 h·μg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.",Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285669/),[h·μg] / [l],564.6,35551,DB00201,Caffeine
,32285669,area under the time-concentration curves,"The observed area under the time-concentration curves were unaffected, except for alprazolam which decreased 7.6% (564.6 ± 46.1 h·μg/L pre-hop and 521.9 ± 36.1 h·μg/L post-hop; p-value 0.047), suggesting minor induction of CYP3A4/5.",Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32285669/),[h·μg] / [l],521.9,35552,DB00201,Caffeine
,6530705,half-life,Caffeine concentration at birth was probably much higher based on the pharmacokinetic extrapolation (caffeine half-life of 100 hours).,Maternal coffee drinking and unusually high concentrations of caffeine in the newborn. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6530705/),h,100,35771,DB00201,Caffeine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,64,36555,DB00201,Caffeine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,67,36556,DB00201,Caffeine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,50,36557,DB00201,Caffeine
,11221281,headache response rates,"In another large trial, headache response rates were significantly higher for both doses of eletriptan (64% for 40 mg and 67% for 80 mg) than for two doses of sumatriptan (50% for 50 mg and 53% for 100 mg).",Pharmacology and efficacy of eletriptan for the treatment of migraine attacks. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11221281/),%,53,36558,DB00201,Caffeine
,28535819,Withdrawal rate,"Withdrawal rate was 4%, 0%, and 4%, respectively.",Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535819/),%,4,37188,DB00201,Caffeine
,28535819,Withdrawal rate,"Withdrawal rate was 4%, 0%, and 4%, respectively.",Does the placebo effect modulate drug bioavailability? Randomized cross-over studies of three drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28535819/),%,0,37189,DB00201,Caffeine
,12678165,clearance,"The mean caffeine clearance 1 day after TOCE (0.51 +/- 0.096) and 5 weeks after TOCE treatment (0.43 +/- 0.07) was significantly reduced compared with the mean caffeine clearance before treatment (0.79 . 0.2 ml/min x kg) with the p = 0.06 and p = 0.03, respectively.",Caffeine clearance in patients with hepatocellular carcinoma after transcatheter oily chemoembolization treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12678165/),,0.51,37766,DB00201,Caffeine
,12678165,clearance,"The mean caffeine clearance 1 day after TOCE (0.51 +/- 0.096) and 5 weeks after TOCE treatment (0.43 +/- 0.07) was significantly reduced compared with the mean caffeine clearance before treatment (0.79 . 0.2 ml/min x kg) with the p = 0.06 and p = 0.03, respectively.",Caffeine clearance in patients with hepatocellular carcinoma after transcatheter oily chemoembolization treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12678165/),,0.43,37767,DB00201,Caffeine
,12678165,clearance,"The mean caffeine clearance 1 day after TOCE (0.51 +/- 0.096) and 5 weeks after TOCE treatment (0.43 +/- 0.07) was significantly reduced compared with the mean caffeine clearance before treatment (0.79 . 0.2 ml/min x kg) with the p = 0.06 and p = 0.03, respectively.",Caffeine clearance in patients with hepatocellular carcinoma after transcatheter oily chemoembolization treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12678165/),[ml] / [kg·min],0.79 . 0.2,37768,DB00201,Caffeine
,9610952,EC50,"The EC50 values were 7.34 and 9.93 microg/ml for i.p. and p.o. caffeine, respectively.",Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610952/),[μg] / [ml],7.34,38290,DB00201,Caffeine
,9610952,EC50,"The EC50 values were 7.34 and 9.93 microg/ml for i.p. and p.o. caffeine, respectively.",Caffeine has similar pharmacokinetics and behavioral effects via the i.p. and p.o. routes of administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9610952/),[μg] / [ml],9.93,38291,DB00201,Caffeine
,7863608,distribution half-life,The harmonic mean for the distribution half-life was 5.2 min (range 1.4-18.7).,Caffeine clearance in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863608/),min,5.2,40657,DB00201,Caffeine
,7863608,elimination half-life,The harmonic mean for the elimination half-life was 10.18 h (range 6.82-20.92).,Caffeine clearance in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863608/),h,10.18,40658,DB00201,Caffeine
,7863608,volume of distribution,The harmonic mean of the volume of distribution was 0.32 L/kg (range 0.22-0.53).,Caffeine clearance in the horse. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7863608/),[l] / [kg],0.32,40659,DB00201,Caffeine
,8856830,t1/2,"Because alprazolam is much shorter-lived (t1/2 = 32 min) than caffeine (t1/2 = 3 h) in rats, potency ratios between alprazolam and caffeine changed across session time (from 123 to 4), which determined the expression of the combined effects.","Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856830/),min,32,40961,DB00201,Caffeine
,8856830,t1/2,"Because alprazolam is much shorter-lived (t1/2 = 32 min) than caffeine (t1/2 = 3 h) in rats, potency ratios between alprazolam and caffeine changed across session time (from 123 to 4), which determined the expression of the combined effects.","Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856830/),h,3,40962,DB00201,Caffeine
,10389569,first serum concentration,The first serum concentration measured was 217.5 mg.l-1 at 36.5 h after dosing.,Caffeine overdose in a premature infant: clinical course and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389569/),[mg] / [l],217.5,41484,DB00201,Caffeine
,10389569,clearance,"Parameter estimates were: clearance 0.01 l.h-1, volume of distribution 1.17 litres, elimination half-life 81 h.",Caffeine overdose in a premature infant: clinical course and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389569/),[l] / [h],0.01,41485,DB00201,Caffeine
,10389569,volume of distribution,"Parameter estimates were: clearance 0.01 l.h-1, volume of distribution 1.17 litres, elimination half-life 81 h.",Caffeine overdose in a premature infant: clinical course and pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389569/),l,1.17,41486,DB00201,Caffeine
,10389569,elimination half-life,"Parameter estimates were: clearance 0.01 l.h-1, volume of distribution 1.17 litres, elimination half-life 81 h.",Caffeine overdose in a premature infant: clinical course and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10389569/),h,81,41487,DB00201,Caffeine
,15667599,volume of distribution for the central compartment,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),l,45.7,41945,DB00201,Caffeine
,15667599,apparent elimination rate constant,The volume of distribution for the central compartment was estimated to be 45.7 l and the apparent elimination rate constant of caffeine at 8 hr after inhalation was 0.150 hr(-1) for a typical individual.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),1/[hr],0.150,41946,DB00201,Caffeine
,15667599,bioavailability,The bioavailability was approximately 60%.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41947,DB00201,Caffeine
,15667599,bioavailability,The bioavailability of inhaled caffeine is approximately 60% in experienced smokers.,"Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15667599/),%,60,41948,DB00201,Caffeine
,10584979,K(i),"In vitro, omeprazole was mainly a competitive CYP1A2 inhibitor with K(i) values of around 150 microM.",Omeprazole weakly inhibits CYP1A2 activity in man. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10584979/),μM,150,42427,DB00201,Caffeine
,22903588,percentage recovery,"The mean percentage recovery (n = 3) for the low, middle and high quality control samples was 86.92 ± 3.89, 85.30 ± 1.09 and 87.24 ± 4.03%, respectively.","A rapid HPLC-ESI-MS/MS method for determination of β-asarone, a potential anti-epileptic agent, in plasma after oral administration of Acorus calamus extract to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22903588/),%,86.92,42485,DB00201,Caffeine
,22903588,percentage recovery,"The mean percentage recovery (n = 3) for the low, middle and high quality control samples was 86.92 ± 3.89, 85.30 ± 1.09 and 87.24 ± 4.03%, respectively.","A rapid HPLC-ESI-MS/MS method for determination of β-asarone, a potential anti-epileptic agent, in plasma after oral administration of Acorus calamus extract to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22903588/),%,85.30,42486,DB00201,Caffeine
,22903588,percentage recovery,"The mean percentage recovery (n = 3) for the low, middle and high quality control samples was 86.92 ± 3.89, 85.30 ± 1.09 and 87.24 ± 4.03%, respectively.","A rapid HPLC-ESI-MS/MS method for determination of β-asarone, a potential anti-epileptic agent, in plasma after oral administration of Acorus calamus extract to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22903588/),%,87.24,42487,DB00201,Caffeine
,11560082,peak oxygen consumption (VO2peak),"Twelve trained endurance athletes [seven male, five female; peak oxygen consumption (VO2peak) = 65.5 ml.kg-1.min-1] performed 60 min of cycle ergometry at 65% VO2peak twice, once after oral caffeine administration (6 mg.kg-1) (CAF) and once following consumption of a placebo (PLA).",An acute oral dose of caffeine does not alter glucose kinetics during prolonged dynamic exercise in trained endurance athletes. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11560082/),[ml] / [kg·min],65.5,44322,DB00201,Caffeine
,14578861,CBT,Cirrhotic patients were characterized by significantly reduced CBT values (1.15 +/- 0.75 delta per thousand mg(-1)) compared with controls (2.23 +/- 0.76; P =.001) and hepatitic patients (1.83 +/- 1.05; P =.04).,"Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578861/),[delta·thousand] / [mg],1.15,44500,DB00201,Caffeine
,14578861,CBT,Cirrhotic patients were characterized by significantly reduced CBT values (1.15 +/- 0.75 delta per thousand mg(-1)) compared with controls (2.23 +/- 0.76; P =.001) and hepatitic patients (1.83 +/- 1.05; P =.04).,"Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578861/),[delta·thousand] / [mg],2.23,44501,DB00201,Caffeine
,14578861,CBT,Cirrhotic patients were characterized by significantly reduced CBT values (1.15 +/- 0.75 delta per thousand mg(-1)) compared with controls (2.23 +/- 0.76; P =.001) and hepatitic patients (1.83 +/- 1.05; P =.04).,"Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578861/),[delta·thousand] / [mg],1.83,44502,DB00201,Caffeine
,14578861,CBT,"Although smoking was associated with an 86% to 141% increase in CBT in all groups, the CBT was able to distinguish control, hepatitic, and cirrhotic smokers (5.36 +/- 0.82, 3.63 +/- 1.21, and 2.14 +/- 1.14, respectively, P =.001).","Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578861/),,5.36,44503,DB00201,Caffeine
,14578861,CBT,"Although smoking was associated with an 86% to 141% increase in CBT in all groups, the CBT was able to distinguish control, hepatitic, and cirrhotic smokers (5.36 +/- 0.82, 3.63 +/- 1.21, and 2.14 +/- 1.14, respectively, P =.001).","Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578861/),,3.63,44504,DB00201,Caffeine
,14578861,CBT,"Although smoking was associated with an 86% to 141% increase in CBT in all groups, the CBT was able to distinguish control, hepatitic, and cirrhotic smokers (5.36 +/- 0.82, 3.63 +/- 1.21, and 2.14 +/- 1.14, respectively, P =.001).","Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578861/),,2.14,44505,DB00201,Caffeine
,24368338,recoveries,Enantiomer recoveries yielded 100.0 ± 15%.,HPLC method with solid-phase extraction for determination of (R)- and (S)-ketoprofen in plasma without caffeine interference: application to pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24368338/),%,100.0,49544,DB00201,Caffeine
,7172970,clearance rate,"In a 6 1/2-month-old infant with hepatic failure secondary to hereditary tyrosinemia, the theophylline clearance rate of 0.016 liter/kg/h was reduced for age and the serum half-life was prolonged to 18.0 h.",The pharmacokinetics of theophylline in an infant with hepatic failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172970/),[l] / [h·kg],0.016,51258,DB00201,Caffeine
,7172970,serum half-life,"In a 6 1/2-month-old infant with hepatic failure secondary to hereditary tyrosinemia, the theophylline clearance rate of 0.016 liter/kg/h was reduced for age and the serum half-life was prolonged to 18.0 h.",The pharmacokinetics of theophylline in an infant with hepatic failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7172970/),h,18.0,51259,DB00201,Caffeine
,20662110,flow rate,"A mobile phase solvent consisting of 20 mm sodium dihydrogenphosphate (pH 3.0) and acetonitrile (85:15, v/v) was pumped at a flow rate of 1.0 mL/min.",A simple chromatographic method for determining norfloxacin and enoxacin in pharmacokinetic study assessing CYP1A2 inhibition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20662110/),[ml] / [min],1.0,52340,DB00201,Caffeine
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],0.86,53686,DB00201,Caffeine
,11907488,clearance,"At the higher but not the lower steady-state dose of fluvoxamine, a significantly lower clearance in PMs compared with EMs was observed (geometric mean, 0.86 versus 1.4 L/h per kilogram; P <.05).",Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11907488/),[l] / [h·kg],1.4,53687,DB00201,Caffeine
,20045386,Recoveries,Recoveries for caffeine and theobromine ranged from 114 to 118% and 99 to 105% at concentration levels of 10 and 300 micromol L(-1).,"Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: a single analytical protocol applicable to cocoa intervention studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20045386/),%,114 to 118,53899,DB00201,Caffeine
,20045386,Recoveries,Recoveries for caffeine and theobromine ranged from 114 to 118% and 99 to 105% at concentration levels of 10 and 300 micromol L(-1).,"Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: a single analytical protocol applicable to cocoa intervention studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20045386/),%,99 to 105,53900,DB00201,Caffeine
,27734219,maximum plasma concentration,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[μg] / [ml],9.46,54009,DB00201,Caffeine
,27734219,maximum plasma concentration,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[μg] / [ml],9.72,54010,DB00201,Caffeine
,27734219,area under the curve from time zero to the last sampling time,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[h·μg] / [ml],34.93,54011,DB00201,Caffeine
,27734219,area under the curve from time zero to the last sampling time,"The geometric mean values for maximum plasma concentration obtained for the reference and test products were 9.46 ± 34.21 and 9.72 ± 32.38 µg/mL, respectively, whereas for the area under the curve from time zero to the last sampling time the values obtained were 34.93 ± 32.58 and 35.89 ± 31.03 µg h/mL for the reference and test formulations, respectively.",Bioequivalence and Pharmacokinetic Evaluation Study of Acetaminophen vs. Acetaminophen Plus Caffeine Tablets in Healthy Mexican Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27734219/),[h·μg] / [ml],35.89,54012,DB00201,Caffeine
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],0.58,54661,DB00201,Caffeine
,8613932,Cl(f),"In phenobarbital-induced rats receiving a nontoxic dose of APAP (100 mg/kg i.v.), a single dose of caffeine (100 mg/kg i.p.) co-administered with APAP increased the Cl(f) of NAPQI formation from 0.58 +/- 0.47 to 2.08 +/- 1.1 1 ml/min/kg (P = .01).",Effects of caffeine and theophylline on acetaminophen pharmacokinetics: P450 inhibition and activation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8613932/),[1·ml] / [kg·min],2.08,54662,DB00201,Caffeine
,29124988,volume of distribution,"Butalbital is a small molecule (approximately 220 Da), with 26% protein binding, a 0.8 L/kg volume of distribution, and is eliminated nearly 80% unchanged in the urine.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[l] / [kg],0.8,56164,DB00201,Caffeine
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mg] / [dl],46.4,56165,DB00201,Caffeine
,29124988,peak salicylate concentration,"Her presentation was notable for a decline in mental status, preserved renal function and a relatively low peak salicylate concentration at 46.4 mg/dL (3.4 mmol/L).",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[mM] / [l],3.4,56166,DB00201,Caffeine
,29124988,total body elimination,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),%,60,56167,DB00201,Caffeine
,29124988,clearance,"At the end of a four-hour hemodialysis session, the total body elimination of butalbital was approximately 60% which corresponded to an intradialytic clearance of 233-300 mL/min.",Extracorporeal elimination of butalbital in acute aspirin-butalbital-caffeine-codeine (Fiorinal with Codeine) poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29124988/),[ml] / [min],233-300,56168,DB00201,Caffeine
,7507589,bioavailability,"Both PPA and PDE are readily and completely absorbed, whereas PE, with a bioavailability of only approximately 38%, is subject to gut wall metabolism and is thought to be absorbed erratically.",Pharmacokinetics of oral decongestants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),%,38,59010,DB00201,Caffeine
,7507589,apparent volume of distribution,All three drugs are extensively distributed into extravascular sites (apparent volume of distribution between 2.6 and 5.0 L/kg).,Pharmacokinetics of oral decongestants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),[l] / [kg],2.6 and 5.0,59011,DB00201,Caffeine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,2.5,59012,DB00201,Caffeine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,4,59013,DB00201,Caffeine
,7507589,Half-lives,"Half-lives are relatively short, approximately 2.5 hours for PE, 4 hours for PPA, and 6 hours for PDE.",Pharmacokinetics of oral decongestants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7507589/),h,6,59014,DB00201,Caffeine
,34100394,CL,"In the present study, the means CL, volume of distribution, and T1/2 of caffeine in preterm infants were 0.0476 L. h-1, 1.1081 L, 16.2284 h, respectively.",Prediction of pharmacokinetic values of two various dosages of caffeine in premature neonates with apnea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100394/),[l] / [h],0.0476,59276,DB00201,Caffeine
,34100394,volume of distribution,"In the present study, the means CL, volume of distribution, and T1/2 of caffeine in preterm infants were 0.0476 L. h-1, 1.1081 L, 16.2284 h, respectively.",Prediction of pharmacokinetic values of two various dosages of caffeine in premature neonates with apnea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100394/),l,1.1081,59277,DB00201,Caffeine
,34100394,T1/2,"In the present study, the means CL, volume of distribution, and T1/2 of caffeine in preterm infants were 0.0476 L. h-1, 1.1081 L, 16.2284 h, respectively.",Prediction of pharmacokinetic values of two various dosages of caffeine in premature neonates with apnea. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34100394/),h,16.2284,59278,DB00201,Caffeine
,1446372,recovery percent,"The mean recovery percent in the brain and CSF were 10.9 and 13.1%, respectively.",Application of microdialysis for study of caffeine distribution into brain and cerebrospinal fluid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1446372/),%,10.9,60663,DB00201,Caffeine
,1446372,recovery percent,"The mean recovery percent in the brain and CSF were 10.9 and 13.1%, respectively.",Application of microdialysis for study of caffeine distribution into brain and cerebrospinal fluid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1446372/),%,13.1,60664,DB00201,Caffeine
more,1446372,time resolution,"Thus, microdialysis was proved useful for determination of drug concentration in the tissue and biological fluids with time resolution of more than 30 s.",Application of microdialysis for study of caffeine distribution into brain and cerebrospinal fluid in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1446372/),s,30,60665,DB00201,Caffeine
,3814465,minimum,When corrected for body weight there were no significant differences in minimum and maximum plateau levels of furafylline between males (1.2-2.0 micrograms ml-1; mean body weight 67.2 kg) and females (1.6-2.6 micrograms ml-1; mean body weight 54.9 kg).,Accumulation of caffeine in healthy volunteers treated with furafylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814465/),[μg] / [ml],1.2-2.0,61521,DB00201,Caffeine
,3814465,maximum plateau levels,When corrected for body weight there were no significant differences in minimum and maximum plateau levels of furafylline between males (1.2-2.0 micrograms ml-1; mean body weight 67.2 kg) and females (1.6-2.6 micrograms ml-1; mean body weight 54.9 kg).,Accumulation of caffeine in healthy volunteers treated with furafylline. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814465/),[μg] / [ml],1.6-2.6,61522,DB00201,Caffeine
,3814465,elimination half-life,Subsequent studies showed that a single dose (90 mg) of furafylline results in a rapid accumulation of caffeine given orally (100 mg twice daily) and that this is accompanied by an elimination half-life of some 50 h and an abrupt decrease in metabolite levels.,Accumulation of caffeine in healthy volunteers treated with furafylline. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3814465/),h,50,61523,DB00201,Caffeine
,3830245,absorption rate constant (Ka,"Pharmacokinetic analysis indicated that at rest, OV had a significantly higher absorption rate constant (Ka 0.0757 vs. 0.0397 min-1), lower elimination rate constant (Ke 0.0027 vs. 0.0045 min-1), and longer serum half-life (t1/2 4.37 vs. 2.59 h) in comparison to LV.",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),1/[min],0.0757,62468,DB00201,Caffeine
,3830245,absorption rate constant (Ka,"Pharmacokinetic analysis indicated that at rest, OV had a significantly higher absorption rate constant (Ka 0.0757 vs. 0.0397 min-1), lower elimination rate constant (Ke 0.0027 vs. 0.0045 min-1), and longer serum half-life (t1/2 4.37 vs. 2.59 h) in comparison to LV.",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),1/[min],0.0397,62469,DB00201,Caffeine
,3830245,elimination rate constant (Ke,"Pharmacokinetic analysis indicated that at rest, OV had a significantly higher absorption rate constant (Ka 0.0757 vs. 0.0397 min-1), lower elimination rate constant (Ke 0.0027 vs. 0.0045 min-1), and longer serum half-life (t1/2 4.37 vs. 2.59 h) in comparison to LV.",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),1/[min],0.0027,62470,DB00201,Caffeine
,3830245,elimination rate constant (Ke,"Pharmacokinetic analysis indicated that at rest, OV had a significantly higher absorption rate constant (Ka 0.0757 vs. 0.0397 min-1), lower elimination rate constant (Ke 0.0027 vs. 0.0045 min-1), and longer serum half-life (t1/2 4.37 vs. 2.59 h) in comparison to LV.",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),1/[min],0.0045,62471,DB00201,Caffeine
,3830245,serum half-life (t1/2,"Pharmacokinetic analysis indicated that at rest, OV had a significantly higher absorption rate constant (Ka 0.0757 vs. 0.0397 min-1), lower elimination rate constant (Ke 0.0027 vs. 0.0045 min-1), and longer serum half-life (t1/2 4.37 vs. 2.59 h) in comparison to LV.",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),h,4.37,62472,DB00201,Caffeine
,3830245,serum half-life (t1/2,"Pharmacokinetic analysis indicated that at rest, OV had a significantly higher absorption rate constant (Ka 0.0757 vs. 0.0397 min-1), lower elimination rate constant (Ke 0.0027 vs. 0.0045 min-1), and longer serum half-life (t1/2 4.37 vs. 2.59 h) in comparison to LV.",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),h,2.59,62473,DB00201,Caffeine
,3830245,volume of distribution,"In exercise, as well as at rest LV and OV had a large difference in the volume of distribution (43.2 vs. 101.1) (rest, 54.1 vs. 103.1).",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),,43.2,62474,DB00201,Caffeine
,3830245,volume of distribution,"In exercise, as well as at rest LV and OV had a large difference in the volume of distribution (43.2 vs. 101.1) (rest, 54.1 vs. 103.1).",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),,101.1,62475,DB00201,Caffeine
,3830245,volume of distribution,"In exercise, as well as at rest LV and OV had a large difference in the volume of distribution (43.2 vs. 101.1) (rest, 54.1 vs. 103.1).",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),,54.1,62476,DB00201,Caffeine
,3830245,volume of distribution,"In exercise, as well as at rest LV and OV had a large difference in the volume of distribution (43.2 vs. 101.1) (rest, 54.1 vs. 103.1).",The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3830245/),,103.1,62477,DB00201,Caffeine
,10492057,area under the plasma concentration-time curve (AUCinf),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),h·mg,93.01,63087,DB00201,Caffeine
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),1/[h],2.88,63088,DB00201,Caffeine
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),h·mg,83.0,63089,DB00201,Caffeine
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),1/[h],2.06,63090,DB00201,Caffeine
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),h·mg,84.7,63091,DB00201,Caffeine
,10492057,absorption rate constant (ka),"The average area under the plasma concentration-time curve (AUCinf) was 93.01 mg 1(-1) x h and the absorption rate constant (ka) was 2.88 h(-1) during the ovulatory phase, 83.0 mg 1(-1) h and 2.06 h(-1), respectively, during the luteal phase and 84.7 mg 1(-1) x h and 1.84 h(-1), respectively, during the follicular phase.","The effect of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10492057/),1/[h],1.84,63092,DB00201,Caffeine
,7329425,plasma half-live,"The mean plasma half-live of theophylline was 22.3 h, the clearance 28.3 ml/kg/h and the volume of distribution 0.9 l/kg.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),h,22.3,65016,DB00201,Caffeine
,7329425,clearance,"The mean plasma half-live of theophylline was 22.3 h, the clearance 28.3 ml/kg/h and the volume of distribution 0.9 l/kg.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[ml] / [h·kg],28.3,65017,DB00201,Caffeine
,7329425,volume of distribution,"The mean plasma half-live of theophylline was 22.3 h, the clearance 28.3 ml/kg/h and the volume of distribution 0.9 l/kg.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[l] / [kg],0.9,65018,DB00201,Caffeine
,7329425,plasma half-live,"For caffeine a plasma half-live of 70.6 h, a clearance of 8.6 ml/h/kg and a volume of distribution of 0.84 l/kg was found.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),h,70.6,65019,DB00201,Caffeine
,7329425,clearance,"For caffeine a plasma half-live of 70.6 h, a clearance of 8.6 ml/h/kg and a volume of distribution of 0.84 l/kg was found.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[ml] / [h·kg],8.6,65020,DB00201,Caffeine
,7329425,volume of distribution,"For caffeine a plasma half-live of 70.6 h, a clearance of 8.6 ml/h/kg and a volume of distribution of 0.84 l/kg was found.",[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[l] / [kg],0.84,65021,DB00201,Caffeine
,7329425,rapidly effective plasma concentrations,A first oral dose of 7-9 mg/kg theophylline or caffeine should be administered to reach rapidly effective plasma concentrations of about 10 micrograms/ml.,[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329425/),[μg] / [ml],10,65022,DB00201,Caffeine
,9629989,Cmax,"The mean +/-SEM value for creatine Cmax was 1.22+/-0.14 mmol x l(-1), tmax 92+/-7 min and plasma half-life (t1/2beta) 172+/-21 min.",Creatine and caffeine in anaerobic and aerobic exercise: effects on physical performance and pharmacokinetic considerations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629989/),[mM] / [l],1.22,65878,DB00201,Caffeine
,9629989,tmax,"The mean +/-SEM value for creatine Cmax was 1.22+/-0.14 mmol x l(-1), tmax 92+/-7 min and plasma half-life (t1/2beta) 172+/-21 min.",Creatine and caffeine in anaerobic and aerobic exercise: effects on physical performance and pharmacokinetic considerations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629989/),min,92,65879,DB00201,Caffeine
,9629989,plasma half-life (t1/2beta),"The mean +/-SEM value for creatine Cmax was 1.22+/-0.14 mmol x l(-1), tmax 92+/-7 min and plasma half-life (t1/2beta) 172+/-21 min.",Creatine and caffeine in anaerobic and aerobic exercise: effects on physical performance and pharmacokinetic considerations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629989/),min,172,65880,DB00201,Caffeine
,30825803,flow rate,"In this study, a reversed-phase chromatography was performed at room temperature on a C18 column with a mobile phase composed of 10 mM Na2HPO4 solution (pH 7.5): acetonitrile (45:55, v/v) at a flow rate of 0.8 mL min-1 using caffeine (CAF) as an internal standard.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[ml] / [min],0.8,66387,DB00201,Caffeine
,30825803,total analysis time,The total analysis time was 6 min.,Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),min,6,66388,DB00201,Caffeine
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.05,66389,DB00201,Caffeine
,30825803,detection limit,"Calibration graphs were linear in the concentration ranges of 0.1-10 and 0.05-10 μg mL-1 with a detection limit of 0.05 and 0.02 μg mL-1 for TMD and SDF, respectively.",Development and validation of an HPLC-UV method for simultaneous determination of sildenafil and tramadol in biological fluids: Application to drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30825803/),[μg] / [ml],0.02,66390,DB00201,Caffeine
,16671554,flow rate,"The analytes and the internal standard, diphenhydramine, were isolated from plasma by protein precipitation with methanol, then chromatographied on a Zorbax SB-C18 column (150 mm x 4.6 mm ID) using a mobile phase consisted of methanol-water-formic acid (80: 20: 0.5, v/v), at a flow rate of 0.5 mL x min(-1).",[Simultaneous determination of ephedrine and chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16671554/),[ml] / [min],0.5,67438,DB00201,Caffeine
,15619608,clearance,"Moreover, the clearance of caffeine mediated by CYP1A2 in CCl(4)-treated rats was estimated as 0.47+/-0.05 mL/min/kg by using the predicted amount of CYP1A2.",Application of the PKCYP test to predict caffeine clearance mediated by CYP1A2 in a rat acute liver injury model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15619608/),[ml] / [kg·min],0.47,67554,DB00201,Caffeine
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.03,69860,DB00201,Caffeine
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.05,69861,DB00201,Caffeine
,20736520,t(1/2λz),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),h,9.68,69862,DB00201,Caffeine
,20736520,Cl(T),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),[h·l] / [kg],0.08,69863,DB00201,Caffeine
,20736520,t(1/2λz),"Elimination of CF was slow in the MK (Cl(T); 0.03 ± 0.01 l hr/kg, t(1/2λz); 15.74 ± 7.35 hr) and AM (Cl(T); 0.05 ± 0.02 l hr/kg, t(1/2λz); 9.68 ± 5.21 hr) breeds when compared with the AK breed (Cl(T); 0.08 ± 0.01 l hr/kg, t(1/2λz); 6.84 ± 0.79 hr).",Comparative pharmacokinetics and metabolisms of caffeine in sheep breeds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736520/),h,6.84,69864,DB00201,Caffeine
,26562367,half-life,The mean caffeine half-life was 87±25 h at 35±1 weeks postmenstrual age.,Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26562367/),h,87,70034,DB00201,Caffeine
,2390669,volume of distribution (Vd),"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),[l] / [kg],1.16,70866,DB00201,Caffeine
,2390669,volume of distribution (Vd),"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),[l] / [kg],0.88,70867,DB00201,Caffeine
,2390669,plasma elimination half-life (t1/2),"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),h,1.25,70868,DB00201,Caffeine
,2390669,plasma elimination half-life (t1/2),"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),h,1.62,70869,DB00201,Caffeine
,2390669,brain t1/2,"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),h,0.93,70870,DB00201,Caffeine
,2390669,brain t1/2,"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),h,1.30,70871,DB00201,Caffeine
,2390669,clearance,"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),[l] / [h·kg],0.64,70872,DB00201,Caffeine
,2390669,clearance,"3. Kinetic variables for caffeine at low and high caffeine doses were: volume of distribution (Vd), 1.16 and 0.88 l kg-1; plasma elimination half-life (t1/2), 1.25 and 1.62 h; brain t1/2, 0.93 and 1.30 h; clearance, 0.64 and 0.38 l h-1 kg-1, respectively, with Vd and brain t1/2 differing significantly between the two caffeine doses.",Caffeine-induced behavioural stimulation is dose- and concentration-dependent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390669/),[l] / [h·kg],0.38,70873,DB00201,Caffeine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],126,71722,DB00201,Caffeine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],106,71723,DB00201,Caffeine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],152.6,71724,DB00201,Caffeine
,10217339,partial metabolic clearance,"Also, the partial metabolic clearance of R-(-)-mexiletine to N-hydroxymexiletine glucuronide was reduced from 126 +/- 48 mL/min to 106 +/- 32 mL/min and 152.6 (73.4-196.2) mL/min to 109 (77-127) mL/min by the coadministration of caffeine in EMs and PMs, respectively.",Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10217339/),[ml] / [min],109,71725,DB00201,Caffeine
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,6.2,73374,DB00201,Caffeine
,7751591,plasma half-life,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),h,3.5,73375,DB00201,Caffeine
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],1.3,73376,DB00201,Caffeine
,7751591,plasma clearance,There were significant changes in caffeine plasma half-life (6.2 vs. 3.5 h; p < 0.004) and caffeine plasma clearance (1.3 vs. 2.2 ml/kg per min; p < 0.004) with rifampin.,The influence of rifampin treatment on caffeine clearance in healthy man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7751591/),[ml] / [kg·min],2.2,73377,DB00201,Caffeine
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],6.88,74098,DB00201,Caffeine
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],10.09,74099,DB00201,Caffeine
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],6.22,74100,DB00201,Caffeine
,23996078,total apparent caffeine clearance (CL),"Among LCCs (n = 16) and MCCs (n = 9), there was no difference in the mean (95% confidence interval) total apparent caffeine clearance (CL) between the MA period [LCCs: 6.88 (5.61-8.16 l/h); MCCs: 10.09 (7.57-12.60 l/h)] versus the no MA period [LCCs: 6.22 (4.97-7.46 l/h); MCCs: 9.68 (7.12-12.24 l/h)].",A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],9.68,74101,DB00201,Caffeine
,23996078,CL,The mean CL among HCCs (n = 5) was considerably higher in the MA period [10.48 (5.62-15.33 l/h)] compared with the no MA period [6.30 (3.40-9.20 l/h)] (P < 0.05).,A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],10.48,74102,DB00201,Caffeine
,23996078,CL,The mean CL among HCCs (n = 5) was considerably higher in the MA period [10.48 (5.62-15.33 l/h)] compared with the no MA period [6.30 (3.40-9.20 l/h)] (P < 0.05).,A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23996078/),[l] / [h],6.30,74103,DB00201,Caffeine
,16734985,CL(uptake),"A kinetic analysis indicated that a compound with a slower CL(uptake) and longer half-life (e.g., theophylline) is more prone to error and that the lower limit of the CL(uptake) of 0.17 mL min(-1) (g brain)(-1) may be set so as to have an error less than 20% of the estimation.",Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16734985/),[ml] / [brain·g·min],0.17,78194,DB00201,Caffeine
greater,16734985,uptake clearance,These results suggest that the sample pooling method is applicable for use in the accelerated estimation of the uptake clearance of compounds in the brain for which the value is greater than 0.17 mL min(-1) (g brain)(-1).,Application of a sample pooling method for the accelerated assessment of the rate of uptake of drugs by the brain in rats. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16734985/),[ml] / [brain·g·min],0.17,78195,DB00201,Caffeine
,32175611,m/,"Precursor-to-product ion transitions were m/z 267.0 → 168.2 and m/z 195.0 → 138.1 for quantitative monitoring of 5-hydroxy-4-methoxycanthin-6-one and IS, respectively.","Pharmacokinetic and bioavailability study of 5-hydroxy-4-methoxycanthin-6-one, a typical canthinone alkaloid, in rats using ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175611/),,267.0,79230,DB00201,Caffeine
,32175611,m/z,"Precursor-to-product ion transitions were m/z 267.0 → 168.2 and m/z 195.0 → 138.1 for quantitative monitoring of 5-hydroxy-4-methoxycanthin-6-one and IS, respectively.","Pharmacokinetic and bioavailability study of 5-hydroxy-4-methoxycanthin-6-one, a typical canthinone alkaloid, in rats using ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175611/),,195.0,79231,DB00201,Caffeine
,32175611,m/z,"Precursor-to-product ion transitions were m/z 267.0 → 168.2 and m/z 195.0 → 138.1 for quantitative monitoring of 5-hydroxy-4-methoxycanthin-6-one and IS, respectively.","Pharmacokinetic and bioavailability study of 5-hydroxy-4-methoxycanthin-6-one, a typical canthinone alkaloid, in rats using ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175611/),,138.1,79232,DB00201,Caffeine
,32175611,elimination half-life,"The result indicated that 5-hydroxy-4-methoxycanthin-6-one was quickly absorbed into the blood and reached the highest concentration at ~33.0-42.0 min, with moderate elimination half-life (0.85-2.11 h) and low bioavailability (16.62-24.42%) after oral administration.","Pharmacokinetic and bioavailability study of 5-hydroxy-4-methoxycanthin-6-one, a typical canthinone alkaloid, in rats using ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175611/),h,0.85-2.11,79233,DB00201,Caffeine
,32175611,bioavailability,"The result indicated that 5-hydroxy-4-methoxycanthin-6-one was quickly absorbed into the blood and reached the highest concentration at ~33.0-42.0 min, with moderate elimination half-life (0.85-2.11 h) and low bioavailability (16.62-24.42%) after oral administration.","Pharmacokinetic and bioavailability study of 5-hydroxy-4-methoxycanthin-6-one, a typical canthinone alkaloid, in rats using ultra-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32175611/),%,16.62-24.42,79234,DB00201,Caffeine
,3356110,serum,"2. In the control group, the mean (+/- SD) serum caffeine clearance was 1.3 +/- 0.4 ml min-1 kg-1 and a mean of 56.4 +/- 16.5% of the administered caffeine was recovered from the urine over 48 h as methyluric acids and methylxanthines.",Caffeine clearance and biotransformation in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356110/),[ml] / [kg·min],1.3,79474,DB00201,Caffeine
,3356110,serum ca,Thus the mean serum caffeine clearance was 1.4 +/- 1.2 ml min-1 kg-1 and a mean of 57.2 +/- 11.7% of the administered caffeine was recovered from the urine over 48 h.,Caffeine clearance and biotransformation in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356110/),[ml] / [kg·min],1.4,79475,DB00201,Caffeine
,3356110,clearance,The mean serum caffeine clearance (0.4 +/- 0.2 ml min-1 kg-1) was significantly impaired compared with controls (P less than 0.01) and a significant delay was observed in metabolite excretion in the urine.,Caffeine clearance and biotransformation in patients with chronic liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3356110/),[ml] / [kg·min],0.4,79476,DB00201,Caffeine
,3371147,Half-life,"Half-life was 6.6 +/- 5.7 h, plasma clearance 0.44 +/- 0.1 litres/kg/h, and calculated volume of distribution 4 +/- 2.7 litres/kg.",Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371147/),h,6.6,80162,DB00201,Caffeine
,3371147,plasma clearance,"Half-life was 6.6 +/- 5.7 h, plasma clearance 0.44 +/- 0.1 litres/kg/h, and calculated volume of distribution 4 +/- 2.7 litres/kg.",Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371147/),[l] / [h·kg],0.44,80163,DB00201,Caffeine
,3371147,volume of distribution,"Half-life was 6.6 +/- 5.7 h, plasma clearance 0.44 +/- 0.1 litres/kg/h, and calculated volume of distribution 4 +/- 2.7 litres/kg.",Pharmacokinetics of doxapram in idiopathic apnea of prematurity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371147/),[l] / [kg],4,80164,DB00201,Caffeine
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.95,81454,DB00201,Caffeine
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.01,81455,DB00201,Caffeine
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.97,81456,DB00201,Caffeine
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81457,DB00201,Caffeine
,29178272,AUC ratios,"Following a single 200 mg dose of modafinil mean (± 95% CI) AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.95 (± 0.08), 1.01 (± 0.35), 0.97 (± 0.10), 0.98 (± 0.10) and 1.36 (± 0.06), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.36,81458,DB00201,Caffeine
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.90,81459,DB00201,Caffeine
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.79,81460,DB00201,Caffeine
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.98,81461,DB00201,Caffeine
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,0.66,81462,DB00201,Caffeine
,29178272,AUC ratios,"Following dosing of modafinil to steady state (200 mg for 7 days), AUC ratios for caffeine, dextromethorphan, losartan, midazolam and omeprazole were 0.90 (± 0.16), 0.79 (± 0.09), 0.98 (± 0.11), 0.66 (± 0.12) and 1.90 (± 0.53), respectively.",Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178272/),,1.90,81463,DB00201,Caffeine
,8489790,steady-state (SS) 'peaks',"Application of these models to an independent group (phase II, n = 20) generated doses which satisfactorily achieved target theophylline loading and steady-state (SS) 'peaks' of 10 micrograms/mL and SS 'troughs' of 7.7 +/- 0.6 micrograms/mL.",Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489790/),[μg] / [ml],10,81657,DB00201,Caffeine
,8489790,SS 'troughs',"Application of these models to an independent group (phase II, n = 20) generated doses which satisfactorily achieved target theophylline loading and steady-state (SS) 'peaks' of 10 micrograms/mL and SS 'troughs' of 7.7 +/- 0.6 micrograms/mL.",Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489790/),[μg] / [ml],7.7,81658,DB00201,Caffeine
,23884660,flow rate,"The mobile phase consisted of methanol and 0.02 mol/L potassium dihydrogen phosphate-phosphoric acid buffer solution (pH 3.2) (30:70, v/v) at a flow rate of 1 mL/min for 8.5 min.",Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),[ml] / [min],1,81926,DB00201,Caffeine
,23884660,retention times,"The retention times of isocorydine and caffeine were approximately 6.5 and 5.1 min, respectively.",Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),min,6.5,81927,DB00201,Caffeine
,23884660,retention times,"The retention times of isocorydine and caffeine were approximately 6.5 and 5.1 min, respectively.",Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),min,5.1,81928,DB00201,Caffeine
≥,23884660,signal to noise ratio (S/N),"The lower limit of quantification (LLOQ) was 0.05 µg/mL [signal to noise ratio (S/N)≥10], and the limit of detection (LOD) was demonstrated as 0.01 µg/mL (S/N≥3).",Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),,10,81929,DB00201,Caffeine
,23884660,limit of detection (LOD),"The lower limit of quantification (LLOQ) was 0.05 µg/mL [signal to noise ratio (S/N)≥10], and the limit of detection (LOD) was demonstrated as 0.01 µg/mL (S/N≥3).",Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),[μg] / [ml],0.01,81930,DB00201,Caffeine
≥,23884660,S/N,"The lower limit of quantification (LLOQ) was 0.05 µg/mL [signal to noise ratio (S/N)≥10], and the limit of detection (LOD) was demonstrated as 0.01 µg/mL (S/N≥3).",Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),,3,81931,DB00201,Caffeine
,23884660,extraction recovery,The mean extraction recovery ranged from 83.7% to 89.5% at 3 quality control (QC) concentrations.,Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),%,83.7,81932,DB00201,Caffeine
,23884660,extraction recovery,The mean extraction recovery ranged from 83.7% to 89.5% at 3 quality control (QC) concentrations.,Development and validation of a high-performance liquid chromatography coupled with ultraviolet detection method for the determination of isocorydine in rat plasma and its application in pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23884660/),%,89.5,81933,DB00201,Caffeine
,17971810,half-lives,"The half-lives of CYP3A4 and CYP1A2 were estimated to be 70 and 105 h, respectively.","Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971810/),h,70,81949,DB00201,Caffeine
,17971810,half-lives,"The half-lives of CYP3A4 and CYP1A2 were estimated to be 70 and 105 h, respectively.","Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17971810/),h,105,81950,DB00201,Caffeine
,8738770,Measurable,Measurable caffeine concentrations in serum ranged from 0.28 to 93.3 mg/L and in saliva from 0.35 to 91.5 mg/L.,Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738770/),,0.28 to 93.3,83243,DB00201,Caffeine
,902456,peak plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],194 to 340,84173,DB00201,Caffeine
,902456,peak codeine plasma concentrations,"Following intramuscular administration, peak plasma concentrations (194 to 340 ng/ml) were observed between 0.25 to 1 hr; after oral dosing, peak codeine plasma concentrations (102 to 140 ng/ml) appeared within 0.75 to 1 hr.",Codeine kinetics as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[ng] / [ml],102 to 140,84174,DB00201,Caffeine
,902456,plasma t1/2,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),h,3.32,84175,DB00201,Caffeine
,902456,volume of distribution,"The mean plasma t1/2 and volume of distribution of codeine following intramuscular injection were 3.32 hr and 5.1 L/kg, respectively.",Codeine kinetics as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),[l] / [kg],5.1,84176,DB00201,Caffeine
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,42,84177,DB00201,Caffeine
,902456,bioavailability,"Oral, relative to intramuscular, bioavailability of codeine, based on areas under the codeine plasma curves, was 42% to 71% (mean, 53%).",Codeine kinetics as determined by radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/902456/),%,53,84178,DB00201,Caffeine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,1.5,84231,DB00201,Caffeine
,15060511,elimination half-life,The mean elimination half-life of tizanidine was prolonged from 1.5 to 4.3 hours (P =.00004) by fluvoxamine.,Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060511/),h,4,84232,DB00201,Caffeine
,33626528,Clearance,"Clearance of caffeine was 9.99 mL/h for a typical preterm neonate with a birth weight of 0.8 kg and 23 days postnatal age and increased with birth weight and postnatal age, resulting in a 4-fold increase in clearance during the first month of life.",The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626528/),[ml] / [h],9.99,84751,DB00201,Caffeine
,3366822,detection limits,The calibration curves were linear (r = 0.999) from 2.5 to 500 micrograms/ml; the detection limits were 100 ng/ml for DACXM and 250 ng/ml for CXM and CFX.,"High-performance liquid chromatographic assay of cefotaxime, desacetylcefotaxime and ceftriaxone in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366822/),[ng] / [ml],100,85908,DB00201,Caffeine
,3366822,detection limits,The calibration curves were linear (r = 0.999) from 2.5 to 500 micrograms/ml; the detection limits were 100 ng/ml for DACXM and 250 ng/ml for CXM and CFX.,"High-performance liquid chromatographic assay of cefotaxime, desacetylcefotaxime and ceftriaxone in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366822/),[ng] / [ml],250,85909,DB00201,Caffeine
,8841149,peak plasma levels,"Nasally administered dihydroergotamine (1 mg) becomes rapidly available to the systemic circulation, with peak plasma levels of 1 ng/ml achieved in 0.9 hour.",Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),[ng] / [ml],1,88362,DB00201,Caffeine
,8841149,relative bioavailability,The relative bioavailability versus intramuscular route is 38.4%.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,38.4,88363,DB00201,Caffeine
,8841149,bioavailability,Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,29,88364,DB00201,Caffeine
,8841149,bioavailability,Intraindividual variations of bioavailability evaluated for a 1-year period were higher (29%) than those found for the intramuscular route (20%) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,20,88365,DB00201,Caffeine
,8841149,bioavailability,Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,25,88366,DB00201,Caffeine
,8841149,bioavailability,Interindividual variations for bioavailability were greater (25% versus 14% by the intramuscular route) but comparable to the oral route.,Human pharmacokinetics of dihydroergotamine administered by nasal spray. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8841149/),%,14,88367,DB00201,Caffeine
,26619825,bioavailability,The bioavailability of orally applied caffeine was also significantly decreased (p = 0.022) after the EO treatment in comparison with the control (57 ± 24% vs. 101 ± 29%).,"Pharmacokinetic Herb-Drug Interaction between Essential Oil of Aniseed (Pimpinella anisum L., Apiaceae) and Acetaminophen and Caffeine: A Potential Risk for Clinical Practice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26619825/),%,57,88607,DB00201,Caffeine
,26619825,bioavailability,The bioavailability of orally applied caffeine was also significantly decreased (p = 0.022) after the EO treatment in comparison with the control (57 ± 24% vs. 101 ± 29%).,"Pharmacokinetic Herb-Drug Interaction between Essential Oil of Aniseed (Pimpinella anisum L., Apiaceae) and Acetaminophen and Caffeine: A Potential Risk for Clinical Practice. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26619825/),%,101,88608,DB00201,Caffeine
,3183872,salivary,The calculated salivary caffeine clearance was comparable in the 34 nonhepatopatic CF patients (1.88 +/- 0.46 ml/min/kg) and in the control group (1.88 +/- 0.44 ml/min/kg).,Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183872/),[ml] / [kg·min],1.88,88790,DB00201,Caffeine
,3183872,salivary,The calculated salivary caffeine clearance was comparable in the 34 nonhepatopatic CF patients (1.88 +/- 0.46 ml/min/kg) and in the control group (1.88 +/- 0.44 ml/min/kg).,Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183872/),[ml] / [kg·min],1.88,88791,DB00201,Caffeine
,3183872,clearance,"The salivary caffeine clearance was reduced in seven hepatopathic CF patients (1.32 +/- 0.63 ml/min/kg, p less than 0.01); nevertheless, the salivary caffeine clearance was reduced (boundary line at 1.1 ml/min/kg) in three CF patients with proven liver cirrhosis but not in four with hepatosplenomegaly and altered liver tests.",Use of salivary levels to predict clearance of caffeine in patients with cystic fibrosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3183872/),[ml] / [kg·min],1.32,88792,DB00201,Caffeine
,6126344,half-life,"The half-life of caffeine in both serum and saliva was approximately 3 hr, with the concentration of caffeine in the saliva samples ranging from 65 to 85% of that found in the serum samples.",Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126344/),h,3,90803,DB00201,Caffeine
,1379152,half-life,It is likely that migraine recurrence is related to the short half-life of the drug (approximately 2 hours).,"Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1379152/),h,2,90807,DB00201,Caffeine
,29173321,maximal trough caffeine concentration,A standard dosing regimen of caffeine citrate (using a 20 mg/kg loading dose and 5 mg/kg/day maintenance dose) is associated with a maximal trough caffeine concentration of 15 mg/L after 1 week of treatment.,Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29173321/),[mg] / [l],15,91431,DB00201,Caffeine
,29173321,trough concentration,"Model-based simulations indicate that an adjusted maintenance dose of 6 mg/kg/day in the second week, 7 mg/kg/day in the third to fourth week and 8 mg/kg/day in the fifth to eighth week assures stable caffeine concentrations with a target trough concentration of 15 mg/L.",Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29173321/),[mg] / [l],15,91432,DB00201,Caffeine
,27662634,EPC,"EPC of theobromine was calculated with 3.80 µg/mL, and irrelevant concentrations of theobromine were determined at 8 ng/mL in plasma and at 142 ng/mL in urine.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[μg] / [ml],3.80,91484,DB00201,Caffeine
,27662634,EPC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[μg] / [ml],3.20,91485,DB00201,Caffeine
,27662634,EPC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[ng] / [ml],6,91486,DB00201,Caffeine
,27662634,IUC,"Toutain modelling of the theophylline data produced an EPC, IPC, and IUC of 3.20 µg/mL, 6 ng/mL, and 75 ng/mL, respectively.","Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27662634/),[ng] / [ml],75,91487,DB00201,Caffeine
,12915014,M/F,"Their medium term was 31.4 weeks (27.4-33.3 weeks), birth weight was 1684 g (1000-2800 g) and sex-ratio M/F was 1.3.",[Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915014/),,1.3,94034,DB00201,Caffeine
,12915014,medium loading residual rate,The medium loading residual rate was 3.26 microg/ml (1.75-7.80) and the medium maintenance residual rate was 4.26 microg/ml (2.13-7.64).,[Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915014/),[μg] / [ml],3.26,94035,DB00201,Caffeine
,12915014,medium maintenance residual rate,The medium loading residual rate was 3.26 microg/ml (1.75-7.80) and the medium maintenance residual rate was 4.26 microg/ml (2.13-7.64).,[Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915014/),[μg] / [ml],4.26,94036,DB00201,Caffeine
,25594527,fractional absorbance,Theophylline may be administered trans-cutaneously by applying this drug to the back or abdomen of the infants and the mean fractional absorbance at 30 hours is 0.25.,"Clinical pharmacology of theophylline in preterm infants: effects, metabolism and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594527/),,0.25,94214,DB00201,Caffeine
,6700656,Peak serum levels,"Peak serum levels of caffeine (13.5 +/- 2.9 mg per liter) occurred at one hour, and peak levels of theophylline (8.4 +/- 1.7 mg per liter) at 2.2 +/- 0.8 hours.",The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),[mg] / [l],13.5,94488,DB00201,Caffeine
,6700656,peak levels,"Peak serum levels of caffeine (13.5 +/- 2.9 mg per liter) occurred at one hour, and peak levels of theophylline (8.4 +/- 1.7 mg per liter) at 2.2 +/- 0.8 hours.",The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),[mg] / [l],8.4,94489,DB00201,Caffeine
,6700656,serum half-time,The mean serum half-time for caffeine was 3.9 +/- 1.4 hours and that for theophylline was 5.8 +/- 1.7 hours.,The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),h,3.9,94490,DB00201,Caffeine
,6700656,serum half-time,The mean serum half-time for caffeine was 3.9 +/- 1.4 hours and that for theophylline was 5.8 +/- 1.7 hours.,The bronchodilator effects and pharmacokinetics of caffeine in asthma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6700656/),h,5.8,94491,DB00201,Caffeine
,434905,half life,"In a pharmacokinetic study, the half life of theophylline was 30.3 +/- 7.2 hours and the clearance rate was 23.9 +/- 5.06 ml/kg per hour (means and SD).",Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434905/),h,30.3,96902,DB00201,Caffeine
,434905,clearance rate,"In a pharmacokinetic study, the half life of theophylline was 30.3 +/- 7.2 hours and the clearance rate was 23.9 +/- 5.06 ml/kg per hour (means and SD).",Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/434905/),[ml] / [h·kg],23.9,96903,DB00201,Caffeine
,12100222,CL,Pharmacokinetic parameter estimates [mean (coefficient of variation%)] were CL=0.00628 (17.5%) l h-1 and V=0.961 (20.3%) l.,Caffeine in apnoeic Asian neonates: a sparse data analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100222/),[l] / [h],0.00628,97048,DB00201,Caffeine
,12100222,V,Pharmacokinetic parameter estimates [mean (coefficient of variation%)] were CL=0.00628 (17.5%) l h-1 and V=0.961 (20.3%) l.,Caffeine in apnoeic Asian neonates: a sparse data analysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12100222/),l,0.961,97049,DB00201,Caffeine
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,79.6,97399,DB00201,Caffeine
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,10.8,97400,DB00201,Caffeine
,3756066,fractional conversion,"The mean (+/- s.d.) fractional conversion of CA to PX, TB and TP was 79.6 +/- 21.0%, 10.8 +/- 2.4% and 3.7 +/- 1.3%, respectively.",Quantitative assessment of caffeine partial clearances in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756066/),%,3.7,97401,DB00201,Caffeine
over,1257607,peak plasma concentration,"Theophylline peak plasma concentration of over 170 ng/ml average was observed when 300 mg of caffeine, equivalent to 2-3 cups of coffee, was administered to humans.",The human metabolism of caffeine to theophylline. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1257607/),[ng] / [ml],170,97595,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.58,98193,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,2.1,98194,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.4,98195,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.1,98196,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.4,98197,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.5,98198,DB00201,Caffeine
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.7,98199,DB00201,Caffeine
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.3,98200,DB00201,Caffeine
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,3.1,98201,DB00201,Caffeine
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.8,98202,DB00201,Caffeine
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.2,98203,DB00201,Caffeine
,3690940,clearance,The clearance of caffeine declined markedly from 110 +/- 17 ml/min (mean +/- SE) in the control study to 34 +/- 5 ml/min after methoxsalen.,Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690940/),[ml] / [min],110,99599,DB00201,Caffeine
,3690940,clearance,The clearance of caffeine declined markedly from 110 +/- 17 ml/min (mean +/- SE) in the control study to 34 +/- 5 ml/min after methoxsalen.,Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690940/),[ml] / [min],34,99600,DB00201,Caffeine
,3690940,elimination half-life,During the period of maximum inhibition the mean elimination half-life of caffeine increased from 5.6 hours at baseline to 57 hours after administration of methoxsalen.,Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690940/),h,5.6,99601,DB00201,Caffeine
,3690940,elimination half-life,During the period of maximum inhibition the mean elimination half-life of caffeine increased from 5.6 hours at baseline to 57 hours after administration of methoxsalen.,Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3690940/),h,57,99602,DB00201,Caffeine
,8485024,Ki,2. In vitro naringin was a potent competitive inhibitor of caffeine 3-demethylation by human liver microsomes (Ki = 7-29 microM).,"Inhibitory effect of grapefruit juice and its bitter principal, naringenin, on CYP1A2 dependent metabolism of caffeine in man. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8485024/),μM,7-29,100340,DB00201,Caffeine
,6824226,apparent beta-phase half-life,"Plasma concentrations of the drug peaked at 10 micrograms/ml and decreased rapidly at first, and then more slowly, with an apparent beta-phase half-life of 18.2 hours.","Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824226/),h,18.2,101218,DB00201,Caffeine
,6824226,apparent bioavailability,"After oral administration, caffeine was absorbed poorly with an apparent bioavailability of 39%.","Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824226/),%,39,101219,DB00201,Caffeine
,6824226,apparent plasma half-life,"Although blood concentrations of caffeine peaked rapidly after oral administration, its apparent plasma half-life by this route was about 42 hours.","Pharmacology, pharmacokinetics, and behavioral effects of caffeine in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6824226/),h,42,101220,DB00201,Caffeine
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],0.1,101755,DB00201,Caffeine
,10096258,inhibition constant (Ki),"In vitro, norfloxacin and pefloxacin competitively inhibited CYP1A2, with inhibition constant (Ki) values of 0.1 and 1 mmol/L, respectively, and CYP1A2 was the only enzyme with a relevant contribution (approximately 50%) to pefloxacin N-4'-demethylation.",Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096258/),[mM] / [l],1,101756,DB00201,Caffeine
,22122233,plasma C(max),AZD7325 reached a plasma C(max) of 0.2 µm after 10 mg daily dosing to steady-state.,"A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122233/),µm,0.2,102647,DB00201,Caffeine
,22122233,CL/F,The mean CL/F of midazolam increased from 62 l h(-1) (midazolam alone) to 76 l h(-1) when co-administered with AZD7325.,"A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122233/),[l] / [h],62,102648,DB00201,Caffeine
,22122233,CL/F,The mean CL/F of midazolam increased from 62 l h(-1) (midazolam alone) to 76 l h(-1) when co-administered with AZD7325.,"A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22122233/),[l] / [h],76,102649,DB00201,Caffeine
,33293242,plasma elimination half-life,The plasma elimination half-life of caffeine in the newborn is approximately 100 h.,"Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33293242/),h,100,103059,DB00201,Caffeine
,1778539,Km,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),[mg] / [l],0.42,106049,DB00201,Caffeine
,1778539,Vm,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),,7.54,106050,DB00201,Caffeine
,1778539,Vm,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),,2.01,106051,DB00201,Caffeine
,1778539,Vm,"Hypothesis testing produced a final model in which Km = 0.42 (mg/l), and Vm (mg/kg per day) was based on cigarette smoking and dosage form, with Vm = 7.54 + 2.01 (smoking) + 1.08 (euphylline).",Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),,1.08,106052,DB00201,Caffeine
,1778539,Residual,Residual variability in dosage rates was estimated as 0.90 mg/kg per day.,Steady-state population pharmacokinetics of sustained release theophylline in adult asthmatic patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1778539/),mg,0.90,106053,DB00201,Caffeine
,6954898,half-life,The half-life of caffeine increases from an average of 3 h for non-pregnant women to 10.5 h during the last 4 weeks of pregnancy.,The effect of pregnancy on the pharmacokinetics of caffeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6954898/),h,3,106677,DB00201,Caffeine
,6954898,half-life,The half-life of caffeine increases from an average of 3 h for non-pregnant women to 10.5 h during the last 4 weeks of pregnancy.,The effect of pregnancy on the pharmacokinetics of caffeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6954898/),h,10.5,106678,DB00201,Caffeine
,3689487,total amount,"The total amount of ceftriaxone excreted in urine and feces was increased significantly (p less than 0.05) from 13.1 +/- 1.8 mg (mean +/- SD, 54.6% of total) to 15.3 +/- 1.1 mg (63.8% of total) by caffeine coadministration.",Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689487/),,13,106986,DB00201,Caffeine
,3689487,total amount,"The total amount of ceftriaxone excreted in urine and feces was increased significantly (p less than 0.05) from 13.1 +/- 1.8 mg (mean +/- SD, 54.6% of total) to 15.3 +/- 1.1 mg (63.8% of total) by caffeine coadministration.",Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689487/),,15,106987,DB00201,Caffeine
,3689487,terminal half-life,"The terminal half-life of ceftriaxone in plasma was shortened from 59 to 47 min, and the area under the plasma drug concentration-time curve (AUC) was reduced from 612 to 516 micrograms hr/ml.",Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689487/),min,59 to 47,106988,DB00201,Caffeine
,3689487,area under the plasma drug concentration-time curve (AUC),"The terminal half-life of ceftriaxone in plasma was shortened from 59 to 47 min, and the area under the plasma drug concentration-time curve (AUC) was reduced from 612 to 516 micrograms hr/ml.",Effect of caffeine on ceftriaxone disposition and plasma protein binding in the rat. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689487/),[h·μg] / [ml],612 to 516,106989,DB00201,Caffeine
,3395670,plasma time to peaks,"Caffeine was rapidly absorbed producing plasma time to peaks ranging from 0.50 to 1.00 h, with values for peak concentrations between 3.60 and 6.15 micrograms ml-1 in plasma.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),h,0.50 to 1.00,108816,DB00201,Caffeine
,3395670,peak concentrations,"Caffeine was rapidly absorbed producing plasma time to peaks ranging from 0.50 to 1.00 h, with values for peak concentrations between 3.60 and 6.15 micrograms ml-1 in plasma.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),[μg] / [ml],3.60 and 6.15,108817,DB00201,Caffeine
,3395670,time to peak,"In breast milk, time to peak ranged from 0.75 to 2.00 h and concentration values between 1.98 and 4.30 micrograms ml-1.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),h,0.75 to 2.00,108818,DB00201,Caffeine
,3395670,overall breast milk/plasma ratio,"The overall breast milk/plasma ratio obtained from the respective area under the curves were 0.815 +/- 0.0521 and 0.809 +/- 0.202 for the right and left breast, respectively, and no statistical differences were observed between the right and left breasts, p greater than 0.05.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),,0.815,108819,DB00201,Caffeine
,3395670,overall breast milk/plasma ratio,"The overall breast milk/plasma ratio obtained from the respective area under the curves were 0.815 +/- 0.0521 and 0.809 +/- 0.202 for the right and left breast, respectively, and no statistical differences were observed between the right and left breasts, p greater than 0.05.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),,0.809,108820,DB00201,Caffeine
,3395670,area,"The overall breast milk/plasma ratio obtained from the respective area under the curves were 0.815 +/- 0.0521 and 0.809 +/- 0.202 for the right and left breast, respectively, and no statistical differences were observed between the right and left breasts, p greater than 0.05.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),,0.815,108821,DB00201,Caffeine
,3395670,area,"The overall breast milk/plasma ratio obtained from the respective area under the curves were 0.815 +/- 0.0521 and 0.809 +/- 0.202 for the right and left breast, respectively, and no statistical differences were observed between the right and left breasts, p greater than 0.05.",Pharmacokinetics of caffeine in breast milk and plasma after single oral administration of caffeine to lactating mothers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3395670/),,0.809,108822,DB00201,Caffeine
,7775610,plasma clearance,Mean plasma clearance of caffeine in patients with no liver disease (1.30 +/- 0.79 ml/kg/min) was significantly higher than in patients with liver disease (0.39 +/- 0.23 ml/kg/min).,Caffeine test assessment for measuring liver function in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775610/),[ml] / [kg·min],1.30,109093,DB00201,Caffeine
,7775610,plasma clearance,Mean plasma clearance of caffeine in patients with no liver disease (1.30 +/- 0.79 ml/kg/min) was significantly higher than in patients with liver disease (0.39 +/- 0.23 ml/kg/min).,Caffeine test assessment for measuring liver function in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775610/),[ml] / [kg·min],0.39,109094,DB00201,Caffeine
,7775610,half-life,Mean half-life of caffeine in patients with liver disease (23.96 +/- 12.19 h) was significantly higher than in patients with no liver disease (7.25 +/- 3.04 h).,Caffeine test assessment for measuring liver function in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775610/),h,23.96,109095,DB00201,Caffeine
,7775610,half-life,Mean half-life of caffeine in patients with liver disease (23.96 +/- 12.19 h) was significantly higher than in patients with no liver disease (7.25 +/- 3.04 h).,Caffeine test assessment for measuring liver function in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7775610/),h,7.25,109096,DB00201,Caffeine
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.40,109827,DB00201,Caffeine
,10976551,formation clearance,The median formation clearance of 3-hydroxyquinidine were 2.40 and 2.33 L/h in the two test periods.,"Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10976551/),[l] / [h],2.33,109828,DB00201,Caffeine
,17164694,oral clearance,Concomitant administration of propafenone decreased caffeine oral clearance from 8.3 +/- 0.9 L/h to 5.4 +/- 0.7 L/h (P < 0.05).,Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164694/),[l] / [h],8.3,110982,DB00201,Caffeine
,17164694,oral clearance,Concomitant administration of propafenone decreased caffeine oral clearance from 8.3 +/- 0.9 L/h to 5.4 +/- 0.7 L/h (P < 0.05).,Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17164694/),[l] / [h],5.4,110983,DB00201,Caffeine
,15556542,flow rate,"Chromatographic separation of the analytes was achieved on a C18 column using a mobile phase of methanol, water and acetic acid (50:50:0.6, v/v/v) at a flow rate of 1.0 ml/min.",Liquid chromatography-mass spectrometry method for determination of tetramethylpyrazine and its metabolite in dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556542/),[ml] / [min],1.0,112546,DB00201,Caffeine
,15556542,m/z,"Selected ion monitoring (SIM) mode was used for analyte quantitation at m/z 137.2 for TMP, m/z 153.2 for HTMP and m/z 195.2 for caffeine.",Liquid chromatography-mass spectrometry method for determination of tetramethylpyrazine and its metabolite in dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556542/),,137.2,112547,DB00201,Caffeine
,15556542,m/z,"Selected ion monitoring (SIM) mode was used for analyte quantitation at m/z 137.2 for TMP, m/z 153.2 for HTMP and m/z 195.2 for caffeine.",Liquid chromatography-mass spectrometry method for determination of tetramethylpyrazine and its metabolite in dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556542/),,153.2,112548,DB00201,Caffeine
,10589372,bioavailability,"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%.",Clinical pharmacokinetics of mexiletine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),%,90,113401,DB00201,Caffeine
,10589372,volume of distribution,Its volume of distribution is large and varies from 5 to 9 L/kg in healthy individuals.,Clinical pharmacokinetics of mexiletine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),[l] / [kg],5 to 9,113402,DB00201,Caffeine
,10589372,elimination half-life,Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours).,Clinical pharmacokinetics of mexiletine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589372/),h,10,113403,DB00201,Caffeine
,30011631,Cmax,"CF was the main methylxanthine found in plasma (Cmax=10.50μM, Tmax=1.2h).",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,10.50,114279,DB00201,Caffeine
,30011631,Tmax,"CF was the main methylxanthine found in plasma (Cmax=10.50μM, Tmax=1.2h).",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),h,1.2,114280,DB00201,Caffeine
,30011631,Cmax,"In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,3.36,114281,DB00201,Caffeine
,30011631,Cmax,"In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,1.44,114282,DB00201,Caffeine
,30011631,Cmax,"In addition, seven methylxanthines and methyluric acids were detected between 0.5 and 12h after coffee intake, paraxanthine (PX) being the major metabolite (Cmax=3.36μM), followed by 1-methyluric acid (1-MU; Cmax=1.44μM) and 1-methylxanthine (1-MX; Cmax=1.27μM), identified in plasma samples for the first time.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,1.27,114283,DB00201,Caffeine
,30011631,Cmax,"In 24h urine, eleven methylxanthines and methyluric acids were detected, 1-MU being the major metabolite (Cmax=150.52μM, Tmax=12h) amounting to 67.7% of the total urinary metabolites.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),μM,150.52,114284,DB00201,Caffeine
,30011631,Tmax,"In 24h urine, eleven methylxanthines and methyluric acids were detected, 1-MU being the major metabolite (Cmax=150.52μM, Tmax=12h) amounting to 67.7% of the total urinary metabolites.",Pharmacokinetics of caffeine and its metabolites in plasma and urine after consuming a soluble green/roasted coffee blend by healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30011631/),h,12,114285,DB00201,Caffeine
,29659178,peak concentrations (Cmax ),"The natural caffeine extract exhibited mean peak concentrations (Cmax ) of 3-CQA (11.4 ng/mL), 4-CQA (6.84 ng/mL), and 5-CQA (7.20 ng/mL).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),[ng] / [ml],11.4,114846,DB00201,Caffeine
,29659178,peak concentrations (Cmax ),"The natural caffeine extract exhibited mean peak concentrations (Cmax ) of 3-CQA (11.4 ng/mL), 4-CQA (6.84 ng/mL), and 5-CQA (7.20 ng/mL).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),[ng] / [ml],6.84,114847,DB00201,Caffeine
,29659178,peak concentrations (Cmax ),"The natural caffeine extract exhibited mean peak concentrations (Cmax ) of 3-CQA (11.4 ng/mL), 4-CQA (6.84 ng/mL), and 5-CQA (7.20 ng/mL).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),[ng] / [ml],7.20,114848,DB00201,Caffeine
,29659178,AUC0-4 h,"The mean systemic 4-hour exposure (AUC0-4 h ) was 3-CQA (27.3 ng·h/mL), 4-CQA (16.1 ng·h/mL), and 5-CQA (15.7 ng·h/mL).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),[h·ng] / [ml],27.3,114849,DB00201,Caffeine
,29659178,AUC0-4 h,"The mean systemic 4-hour exposure (AUC0-4 h ) was 3-CQA (27.3 ng·h/mL), 4-CQA (16.1 ng·h/mL), and 5-CQA (15.7 ng·h/mL).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),[h·ng] / [ml],16.1,114850,DB00201,Caffeine
,29659178,AUC0-4 h,"The mean systemic 4-hour exposure (AUC0-4 h ) was 3-CQA (27.3 ng·h/mL), 4-CQA (16.1 ng·h/mL), and 5-CQA (15.7 ng·h/mL).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),[h·ng] / [ml],15.7,114851,DB00201,Caffeine
,29659178,tmax,"The median tmax was 3-CQA (1.00 hour), 4-CQA (1.00 hour), and 5-CQA (1.50 hours).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),h,1.00,114852,DB00201,Caffeine
,29659178,tmax,"The median tmax was 3-CQA (1.00 hour), 4-CQA (1.00 hour), and 5-CQA (1.50 hours).","A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),h,1.50,114853,DB00201,Caffeine
,29659178,tmax,The tmax of caffeine was 0.75 hours (natural extract) and 0.63 hours (synthetic caffeine).,"A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),h,0.75,114854,DB00201,Caffeine
,29659178,tmax,The tmax of caffeine was 0.75 hours (natural extract) and 0.63 hours (synthetic caffeine).,"A Prospective Randomized, Double-Blind, Two-Period Crossover Pharmacokinetic Trial Comparing Green Coffee Bean Extract-A Botanically Sourced Caffeine-With a Synthetic USP Control. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29659178/),h,0.63,114855,DB00201,Caffeine
,12915954,t(max),Co-administration of menthol resulted in an increase of caffeine t(max) values from 43.6+/-20.6 min (mean+/-SD) to 76.4+/-28.0 min ( P<0.05).,Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915954/),min,43.6,116060,DB00201,Caffeine
,12915954,t(max),Co-administration of menthol resulted in an increase of caffeine t(max) values from 43.6+/-20.6 min (mean+/-SD) to 76.4+/-28.0 min ( P<0.05).,Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12915954/),min,76.4,116061,DB00201,Caffeine
,31442620,AUC,"After exposure to EPP-AF®, it was observed decrease in the AUC0-∞ of fexofenadine, caffeine and losartan of approximately 18% (62.20 × 51.00 h.ng/mL), 8% (1085 × 999 h.ng/mL) and 13% (9.01 × 7.86 h.ng/mL), respectively, with all 90% CIs within the equivalence range of 0.80-1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),,62,116459,DB00201,Caffeine
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],18,116460,DB00201,Caffeine
,31442620,AUC0-∞,"On the other hand, omeprazole and midazolam exhibited an increase in AUC0-∞ of, respectively, approximately 18% (18.90 × 22.30 h.ng/mL) and 14% (1.25 × 1.43 h.ng/mL), with the upper bounds of 90% CIs slightly above 1.25.",Evaluation of potential herbal-drug interactions of a standardized propolis extract (EPP-AF®) using an in vivo cocktail approach. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31442620/),[h·ng] / [ml],1.,116461,DB00201,Caffeine
,8866634,AUC,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),[h·μM] / [l],43.2,116665,DB00201,Caffeine
,8866634,AUC,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),[h·μM] / [l],19.9,116666,DB00201,Caffeine
,8866634,clearance,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),[l] / [h],5.0,116667,DB00201,Caffeine
,8866634,clearance,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),[l] / [h],11.8,116668,DB00201,Caffeine
,8866634,volume of distribution,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),l,130,116669,DB00201,Caffeine
,8866634,volume of distribution,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),l,230,116670,DB00201,Caffeine
,8866634,half-life,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),h,19.0,116671,DB00201,Caffeine
,8866634,half-life,"In the elderly the AUC of brofaromine was significantly increased (e.g. for the 75 mg dose 43.2 vs 19.9 mumol*h.l-1, clearance was reduced (5.0 vs. 11.8 l.h-1), the volume of distribution was smaller (130 vs. 230 l), and the half-life was slightly increased (19.0 vs. 14.2 h).","Influence of age, frailty and liver function on the pharmacokinetics of brofaromine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866634/),h,14.2,116672,DB00201,Caffeine
,14674790,k(a),"NPEM median estimates of caffeine absorption and elimination rate constants, k(a) = 4.54 h(-1) and k(el) = 0.139 h(-1), as well as of fractional volume of distribution and plasma clearance, V(S1) = 0.58 L/kg and CL(S1) = 0.057 L/h/kg, agreed well with reported values from more 'data rich' studies.",Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14674790/),1/[h],4.54,117292,DB00201,Caffeine
,14674790,k(el),"NPEM median estimates of caffeine absorption and elimination rate constants, k(a) = 4.54 h(-1) and k(el) = 0.139 h(-1), as well as of fractional volume of distribution and plasma clearance, V(S1) = 0.58 L/kg and CL(S1) = 0.057 L/h/kg, agreed well with reported values from more 'data rich' studies.",Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14674790/),1/[h],0.139,117293,DB00201,Caffeine
,14674790,V(S1),"NPEM median estimates of caffeine absorption and elimination rate constants, k(a) = 4.54 h(-1) and k(el) = 0.139 h(-1), as well as of fractional volume of distribution and plasma clearance, V(S1) = 0.58 L/kg and CL(S1) = 0.057 L/h/kg, agreed well with reported values from more 'data rich' studies.",Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14674790/),[l] / [kg],0.58,117294,DB00201,Caffeine
,14674790,CL(S1),"NPEM median estimates of caffeine absorption and elimination rate constants, k(a) = 4.54 h(-1) and k(el) = 0.139 h(-1), as well as of fractional volume of distribution and plasma clearance, V(S1) = 0.58 L/kg and CL(S1) = 0.057 L/h/kg, agreed well with reported values from more 'data rich' studies.",Nonparametric expectation maximisation (NPEM) population pharmacokinetic analysis of caffeine disposition from sparse data in adult caucasians: systemic caffeine clearance as a biomarker for cytochrome P450 1A2 activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14674790/),[l] / [h·kg],0.057,117295,DB00201,Caffeine
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],127.7,122128,DB00201,Caffeine
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],182.3,122129,DB00201,Caffeine
,17085857,effective dose (ED50),"Moreover, CAF at doses of and 92.4 mg/kg attenuated the protective action of ETS against PTZ-induced seizures, by increasing its median effective dose (ED50) from 127.7 to 182.3 (p<0.05), and 198.3 mg/kg (p<0.01), respectively.","Acute exposure to caffeine decreases the anticonvulsant action of ethosuximide, but not that of clonazepam, phenobarbital and valproate against pentetrazole-induced seizures in mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17085857/),[mg] / [kg],198.3,122130,DB00201,Caffeine
,8738854,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),%,77,126641,DB00201,Caffeine
,8738854,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[mg] / [l],2.5,126642,DB00201,Caffeine
,8738854,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,2-3,126643,DB00201,Caffeine
,8738854,AUC(O,"The AUC(O,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[h·mg] / [l],5,126644,DB00201,Caffeine
,8738854,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [h·kg],0.1,126645,DB00201,Caffeine
,8738854,serum elimination halflife,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.1,126646,DB00201,Caffeine
,8738854,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination halflife of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),[l] / [kg],0.15,126647,DB00201,Caffeine
,8738854,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,7-9,126648,DB00201,Caffeine
,8738854,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738854/),h,1.25,126649,DB00201,Caffeine
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,120,127131,DB00201,Caffeine
,7194086,relative bioavailabilities,The estimated relative bioavailabilities of the single substances in the suppository formulation vary between 120% for propyphenazone and 83% for phenobarbital in comparison to the tablets.,"[A comparative pharmacokinetic study for tablet and suppository formulations of a combination product of caffeine, ethaverine, propyphenazone, paracetamol and phenobarbital (author's transl)]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7194086/),%,83,127132,DB00201,Caffeine
,10839467,clearance,"Initial (day 2) caffeine clearance (n = 15, geometric mean) was 1.37 ml/min/kg body weight (coefficient of variation (CV) 48%).",Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839467/),[ml] / [body·kg·min·weight],1.37,127292,DB00201,Caffeine
,8947977,area under the serum caffeine concentration-time curve (AUC0-infinity),"The mean area under the serum caffeine concentration-time curve (AUC0-infinity) values +/- SD for the caffeine with water group, caffeine with GFJ group, and caffeine with multiple GFJ group were 47.0 +/- 10.8, 48.7 +/- 15.2, and 49.6 +/- 7.0 micrograms/ml.hr, respectively (NS).",Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947977/),[μg] / [h·ml],47.0,128134,DB00201,Caffeine
,8947977,area under the serum caffeine concentration-time curve (AUC0-infinity),"The mean area under the serum caffeine concentration-time curve (AUC0-infinity) values +/- SD for the caffeine with water group, caffeine with GFJ group, and caffeine with multiple GFJ group were 47.0 +/- 10.8, 48.7 +/- 15.2, and 49.6 +/- 7.0 micrograms/ml.hr, respectively (NS).",Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947977/),[μg] / [h·ml],48.7,128135,DB00201,Caffeine
,8947977,area under the serum caffeine concentration-time curve (AUC0-infinity),"The mean area under the serum caffeine concentration-time curve (AUC0-infinity) values +/- SD for the caffeine with water group, caffeine with GFJ group, and caffeine with multiple GFJ group were 47.0 +/- 10.8, 48.7 +/- 15.2, and 49.6 +/- 7.0 micrograms/ml.hr, respectively (NS).",Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947977/),[μg] / [h·ml],49.6,128136,DB00201,Caffeine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.34,128355,DB00201,Caffeine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.06,128356,DB00201,Caffeine
,2612543,clearance,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),[ml] / [kg·min],1.21,128357,DB00201,Caffeine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,5.8,128358,DB00201,Caffeine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,7.6,128359,DB00201,Caffeine
,2612543,half-life,"The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively.",Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612543/),h,6.7,128360,DB00201,Caffeine
,421728,peak concentration,"The highest and longest lasting levels were found after i.m. administration, the peak concentration being 1.94 +/- 0.34 (SEM) ng/ml at 1/2 h.","Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421728/),[ng] / [ml],1.94,131135,DB00201,Caffeine
,421728,maximum concentrations,The corresponding maximum concentrations after oral and rectal administration were 0.36 +/- 0.08 ng/ml at 2 h and 0.42 +/- 0.09 ng/ml at 1 h.,"Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421728/),[ng] / [ml],0.36,131136,DB00201,Caffeine
,421728,maximum concentrations,The corresponding maximum concentrations after oral and rectal administration were 0.36 +/- 0.08 ng/ml at 2 h and 0.42 +/- 0.09 ng/ml at 1 h.,"Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/421728/),[ng] / [ml],0.42,131137,DB00201,Caffeine
,19057373,Vd,"Clearance (CL) increased nonlinearly with increasing PNA, whereas volume of distribution (Vd) increased linearly with WT, according to the following allometric models: CL (L/h) = 0.167 (WT/70) (PNA/12); Vd (L) = 58.7 (WT/70).","Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19057373/),,58,131559,DB00201,Caffeine
,19057373,elimination half-life,The mean elimination half-life was 101.,"Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19057373/),,101,131560,DB00201,Caffeine
,32737938,clearance,"The typical scaled values for the parameters clearance and volume of distribution (V) were 0.268 L/h and 109 L per 70 kg, respectively.",Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737938/),[l] / [h],0.268,132021,DB00201,Caffeine
,32737938,volume of distribution (V),"The typical scaled values for the parameters clearance and volume of distribution (V) were 0.268 L/h and 109 L per 70 kg, respectively.",Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32737938/),[l] / [70·kg],109,132022,DB00201,Caffeine
,7350785,Elimination half-life,"Elimination half-life values of 14.5 and 15.2 hours, respectively, were shorter than reported in premature infants but longer than in infants aged 3 months or older.",Theophylline toxicity in term infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7350785/),h,14.5,132498,DB00201,Caffeine
,7350785,Elimination half-life,"Elimination half-life values of 14.5 and 15.2 hours, respectively, were shorter than reported in premature infants but longer than in infants aged 3 months or older.",Theophylline toxicity in term infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7350785/),h,15.2,132499,DB00201,Caffeine
,2714159,half-life,The caffeine half-life was 52.03 +/- 23.87 h (means +/- SD) and the theophylline half-life was 77.04 +/- 65.01 h (mean +/- SD).,Caffeine pharmacokinetics in preterm infants older than 2 weeks. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714159/),h,52.03,135752,DB00201,Caffeine
,2714159,half-life,The caffeine half-life was 52.03 +/- 23.87 h (means +/- SD) and the theophylline half-life was 77.04 +/- 65.01 h (mean +/- SD).,Caffeine pharmacokinetics in preterm infants older than 2 weeks. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2714159/),h,77.04,135753,DB00201,Caffeine
,1505152,percentage exhalation,"The mean percentage exhalation of the 13C test dose, as determined by 13CO2 in breath during 8 hours, was 23.0% +/- 8.0% (n = 18) before treatment.",Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505152/),%,23.0,137108,DB00201,Caffeine
,1505152,exhalation rates,In both groups exhalation rates of 13CO2 returned to near pretreatment values within the 7-day washout period (24.2% +/- 7.8%; n = 17).,Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505152/),%,24.2,137109,DB00201,Caffeine
,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,80,137185,DB00201,Caffeine
less,23208431,Bioavailabilities,"Bioavailabilities were approximately 80% for caffeine and warfarin, but less than 10% for omeprazole, metoprolol, and midazolam.","Simultaneous pharmacokinetics assessment of caffeine, warfarin, omeprazole, metoprolol, and midazolam intravenously or orally administered to Microminipigs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23208431/),%,10,137186,DB00201,Caffeine
,8768380,clearance,"The serum caffeine clearance was significantly higher in the control group than in the patient group (1.72 +/- 1.06 vs. 0.78 +/- 0.77 ml/min/kg, p < 0.0001).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],1.72,137484,DB00201,Caffeine
,8768380,clearance,"The serum caffeine clearance was significantly higher in the control group than in the patient group (1.72 +/- 1.06 vs. 0.78 +/- 0.77 ml/min/kg, p < 0.0001).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],0.78,137485,DB00201,Caffeine
,8768380,Elimination half-life,"Elimination half-life was significantly prolonged in the patient group (3.74 +/- 1.05 vs. 2.69 +/- 0.75 hours, p < 0.0001).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),h,3.74,137486,DB00201,Caffeine
,8768380,Elimination half-life,"Elimination half-life was significantly prolonged in the patient group (3.74 +/- 1.05 vs. 2.69 +/- 0.75 hours, p < 0.0001).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),h,2.69,137487,DB00201,Caffeine
,8768380,clearance,"In the non-smokers, caffeine clearance was 1.30 +/- 0.90 and 0.51 +/- 0.47 ml/min/kg and half-life of caffeine was 2.89 +/- 0.78 and 4.06 +/- 0.93 hours, respectively (control vs. patient, p < 0.05).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],1.30,137488,DB00201,Caffeine
,8768380,clearance,"In the non-smokers, caffeine clearance was 1.30 +/- 0.90 and 0.51 +/- 0.47 ml/min/kg and half-life of caffeine was 2.89 +/- 0.78 and 4.06 +/- 0.93 hours, respectively (control vs. patient, p < 0.05).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],0.51,137489,DB00201,Caffeine
,8768380,half-life,"In the non-smokers, caffeine clearance was 1.30 +/- 0.90 and 0.51 +/- 0.47 ml/min/kg and half-life of caffeine was 2.89 +/- 0.78 and 4.06 +/- 0.93 hours, respectively (control vs. patient, p < 0.05).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),h,2.89,137490,DB00201,Caffeine
,8768380,half-life,"In the non-smokers, caffeine clearance was 1.30 +/- 0.90 and 0.51 +/- 0.47 ml/min/kg and half-life of caffeine was 2.89 +/- 0.78 and 4.06 +/- 0.93 hours, respectively (control vs. patient, p < 0.05).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),h,4.06,137491,DB00201,Caffeine
,8768380,clearance,"In the smokers, caffeine clearance was 2.30 +/- 0.98 and 1.13 +/- 0.96 ml/min/kg and half-life of caffeine was 2.41 +/- 0.63 vs.",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],2.30,137492,DB00201,Caffeine
,8768380,clearance,"In the smokers, caffeine clearance was 2.30 +/- 0.98 and 1.13 +/- 0.96 ml/min/kg and half-life of caffeine was 2.41 +/- 0.63 vs.",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],1.13,137493,DB00201,Caffeine
,8768380,half-life,"In the smokers, caffeine clearance was 2.30 +/- 0.98 and 1.13 +/- 0.96 ml/min/kg and half-life of caffeine was 2.41 +/- 0.63 vs.",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),,2.41,137494,DB00201,Caffeine
less,8768380,clearance,"During the mean six-month period of follow-up, the mortality rate was significantly higher in those patients with caffeine clearance less than 0.5 ml/min/kg than in those with clearance more than 0.5 ml/min/kg (46.1% vs. 6.7%, p < 0.05).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],0.5,137495,DB00201,Caffeine
more,8768380,clearance,"During the mean six-month period of follow-up, the mortality rate was significantly higher in those patients with caffeine clearance less than 0.5 ml/min/kg than in those with clearance more than 0.5 ml/min/kg (46.1% vs. 6.7%, p < 0.05).",Caffeine clearance test: a quantitative liver function assessment in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8768380/),[ml] / [kg·min],0.5,137496,DB00201,Caffeine
,7582380,Cmax,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,0.90,139131,DB00201,Caffeine
,7582380,AUC,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,1.02,139132,DB00201,Caffeine
,7582380,Cmax/AUC,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,0.88,139133,DB00201,Caffeine
,7582380,T 1/2el,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),,1.03,139134,DB00201,Caffeine
,7582380,Tmax,"These were: Cmax 0.90 (0.81-1.00), AUC 1.02 (0.95-1.11), Cmax/AUC 0.88 (0.81-0.95), T 1/2el 1.03 (0.98-1.09), Tmax 0.15 h (-0.11h-0.41 h).",Lacking effect of grapefruit juice on theophylline pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582380/),h,0.15,139135,DB00201,Caffeine
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB00201,Caffeine
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB00201,Caffeine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB00201,Caffeine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB00201,Caffeine
,2058339,t1/2,"Deposiston was found markedly delay the elimination half-life life of caffeine (p less than 0.05): t1/2 prior to therapy 4.9 +/- 2.6 h and, after as little as 2 mg ethinylestradiol sulphonate 8.0 +/- 3.5 h.",[Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058339/),h,4.9,141771,DB00201,Caffeine
,2058339,t1/2,"Deposiston was found markedly delay the elimination half-life life of caffeine (p less than 0.05): t1/2 prior to therapy 4.9 +/- 2.6 h and, after as little as 2 mg ethinylestradiol sulphonate 8.0 +/- 3.5 h.",[Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058339/),h,8.0,141772,DB00201,Caffeine
,32055555,Kout,"For the selected PD model, parameter estimates were 0.613 hr -1 for Kout , 0.192 for Emax , 730 ng/ml for EC 50 and 5.137 for γ.",Population pharmacodynamics of cilostazol in healthy Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055555/),-1·h,0.613,142380,DB00201,Caffeine
,32055555,Emax,"For the selected PD model, parameter estimates were 0.613 hr -1 for Kout , 0.192 for Emax , 730 ng/ml for EC 50 and 5.137 for γ.",Population pharmacodynamics of cilostazol in healthy Korean subjects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055555/),,0.192,142381,DB00201,Caffeine
,32055555,EC 50,"For the selected PD model, parameter estimates were 0.613 hr -1 for Kout , 0.192 for Emax , 730 ng/ml for EC 50 and 5.137 for γ.",Population pharmacodynamics of cilostazol in healthy Korean subjects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055555/),[ng] / [ml],730,142382,DB00201,Caffeine
,32055555,γ,"For the selected PD model, parameter estimates were 0.613 hr -1 for Kout , 0.192 for Emax , 730 ng/ml for EC 50 and 5.137 for γ.",Population pharmacodynamics of cilostazol in healthy Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055555/),,5.137,142383,DB00201,Caffeine
,32055555,CT,"Sex and caffeine drinking status significantly influenced the baseline CT, which was 85.36 seconds in male non-caffeine drinkers and increased by 15.5% and 16.4% in females and caffeine drinkers, respectively.",Population pharmacodynamics of cilostazol in healthy Korean subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32055555/),seconds,85.36,142384,DB00201,Caffeine
,15856409,trough concentrations,"On day 11, trough concentrations were 2.0 (range 0.6 - 4.1) microg/L and 1.0 (0.2 - 3.9) microg/L for hypericin and pseudohypericin, respectively, whereas hyperforin concentrations were below the quantification limit (< 1 microg/L).","No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856409/),[μg] / [l],2.0,142839,DB00201,Caffeine
,15856409,trough concentrations,"On day 11, trough concentrations were 2.0 (range 0.6 - 4.1) microg/L and 1.0 (0.2 - 3.9) microg/L for hypericin and pseudohypericin, respectively, whereas hyperforin concentrations were below the quantification limit (< 1 microg/L).","No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15856409/),[μg] / [l],1.0,142840,DB00201,Caffeine
,3981454,distribution half-life,The mean (n = 4) distribution half-life was 0.2 hr and the mean elimination half-life was 3.8 hr.,"Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981454/),h,0.2,142946,DB00201,Caffeine
,3981454,elimination half-life,The mean (n = 4) distribution half-life was 0.2 hr and the mean elimination half-life was 3.8 hr.,"Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981454/),h,3.8,142947,DB00201,Caffeine
,3981454,clearance,The mean clearance was 0.20 liters/kg/hr and the mean volume of distribution was 0.82 liters/kg.,"Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981454/),[l] / [h·kg],0.20,142948,DB00201,Caffeine
,3981454,volume of distribution,The mean clearance was 0.20 liters/kg/hr and the mean volume of distribution was 0.82 liters/kg.,"Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981454/),[l] / [kg],0.82,142949,DB00201,Caffeine
,3981454,semen/blood concentration ratio,The mean semen/blood concentration ratio of caffeine was 1.0.,"Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981454/),,1.0,142950,DB00201,Caffeine
,3981454,tissue/blood concentration ratio,Most tissues exhibited a tissue/blood concentration ratio of approximately 1.0.,"Metabolism, distribution, seminal excretion and pharmacokinetics of caffeine in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3981454/),,1.0,142951,DB00201,Caffeine
,15051740,clearance,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),[l] / [h·kg],0.035,142979,DB00201,Caffeine
,15051740,clearance,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),[l] / [h·kg],0.094,142980,DB00201,Caffeine
,15051740,elimination coefficient,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),1/[h],0.061,142981,DB00201,Caffeine
,15051740,elimination coefficient,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),1/[h],0.153,142982,DB00201,Caffeine
,15051740,half-life,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),h,11.4,142983,DB00201,Caffeine
,15051740,half-life,"Elimination of caffeine was decreased in cirrhotics in comparison with healthy volunteers, as proved by the values of clearance (0.035 vs. 0.094 L/h/kg), elimination coefficient (0.061 vs. 0.153 h(-1)), and half-life (11.4 vs. 4.3 h).",Serum metabolite/caffeine ratios as a test for liver function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15051740/),h,4.3,142984,DB00201,Caffeine
,2236898,elimination rate constant,"For doses less than 10 mg/kg or mg/L, caffeine blood or perfusate concentrations/time profiles followed first-order kinetics and the elimination rate constant (average 0.013 min-1) and half-life (55 min) were similar for the in vivo and ex vivo conditions.",In vivo and perfused liver caffeine kinetics in the rat. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236898/),1/[min],0.013,143697,DB00201,Caffeine
,2236898,half-life,"For doses less than 10 mg/kg or mg/L, caffeine blood or perfusate concentrations/time profiles followed first-order kinetics and the elimination rate constant (average 0.013 min-1) and half-life (55 min) were similar for the in vivo and ex vivo conditions.",In vivo and perfused liver caffeine kinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236898/),min,55,143698,DB00201,Caffeine
,2236898,Km,"The area under the blood or medium concentration-time curve increased, but not in proportion to the dose, and modifications of pharmacokinetic parameters were observed, with significant differences for t 1/2 and CL after 10 and 25 mg/kg or mg/L, due to dose-dependent elimination of caffeine at these doses (Km of 8.3 and 7.8 micrograms/ml in vivo and in vitro, respectively).",In vivo and perfused liver caffeine kinetics in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236898/),[μg] / [ml],8.3,143699,DB00201,Caffeine
,2236898,Km,"The area under the blood or medium concentration-time curve increased, but not in proportion to the dose, and modifications of pharmacokinetic parameters were observed, with significant differences for t 1/2 and CL after 10 and 25 mg/kg or mg/L, due to dose-dependent elimination of caffeine at these doses (Km of 8.3 and 7.8 micrograms/ml in vivo and in vitro, respectively).",In vivo and perfused liver caffeine kinetics in the rat. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236898/),[μg] / [ml],7.8,143700,DB00201,Caffeine
,8735418,elimination half-life,For caffeine the mean elimination half-life was calculated to be 47 h.,Pharmacokinetics of caffeine in the oestrogen-implanted ovariectomized ewe. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735418/),h,47,145402,DB00201,Caffeine
,8422743,half-life,The half-life of equilibration of effect with plasma caffeine concentration is about 20 minutes.,Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422743/),min,20,145448,DB00201,Caffeine
,8422743,half-life of development,"The half-life of development and regression of tolerance is estimated to be about 1 hour, and the model suggests that tolerance, at its fullest, causes more than a 90% reduction of initial (nontolerant) effect.",Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422743/),h,1,145449,DB00201,Caffeine
,8422743,regression of tolerance,"The half-life of development and regression of tolerance is estimated to be about 1 hour, and the model suggests that tolerance, at its fullest, causes more than a 90% reduction of initial (nontolerant) effect.",Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8422743/),h,1,145450,DB00201,Caffeine
,9025802,plasmatic Cmax,This SRC was well tolerated probably due to its relative low plasmatic Cmax (10.37 micrograms.ml-1).,The effects of 600 mg of slow release caffeine on mood and alertness. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9025802/),[μg] / [ml],10.37,145893,DB00201,Caffeine
,19125908,elimination half-lives,The extrapolated elimination half-lives of caffeine in the non-smokers and the smokers were 4.3 +/- 1.5 and 3.0 +/- 0.7 h respectively.,Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19125908/),h,4.3,147906,DB00201,Caffeine
,19125908,elimination half-lives,The extrapolated elimination half-lives of caffeine in the non-smokers and the smokers were 4.3 +/- 1.5 and 3.0 +/- 0.7 h respectively.,Population pharmacokinetics of caffeine in healthy male adults using mixed-effects models. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19125908/),h,3.0,147907,DB00201,Caffeine
,8688997,Clearance,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[ml] / [min],350,152437,DB00201,Caffeine
,8688997,t1/2,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),h,4,152438,DB00201,Caffeine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],0.7,152439,DB00201,Caffeine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],1.7,152440,DB00201,Caffeine
,8688997,Cmax,"Clearance and t1/2 were about 350 ml/min and 4 h, respectively, the Cmax values of 0.7, 1.7, and 4.4 micrograms/ml were reached after 2.5 h.","Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688997/),[μg] / [ml],4.4,152441,DB00201,Caffeine
>,24186263,AUC ratio,The static model predicted in vivo interaction with predicted AUC ratio values of >1.1 for all CYP (except CYP3A4).,"Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24186263/),,1.1,154701,DB00201,Caffeine
,18197403,K(i) (inhibitor constant),Celecoxib was found to be a moderately potent competitive inhibitor of CYP1A2 in vitro with a K(i) (inhibitor constant) of 25.4 microM.,Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18197403/),μM,25.4,155529,DB00201,Caffeine
,32687613,CL,The median (range) of 95% confidence intervals of CL were 0.0128 (0.0128-0.0131) L/h/kg.,Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32687613/),[l] / [h·kg],0.0128,155810,DB00201,Caffeine
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"1,3",155977,DB00201,Caffeine
,6435136,time up to the maximum serum concentration,"The absorption kinetics of the preparations were different: the time up to the maximum serum concentration was at Turivital with 1,3 +/- 0,7 h and Micristin (2,1 +/- 0,8 h) the shortest, because the resorption delay was at Turivital the smallest.","[Comparison of the pharmacokinetic behavior of Turivital, Acesal and Micristin]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6435136/),h,"2,1",155978,DB00201,Caffeine
,15752380,clearance,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.083,156667,DB00201,Caffeine
,15752380,clearance,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.038,156668,DB00201,Caffeine
,15752380,volume of distribution,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),l,38.6,156669,DB00201,Caffeine
,15752380,absorption rate constant,"Caffeine clearance was 0.083 l min(-1) (CV 38%) and decreased to 0.038 l min(-1) in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l min(-1) (CV 50%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.064,156670,DB00201,Caffeine
,15752380,clearance,"Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),[l] / [min],0.34,156671,DB00201,Caffeine
,15752380,volume of distribution,"Ephedrine was eliminated mostly renally, with a clearance of 0.34 l min(-1) (CV 11%), and a volume of distribution of 181 l (CV 19%).","Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752380/),l,181,156672,DB00201,Caffeine
,32558923,turnover half-life,"Based on the recovery of R-pantoprazole oral clearance, the turnover half-life of CYP2C19 was estimated to average 53 hours.","Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32558923/),h,53,159396,DB00201,Caffeine
,6729831,fraction of,In in vitro and in vivo the fraction of theobromine unbound to plasma proteins averaged 0.90 over a wide range of concentrations.,Kinetics and metabolism of theobromine in male rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6729831/),,0.90,159440,DB00201,Caffeine
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.4,161347,DB00201,Caffeine
,12110375,K(M),"In human LM, the main metabolite of caffeine was paraxanthine (K(M) 0.4 and 0.5 mmol L(-1)).",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.5,161348,DB00201,Caffeine
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161349,DB00201,Caffeine
,12110375,Apparent K(M),"Apparent K(M) for paraxanthine formation from caffeine in wild-type and CYP1A2-null murine LM were 0.2 and 4.9 mmol L(-1), respectively.",Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],4.9,161350,DB00201,Caffeine
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.13,161351,DB00201,Caffeine
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.2,161352,DB00201,Caffeine
,12110375,K(M),The main metabolite of paraxanthine was 1-methylxanthine in human (K(M) 0.13 and 0.2 mmol L(-1)) and in wild-type mice LM (K(M) 0.53 mmol L(-1)).,Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110375/),[mM] / [l],0.53,161353,DB00201,Caffeine
,3191817,mean plasma concentration,"Dose regimen guidelines as a function of postnatal age were derived from individually calculated doses and dosing intervals in order to achieve, at steady state, a caffeine mean plasma concentration of 11 mg/l with a minimum of 7.5 mg/l and a maximum of 14.5 mg/l.",Developmental changes of caffeine elimination in infancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191817/),[mg] / [l],11,161664,DB00201,Caffeine
,3191817,mean plasma concentration,"Dose regimen guidelines as a function of postnatal age were derived from individually calculated doses and dosing intervals in order to achieve, at steady state, a caffeine mean plasma concentration of 11 mg/l with a minimum of 7.5 mg/l and a maximum of 14.5 mg/l.",Developmental changes of caffeine elimination in infancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191817/),[mg] / [l],7.5,161665,DB00201,Caffeine
,3191817,mean plasma concentration,"Dose regimen guidelines as a function of postnatal age were derived from individually calculated doses and dosing intervals in order to achieve, at steady state, a caffeine mean plasma concentration of 11 mg/l with a minimum of 7.5 mg/l and a maximum of 14.5 mg/l.",Developmental changes of caffeine elimination in infancy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3191817/),[mg] / [l],14.5,161666,DB00201,Caffeine
,9272409,metabolic ratio (MR),"Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml.min-1 (expected CLM = 1220 in extensive metabolisers of CYP2D6).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),,9.2,162238,DB00201,Caffeine
,9272409,MRp,"Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml.min-1 (expected CLM = 1220 in extensive metabolisers of CYP2D6).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),,2.4,162239,DB00201,Caffeine
,9272409,clearance,"Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml.min-1 (expected CLM = 1220 in extensive metabolisers of CYP2D6).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),[ml] / [min],4190,162240,DB00201,Caffeine
,9272409,half-life,"The patient's caffeine half-life was 10 h, thus, precluding ultra-rapid metabolism for CYP1A2.",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),h,10,162241,DB00201,Caffeine
,9272409,MRP,"Subsequently, MRP of maprotiline (4.9) and CLM were reduced (1900 ml.min-1; expected CLM in poor metabolisers: of CYP2D6 364).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),[ml] / [min],4.9,162242,DB00201,Caffeine
,9272409,MRP,"Subsequently, MRP of maprotiline (4.9) and CLM were reduced (1900 ml.min-1; expected CLM in poor metabolisers: of CYP2D6 364).",Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6? ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9272409/),[ml] / [min],1900,162243,DB00201,Caffeine
,11476153,pulmonary retention,"The average pulmonary retention of styrene was 62 +/- 7% at both exposure concentrations, and the 24-h excretion of MA and PGA accounted for 58% of the dose at both concentrations.",Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11476153/),%,62,162727,DB00201,Caffeine
,11476153,apparent blood clearance,"Although other explanations cannot be excluded, this lack of correlation might be due to the high apparent blood clearance (1.4 l/min) of styrene, indicating that styrene metabolism is liver-blood-flow-dependent.",Metabolic capacity and interindividual variation in toxicokinetics of styrene in volunteers. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11476153/),[l] / [min],1.4,162728,DB00201,Caffeine
,12400698,half-life (T 1/2) of elimination,"When a lipid emulsion (Intralipid 20%; a lipid emulsion containing 20% soybean oil) was injected intravenously into mice, the restraint stress prolonged the half-life (T 1/2) of elimination for plasma triglyceride (TG) from 28.7 to 55.5 min.",Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),min,28.7,162904,DB00201,Caffeine
,12400698,half-life (T 1/2) of elimination,"When a lipid emulsion (Intralipid 20%; a lipid emulsion containing 20% soybean oil) was injected intravenously into mice, the restraint stress prolonged the half-life (T 1/2) of elimination for plasma triglyceride (TG) from 28.7 to 55.5 min.",Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),min,55.5,162905,DB00201,Caffeine
,12400698,elimination rate per minute,The elimination rate per minute was 48.2% in stressed mice with the rate in starved control mice as 100%.,Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),%,48.2,162906,DB00201,Caffeine
,12400698,elimination rate per minute,The elimination rate per minute was 48.2% in stressed mice with the rate in starved control mice as 100%.,Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),%,100,162907,DB00201,Caffeine
,12400698,Plasma TG,"Plasma TG was 515.9 +/- 29.9mg/dl 35min after Intralipid administration in control stressed mice, 478.7 +/- 26.7 mg/dl in the stressed group given caffeine 100 mg/kg of body weight, and 418.3 +/- 18.4 mg/dl in the stressed group given 1,000 mg/kg oolong tea, an improvement by 7.2% and 18.9%, respectively, with the value for the untreated control group.",Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),[mg] / [dl],515.9,162908,DB00201,Caffeine
,12400698,Plasma TG,"Plasma TG was 515.9 +/- 29.9mg/dl 35min after Intralipid administration in control stressed mice, 478.7 +/- 26.7 mg/dl in the stressed group given caffeine 100 mg/kg of body weight, and 418.3 +/- 18.4 mg/dl in the stressed group given 1,000 mg/kg oolong tea, an improvement by 7.2% and 18.9%, respectively, with the value for the untreated control group.",Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),mg,478.7,162909,DB00201,Caffeine
,12400698,Plasma TG,"Plasma TG was 515.9 +/- 29.9mg/dl 35min after Intralipid administration in control stressed mice, 478.7 +/- 26.7 mg/dl in the stressed group given caffeine 100 mg/kg of body weight, and 418.3 +/- 18.4 mg/dl in the stressed group given 1,000 mg/kg oolong tea, an improvement by 7.2% and 18.9%, respectively, with the value for the untreated control group.",Effects of oolong tea on metabolism of plasma fat in mice under restraint stress. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12400698/),mg,418.3,162910,DB00201,Caffeine
,7075114,total body clearance (TBC),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],2.49,163735,DB00201,Caffeine
,7075114,total body clearance (TBC),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],1.59,163736,DB00201,Caffeine
,7075114,elimination half-life (t1/2),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,190,163737,DB00201,Caffeine
,7075114,elimination half-life (t1/2),"The total body clearance (TBC) of caffeine was higher (2.49 +/- 0.35 and 1.59 +/- 0.19 ml/kg/min, P less than 0.05) and the elimination half-life (t1/2) shorter (190 +/- 15 and 276 +/- 30 min, P less than 0.05) in smokers than nonsmokers, but Cmax, tmax, and the apparent volume of distribution (Vd, app) did not differ (P greater than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,276,163738,DB00201,Caffeine
,7075114,TBC,"Cimetidine decreased the TBC of caffeine by 31% (to 1.73 +/- 0.28 ml/kg/min, P less than 0.05) and by 42% (to 0.92 +/- 0.11 ml/kg/min, P less than 0.01) in smokers and nonsmokers.",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],1.73,163739,DB00201,Caffeine
,7075114,TBC,"Cimetidine decreased the TBC of caffeine by 31% (to 1.73 +/- 0.28 ml/kg/min, P less than 0.05) and by 42% (to 0.92 +/- 0.11 ml/kg/min, P less than 0.01) in smokers and nonsmokers.",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),[ml] / [kg·min],0.92,163740,DB00201,Caffeine
,7075114,t1/2,"The increases in t1/2 were 45% (to 276 +/- 25 min, P less than 0.05) and 96% (to 542 +/- 123 min, P less than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,276,163741,DB00201,Caffeine
,7075114,t1/2,"The increases in t1/2 were 45% (to 276 +/- 25 min, P less than 0.05) and 96% (to 542 +/- 123 min, P less than 0.05).",Effects of cimetidine on caffeine disposition in smokers and nonsmokers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7075114/),min,542,163742,DB00201,Caffeine
,17618427,IC(50),Tolfenamic acid strongly inhibited phenacetin-O-deethylation in vitro (IC(50) 1.8 microM without albumin).,Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618427/),μM,1.8,164396,DB00201,Caffeine
exceeded,17618427,IC(50),Albumin decreased its inhibitory effect in a concentration-dependent manner; the IC(50) exceeded 100 microM with 10 mg/ml of albumin.,Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17618427/),μM,100,164397,DB00201,Caffeine
,31480657,flow rate,The mobile phase was composed of 0.1% formic acid in water and methanol at a flow rate of 0.3 mL/min.,Pharmacokinetics and Tissue Distribution of Alnustone in Rats after Intravenous Administration by Liquid Chromatography-Mass Spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31480657/),[ml] / [min],0.3,164585,DB00201,Caffeine
,31480657,peak plasma concentration (Cmax),"After single-dose intravenous administration of alnustone (5 mg/kg), the mean peak plasma concentration (Cmax) value was 7066.36 ± 820.62 ng/mL, and the mean area under the concentration-time curve (AUC0-t) value was 6009.79 ± 567.30 ng/mL∙h.",Pharmacokinetics and Tissue Distribution of Alnustone in Rats after Intravenous Administration by Liquid Chromatography-Mass Spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31480657/),[ng] / [ml],7066.36,164586,DB00201,Caffeine
,31480657,area under the concentration-time curve (AUC0-t),"After single-dose intravenous administration of alnustone (5 mg/kg), the mean peak plasma concentration (Cmax) value was 7066.36 ± 820.62 ng/mL, and the mean area under the concentration-time curve (AUC0-t) value was 6009.79 ± 567.30 ng/mL∙h.",Pharmacokinetics and Tissue Distribution of Alnustone in Rats after Intravenous Administration by Liquid Chromatography-Mass Spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31480657/),[ng] / [ml∙h],6009.79,164587,DB00201,Caffeine
,1910493,elimination half-life,The elimination half-life of intravenous indocyanine green was only 1 hour after oral nifedipine (20 mg) significantly decreased.,[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910493/),h,1,165139,DB00201,Caffeine
,20648686,recovery,The recovery of pramipexole from plasma ranged from 82.4 ± 7.1 to 87.8 ± 5.7%.,Development and validation of GC/MS method for determination of pramipexole in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20648686/),%,82.4,165263,DB00201,Caffeine
,20648686,recovery,The recovery of pramipexole from plasma ranged from 82.4 ± 7.1 to 87.8 ± 5.7%.,Development and validation of GC/MS method for determination of pramipexole in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20648686/),%,87.8,165264,DB00201,Caffeine
,11903871,peak blood level,"Following i.v. injection, CA (3 mg/kg) attained a peak blood level of nearly 5400 +/- 600 ng/mL and decreased with a half-life of 15.3 +/- 0.7 h.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],5400,165824,DB00201,Caffeine
,11903871,half-life,"Following i.v. injection, CA (3 mg/kg) attained a peak blood level of nearly 5400 +/- 600 ng/mL and decreased with a half-life of 15.3 +/- 0.7 h.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),h,15.3,165825,DB00201,Caffeine
,11903871,peak concentrations,"In contrast, the CA metabolites theophylline (TP) and theobromine (TB) exhibited delayed appearances in muscle and blood with peak concentrations of 300 +/- 60 ng/mL (TP) and 150 +/- 50 ng/mL (TB) detected in both tissues 1 day following CA administration.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],300,165826,DB00201,Caffeine
,11903871,peak concentrations,"In contrast, the CA metabolites theophylline (TP) and theobromine (TB) exhibited delayed appearances in muscle and blood with peak concentrations of 300 +/- 60 ng/mL (TP) and 150 +/- 50 ng/mL (TB) detected in both tissues 1 day following CA administration.",Continuous measurement of caffeine and two metabolites in blood and skeletal muscle of unrestrained adult horses by semi-automated in vivo microdialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903871/),[ng] / [ml],150,165827,DB00201,Caffeine
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],32,166423,DB00201,Caffeine
,14749695,systemic clearance,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],43,166424,DB00201,Caffeine
,14749695,area under the concentration-time curve,"Echinacea administration significantly increased the systemic clearance of midazolam by 34%, from 32 +/- 7 L/h to 43 +/- 16 L/h (P =.003; 90% confidence interval [CI], 116%-150%), and significantly reduced the midazolam area under the concentration-time curve by 23%, from 127 +/- 36 microg.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),μg,127,166425,DB00201,Caffeine
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],137,166426,DB00201,Caffeine
,14749695,oral clearance,"In contrast, the oral clearance of midazolam was not significantly altered (P =.655; 90% CI, 75%-124%), 137 +/- 19 L/h compared with 146 +/- 71 L/h.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],146,166427,DB00201,Caffeine
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),%,108,166428,DB00201,Caffeine
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.23,166429,DB00201,Caffeine
,14749695,oral availability,"The oral availability of midazolam after echinacea dosing was significantly increased (P =.028; 90% CI, 108%-153%), from 0.23 +/- 0.06 to 0.33 +/- 0.13.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166430,DB00201,Caffeine
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.72,166431,DB00201,Caffeine
,14749695,Hepatic availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166432,DB00201,Caffeine
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.33,166433,DB00201,Caffeine
,14749695,intestinal availability,"Hepatic availability (0.72 +/- 0.08 versus 0.61 +/- 0.16; P =.006; 90% CI, 73%-90%) and intestinal availability (0.33 +/- 0.11 versus 0.61 +/- 0.38; P =.015; 90% CI, 125%-203%) were significantly altered in opposite directions.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),,0.61,166434,DB00201,Caffeine
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],6.6,166435,DB00201,Caffeine
,14749695,oral clearance,"Echinacea dosing significantly reduced the oral clearance of caffeine, from 6.6 +/- 3.8 L/h to 4.9 +/- 2.3 L/h (P =.049; 90% CI, 58%-96%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],4.9,166436,DB00201,Caffeine
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.81,166437,DB00201,Caffeine
,14749695,oral clearance,"The oral clearance of tolbutamide was reduced by 11%, from 0.81 +/- 0.18 L/h to 0.72 +/- 0.19 L/h, but this change was not considered to be clinically relevant because the 90% CIs were within the 80% to 125% range.",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],0.72,166438,DB00201,Caffeine
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1289,166439,DB00201,Caffeine
,14749695,oral clearance,"The oral clearance of dextromethorphan in 11 CYP2D6 extensive metabolizers was not affected by echinacea dosing (1289 +/- 414 L/h compared with 1281 +/- 483 L/h; P =.732; 90% CI, 89%-108%).",The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749695/),[l] / [h],1281,166440,DB00201,Caffeine
,9880911,Tmax,"The Tmax of the CIB layer tablet was about 52 min, while that of the commercial tablet was about 103 min.",Absorption of ibuprofen coated by anhydrous silicic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9880911/),min,52,166800,DB00201,Caffeine
,9880911,Tmax,"The Tmax of the CIB layer tablet was about 52 min, while that of the commercial tablet was about 103 min.",Absorption of ibuprofen coated by anhydrous silicic acid. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9880911/),min,103,166801,DB00201,Caffeine
,7333346,apparent first-order elimination rate constant,The apparent first-order elimination rate constant decreased linearly with dose and was 0.163 +/- 0.081 h-1 for 50 mg and 0.098 +/- 0.027 h-1 for 750 mg.,Plasma and salivary pharmacokinetics of caffeine in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333346/),1/[h],0.163,168164,DB00201,Caffeine
,7333346,apparent first-order elimination rate constant,The apparent first-order elimination rate constant decreased linearly with dose and was 0.163 +/- 0.081 h-1 for 50 mg and 0.098 +/- 0.027 h-1 for 750 mg.,Plasma and salivary pharmacokinetics of caffeine in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333346/),1/[h],0.098,168165,DB00201,Caffeine
,7333346,total body clearance,The total body clearance was unaffected by dose and was 0.98 +/- 0.38 ml/min/kg.,Plasma and salivary pharmacokinetics of caffeine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333346/),[ml] / [kg·min],0.98,168166,DB00201,Caffeine
,7333346,saliva/plasma concentration ratio,Overall the saliva/plasma concentration ratio was 0.74 +/- 0.08 but within subjects some time-dependence of the ratio was found with higher ratios initially (even after intravenous administration) and lower ratios at longer time intervals after the dose.,Plasma and salivary pharmacokinetics of caffeine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7333346/),,0.74,168167,DB00201,Caffeine
,28444958,clearance,"Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test).",Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444958/),[l] / [h],3.15,168505,DB00201,Caffeine
,28444958,clearance,"Erlotinib clearance was lower in patients experiencing grade 2 or 3 rash as compared to patients experiencing grade 0 or 1 rash (3.15 versus 3.93 L/hr, p = 0.086 for Student's t-test).",Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444958/),[l] / [h],3.93,168506,DB00201,Caffeine
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],4.6,168775,DB00201,Caffeine
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.7,168776,DB00201,Caffeine
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],3.3,168777,DB00201,Caffeine
,25364857,maximum concentrations,"3. The mean maximum concentrations of R- and S-warfarin (4.6 and 3.7 µg/mL, respectively) in aged monkeys after oral administration were significantly higher than those in young monkeys (3.3 and 2.7 µg/mL).","Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[μg] / [ml],2.7,168778,DB00201,Caffeine
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],9.5,168779,DB00201,Caffeine
,25364857,clearance (CL),The mean clearance (CL) values of midazolam in aged monkeys (9.5 mL/min/kg) were significantly lower than those in young monkeys (13 mL/min/kg).,"Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25364857/),[ml] / [kg·min],13,168780,DB00201,Caffeine
,3731681,t1/2,"With a low-protein diet, mean theophylline clearance fell 21% (P less than 0.04) and the t1/2 rose from 8.0 to 10.6 hours (P less than 0.02).",Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731681/),h,8.0,168806,DB00201,Caffeine
,3731681,t1/2,"With a low-protein diet, mean theophylline clearance fell 21% (P less than 0.04) and the t1/2 rose from 8.0 to 10.6 hours (P less than 0.02).",Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731681/),h,10.6,168807,DB00201,Caffeine
,3731681,t1/2,"With a high-protein diet, mean theophylline clearance rose 26% (P less than 0.004) and the t1/2 shortened to 7.4 hours (P less than 0.03).",Effects of dietary protein on theophylline pharmacokinetics and caffeine and aminopyrine breath tests. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3731681/),h,7.4,168808,DB00201,Caffeine
,6691042,peak levels,Caffeine was detected by 15 minutes in saliva and milk; peak levels in milk (2.09 to 7.17 micrograms/mL) and saliva (1.24 to 9.22 micrograms/mL) were achieved within 1 hour.,"Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691042/),[μg] / [ml],2.09 to 7.17,169248,DB00201,Caffeine
,6691042,peak levels,Caffeine was detected by 15 minutes in saliva and milk; peak levels in milk (2.09 to 7.17 micrograms/mL) and saliva (1.24 to 9.22 micrograms/mL) were achieved within 1 hour.,"Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691042/),[μg] / [ml],1.24 to 9.22,169249,DB00201,Caffeine
,6691042,Elimination half-lives,Elimination half-lives were 1.3 to 13.5 hours (mean 4.0 +/- 3.7 [SD] hours) for saliva and 1.5 to 14.5 hours (mean 6.1 +/- 4.4 [SD] hours) for milk.,"Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691042/),h,1.3 to 13.5,169250,DB00201,Caffeine
,6691042,Elimination half-lives,Elimination half-lives were 1.3 to 13.5 hours (mean 4.0 +/- 3.7 [SD] hours) for saliva and 1.5 to 14.5 hours (mean 6.1 +/- 4.4 [SD] hours) for milk.,"Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691042/),h,4.0,169251,DB00201,Caffeine
,6691042,Elimination half-lives,Elimination half-lives were 1.3 to 13.5 hours (mean 4.0 +/- 3.7 [SD] hours) for saliva and 1.5 to 14.5 hours (mean 6.1 +/- 4.4 [SD] hours) for milk.,"Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691042/),h,1.5 to 14.5,169252,DB00201,Caffeine
,6691042,Elimination half-lives,Elimination half-lives were 1.3 to 13.5 hours (mean 4.0 +/- 3.7 [SD] hours) for saliva and 1.5 to 14.5 hours (mean 6.1 +/- 4.4 [SD] hours) for milk.,"Disposition of dietary caffeine in milk, saliva, and plasma of lactating women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691042/),h,6.1,169253,DB00201,Caffeine
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.1,169892,DB00201,Caffeine
,6626419,clearance,"The combination of main effects tended to cancel one another (clearance of 49.1 ml h-1 kg-1 ideal body weight for OC non-user, non-smoker, vs 49.7 ml h-1 kg-1 for OC user-smoker).",Effects of tobacco smoking and oral contraceptive use on theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626419/),[ml] / [h·kg],49.7,169893,DB00201,Caffeine
,8491248,apparent elimination,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,6.3,173369,DB00201,Caffeine
,8491248,apparent elimination,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,8.3,173370,DB00201,Caffeine
,8491248,half-life,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,6.3,173371,DB00201,Caffeine
,8491248,half-life,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),h,8.3,173372,DB00201,Caffeine
,8491248,total body clearance,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),[ml] / [h·kg],55.0,173373,DB00201,Caffeine
,8491248,total body clearance,"The apparent elimination of theophylline half-life was prolonged from 6.3 (0.61) h (mean with (SEM)) to 8.3 (0.47) h (32% increase, P < 0.01) and the total body clearance was reduced from 55.0 (1.31) ml.h-1.kg-1 to 42.5 (2.63) ml.h-1.kg-1 (23% decrease, P < 0.001).",Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8491248/),[ml] / [h·kg],42.5,173374,DB00201,Caffeine
,9190832,t(1/2),"Inasmuch as alprazolam was more potent and short-lived than caffeine in decreasing the reinforcement rate (consonant with their respective t(1/2) values, 0.44 and 3.1 hr), the alprazolam/caffeine potency ratio decreased across the session time, which determined the expression of the combined effects.","Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and caffeine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190832/),h,0.44,173572,DB00201,Caffeine
,9190832,t(1/2),"Inasmuch as alprazolam was more potent and short-lived than caffeine in decreasing the reinforcement rate (consonant with their respective t(1/2) values, 0.44 and 3.1 hr), the alprazolam/caffeine potency ratio decreased across the session time, which determined the expression of the combined effects.","Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: independent interaction of alprazolam and caffeine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190832/),h,3.1,173573,DB00201,Caffeine
,16236038,apparent oral clearance,Fluvoxamine significantly reduced apparent oral clearance of caffeine (105 vs.,Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236038/),,105,175340,DB00201,Caffeine
,16236038,elimination half-life,"9.1 mL min(-1), P < 0.01; mean difference: 95.7 mL min(-1), 95% CI: 54.9-135.6), and prolonged its elimination half-life (4.9 vs. 56 h, P < 0.01; mean difference: 51 h, 95% CI: 26-76).",Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236038/),h,4.9,175341,DB00201,Caffeine
,16236038,elimination half-life,"9.1 mL min(-1), P < 0.01; mean difference: 95.7 mL min(-1), 95% CI: 54.9-135.6), and prolonged its elimination half-life (4.9 vs. 56 h, P < 0.01; mean difference: 51 h, 95% CI: 26-76).",Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16236038/),h,56,175342,DB00201,Caffeine
,7627246,elimination half-life (T1/2),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),h,6.54,175396,DB00201,Caffeine
,7627246,clearance (CLo),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),h,6.08,175397,DB00201,Caffeine
,7627246,clearance (CLo),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[ml] / [min],100.7,175398,DB00201,Caffeine
,7627246,clearance (CLo),"Caffeine elimination half-life (T1/2) and clearance (CLo) were similar in obese and lean subjects (6.54 +/- 2.85 vs 6.08 +/- 2.23 h respectively and 100.7 +/- 49.5 vs 82.6 +/- 34.0 ml/min respectively, P > 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[ml] / [min],82.6,175399,DB00201,Caffeine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,48.3,175400,DB00201,Caffeine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,40.1,175401,DB00201,Caffeine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.44,175402,DB00201,Caffeine
,7627246,Varea,"Caffeine Varea was greater in group A than in Group B (48.3 +/- 11.4 vs 40.1 +/- 13.0 L respectively, P = 0.06) but when corrected for body weight significantly reduced values were obtained in the obese group (0.44 +/- 0.06 vs 0.59 +/- 0.10 L/kg respectively, P < 0.001).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.59,175403,DB00201,Caffeine
,7627246,Varea,"In group A subjects caffeine and antipyrine Varea were similar (48.3 +/- 11.4 vs 49.9 +/- 9.3 L respectively, P > 0.3).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,48.3,175404,DB00201,Caffeine
,7627246,Varea,"In group A subjects caffeine and antipyrine Varea were similar (48.3 +/- 11.4 vs 49.9 +/- 9.3 L respectively, P > 0.3).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,49.9,175405,DB00201,Caffeine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,55.6,175406,DB00201,Caffeine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),l,47.8,175407,DB00201,Caffeine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.46,175408,DB00201,Caffeine
,7627246,Varea,"Caffeine T1/2 and CLo were not significantly altered by the 30.2 +/- 12.3 kg weight loss obtained in Group C subjects, but caffeine Varea was significantly reduced (55.6 +/- 9.3 L before, 47.8 +/- 9.5 L after, P < 0.04) and Varea corrected for body weight was significantly increased (0.46 +/- 0.03 L/kg before, 0.52 +/- 0.05 L/kg after, P < 0.05).",Caffeine pharmacokinetics in obesity and following significant weight reduction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7627246/),[l] / [kg],0.52,175409,DB00201,Caffeine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,15.5,176054,DB00201,Caffeine
,12087345,half-lives,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),h,5.6,176055,DB00201,Caffeine
,12087345,oral clearance,Two subjects who were taking oral contraceptives had longer caffeine half-lives (15.5 +/- 0.3 hours versus 5.6 +/- 1.7 hours) and lower values for oral clearance (0.34 +/- 0.01 mL/min.,Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12087345/),[ml] / [min],0.34,176056,DB00201,Caffeine
,30956977,concentration,"Mean ± standard deviation for CZP and NCZP concentration was 421 ± 262 ng/mL and 275 ± 180 ng/mL, respectively.",Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956977/),[ng] / [ml],421,176108,DB00201,Caffeine
,30956977,concentration,"Mean ± standard deviation for CZP and NCZP concentration was 421 ± 262 ng/mL and 275 ± 180 ng/mL, respectively.",Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30956977/),[ng] / [ml],275,176109,DB00201,Caffeine
,1747504,half-life,"After each bolus, the time course of serum concentration was described by a single exponential, yielding an estimation of caffeine half-life: 310 +/- 46 (n = 9) and 453 +/- 59 min (n = 9), respectively.",Investigations on caffeine passage into the canine gastric juice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747504/),min,310,177415,DB00201,Caffeine
,1747504,half-life,"After each bolus, the time course of serum concentration was described by a single exponential, yielding an estimation of caffeine half-life: 310 +/- 46 (n = 9) and 453 +/- 59 min (n = 9), respectively.",Investigations on caffeine passage into the canine gastric juice. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747504/),min,453,177416,DB00201,Caffeine
,1747504,apparent volume of distribution,In both cases the same apparent volume of distribution: 0.87 +/- 0.02 l/kg (n = 9) was found.,Investigations on caffeine passage into the canine gastric juice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1747504/),[l] / [kg],0.87,177417,DB00201,Caffeine
,23112399,C(max),"B5 revealed non-significant mean C(max), t(1/2), and AUC of 1.88 μg/ml, 5.52 h and 9.67 μg.h/ml respectively compared to B7.",Determination and estimation of pharmacokinetic profile of caffeine in form of extract of green tea leaves and its analogy with synthetic form. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112399/),[μg] / [ml],1.88,177795,DB00201,Caffeine
,23112399,t(1/2),"B5 revealed non-significant mean C(max), t(1/2), and AUC of 1.88 μg/ml, 5.52 h and 9.67 μg.h/ml respectively compared to B7.",Determination and estimation of pharmacokinetic profile of caffeine in form of extract of green tea leaves and its analogy with synthetic form. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112399/),h,5.52,177796,DB00201,Caffeine
,23112399,AUC,"B5 revealed non-significant mean C(max), t(1/2), and AUC of 1.88 μg/ml, 5.52 h and 9.67 μg.h/ml respectively compared to B7.",Determination and estimation of pharmacokinetic profile of caffeine in form of extract of green tea leaves and its analogy with synthetic form. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23112399/),[h·μg] / [ml],9.67,177797,DB00201,Caffeine
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,7.1,179595,DB00201,Caffeine
,23355638,steady-state plasma concentration (Css) ratio,The predicted mean PAR steady-state plasma concentration (Css) ratio (PP:T3) was 7.1 versus the observed value 3.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,3.7,179596,DB00201,Caffeine
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,2.2,179597,DB00201,Caffeine
,23355638,AUC ratio,Predicted mean CLO AUC ratio (PP:T3) was 2.2 versus the observed value 1.7.,A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23355638/),,1.7,179598,DB00201,Caffeine
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],77.8,180503,DB00201,Caffeine
,1319876,area under the plasma concentration-time curve,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),[mg] / [h·l],31.8,180504,DB00201,Caffeine
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,9.7,180505,DB00201,Caffeine
,1319876,terminal-phase half-life,A doubling of the area under the plasma concentration-time curve (77.8 vs 31.8 mg/L.h) and terminal-phase half-life (9.7 vs 4.5h) of caffeine were observed in the presence of ciprofloxacin.,Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1319876/),h,4.5,180506,DB00201,Caffeine
,20853468,extraction recovery,The extraction recovery for paraxanthine and caffeine was approximately 70% in both saliva and plasma.,Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853468/),%,70,181494,DB00201,Caffeine
,20853468,Detection limits,"Detection limits were 0.015 µg/mL for paraxanthine and caffeine in saliva, while it was 0.005 µg/mL for paraxanthine and caffeine in plasma.",Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853468/),[μg] / [ml],0.015,181495,DB00201,Caffeine
,20853468,Detection limits,"Detection limits were 0.015 µg/mL for paraxanthine and caffeine in saliva, while it was 0.005 µg/mL for paraxanthine and caffeine in plasma.",Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853468/),[μg] / [ml],0.005,181496,DB00201,Caffeine
,15319329,maximum concentration,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[ng] / [ml],33,182925,DB00201,Caffeine
,15319329,maximum concentration,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[ng] / [ml],34,182926,DB00201,Caffeine
,15319329,time to reach maximum concentration,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),h,1.4,182927,DB00201,Caffeine
,15319329,area under the plasma concentration versus time curve,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[h·ng] / [ml],480,182928,DB00201,Caffeine
,15319329,area under the plasma concentration versus time curve,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),[h·ng] / [ml],510,182929,DB00201,Caffeine
,15319329,half-life of elimination,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),h,12.3,182930,DB00201,Caffeine
,15319329,half-life of elimination,"There were no significant differences in ALPZ pharmacokinetics at baseline and after DGT treatment (all P values >/= 0.05; maximum concentration in plasma, 33 +/- 8 versus 34 +/- 13 ng/ml; time to reach maximum concentration in plasma, 1.4 +/- 1.2 versus 1.4 +/- 1.2 h; area under the plasma concentration versus time curve, 480 +/- 119 versus 510 +/- 107 h. ng. ml(-1); half-life of elimination, 12.3 +/- 1.7 versus 13.1 +/- 3.4 h).",Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),h,13.1,182931,DB00201,Caffeine
,15319329,DMR,The DMR was 0.053 +/- 0.045 at baseline and 0.041 +/- 0.032 after DGT supplementation (P > 0.05).,Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),,0.053,182932,DB00201,Caffeine
,15319329,DMR,The DMR was 0.053 +/- 0.045 at baseline and 0.041 +/- 0.032 after DGT supplementation (P > 0.05).,Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319329/),,0.041,182933,DB00201,Caffeine
,6886969,half-lives,"Although the average elimination rate constant was greater in the elderly, the difference did not reach statistical significance, possibly because of the considerable intersubject variability in the elimination rate of caffeine, with half-lives ranging from 2.27 to 9.87 hr.",Comparative pharmacokinetics of caffeine in young and elderly men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6886969/),h,2.27 to 9.87,184620,DB00201,Caffeine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],11.1,185244,DB00201,Caffeine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],12.0,185245,DB00201,Caffeine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],27.7,185246,DB00201,Caffeine
,18704388,AUC,"Geometric mean (CV%) values in study A for slow [rapid] acetylators were as follows: mesalazine AUC 11.1 microg/mL.h (51%) [12.0 microg/mL.h (52%)], N-acetylmesalazine AUC 27.7 microg/mL.h (32%) [30.5 microg/mL.h (27%)], mesalazine Ae 8.53% (89%) [9.03% (52%)], N-acetylmesalazine Ae 31.4% (46%) [32.2 (41%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],30.5,185247,DB00201,Caffeine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],3.45,185248,DB00201,Caffeine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],2.36,185249,DB00201,Caffeine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],21.3,185250,DB00201,Caffeine
,18704388,AUC,"Values in study B were as follows: mesalazine AUC 3.45 microg/mL.h (113%) [2.36 microg/mL.h (87%)], N-acetylmesalazine AUC 21.3 microg/mL.h (29%) [18.0 microg/mL.h (39%)], mesalazine Ae 0.2% (256%) [0.1% (359%)], N-acetylmesalazine Ae 30.9% (44%) [18.1% (84%)].",Mesalazine pharmacokinetics and NAT2 phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18704388/),[μg] / [h·ml],18.0,185251,DB00201,Caffeine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],8.0,185266,DB00201,Caffeine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],2.1,185267,DB00201,Caffeine
,2357862,t[24],"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),,2.4,185268,DB00201,Caffeine
,2713214,peak salivary caffeine concentration,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[mg] / [l],10.9,186571,DB00201,Caffeine
,2713214,peak salivary caffeine concentration,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[mg] / [l],7.1,186572,DB00201,Caffeine
,2713214,apparent volume of distribution,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[l] / [kg],0.38,186573,DB00201,Caffeine
,2713214,apparent volume of distribution,"4. In the patients with compensated cirrhosis, the median peak salivary caffeine concentration, 10.9 (8.2-16.5) mg l-1 was significantly greater than in controls, 7.1 (4.7-11.8) mg l-1 (P less than 0.01) and the median apparent volume of distribution was significantly reduced, 0.38 (0.19-0.49) vs 0.41 (0.23-0.63) l kg-1 (P less than 0.05).",The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713214/),[l] / [kg],0.41,186574,DB00201,Caffeine
,23501441,recoveries,The mean recoveries of doxofylline from DBS and urine were 93.46 and 89.86% respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),%,93.46,186824,DB00201,Caffeine
,23501441,recoveries,The mean recoveries of doxofylline from DBS and urine were 93.46 and 89.86% respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),%,89.86,186825,DB00201,Caffeine
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],0.24,186826,DB00201,Caffeine
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],0.84,186827,DB00201,Caffeine
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],0.28,186828,DB00201,Caffeine
,23501441,limit of detection,The limit of detection and quantification were 0.24 and 0.84 ng/mL in DBS and 0.28 and 1.00 ng/mL in urine samples respectively.,Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23501441/),[ng] / [ml],1.00,186829,DB00201,Caffeine
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.5,187837,DB00201,Caffeine
,15592331,elimination half-life,"Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(0-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007).",Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592331/),h,1.8,187838,DB00201,Caffeine
,28011360,metabolic ratio,NAT2 metabolic ratio was significantly reduced following peppermint consumption (0.15 ± 0.13 vs 0.14 ± 0.13; p < 0.05).,"Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28011360/),,0.15,188963,DB00201,Caffeine
,28011360,metabolic ratio,NAT2 metabolic ratio was significantly reduced following peppermint consumption (0.15 ± 0.13 vs 0.14 ± 0.13; p < 0.05).,"Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28011360/),,0.14,188964,DB00201,Caffeine
,16158445,T(max),The mean T(max) after the third dosing ranged from 0.37 to 1.12 h.,Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),h,0.37 to 1.12,189110,DB00201,Caffeine
,16158445,C(max),"C(max) for 50, 100 and 200 mg was 2.69, 3.45 and 6.33 mg/l, respectively.",Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),[mg] / [l],2.69,189111,DB00201,Caffeine
,16158445,C(max),"C(max) for 50, 100 and 200 mg was 2.69, 3.45 and 6.33 mg/l, respectively.",Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),[mg] / [l],3.45,189112,DB00201,Caffeine
,16158445,C(max),"C(max) for 50, 100 and 200 mg was 2.69, 3.45 and 6.33 mg/l, respectively.",Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),[mg] / [l],6.33,189113,DB00201,Caffeine
,16158445,AUC(inf),"AUC(inf) for 50, 100 and 200 mg group was 33.2, 46.94 and 86.94 mg/l * h, respectively.",Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),[mg] / [h·l],33.2,189114,DB00201,Caffeine
,16158445,AUC(inf),"AUC(inf) for 50, 100 and 200 mg group was 33.2, 46.94 and 86.94 mg/l * h, respectively.",Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),[mg] / [h·l],46.94,189115,DB00201,Caffeine
,16158445,AUC(inf),"AUC(inf) for 50, 100 and 200 mg group was 33.2, 46.94 and 86.94 mg/l * h, respectively.",Multiple dose pharmacokinetics of caffeine administered in chewing gum to normal healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16158445/),[mg] / [h·l],86.94,189116,DB00201,Caffeine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,21.5,189217,DB00201,Caffeine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,12.2,189218,DB00201,Caffeine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,15.1,189219,DB00201,Caffeine
,21092089,terminal half-life,Placebo-plus-interaction effect increased caffeine terminal half-life by 0.40 [0.12 to 0.68] hr (P=0.007).,Interaction between drug and placebo effects: a cross-over balanced placebo design trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21092089/),h,0.40,189740,DB00201,Caffeine
,21476905,clearance,"The clearance of CF was 0.08 ± 0.02 L/h/kg, and the volume of distribution was 0.91 ± 0.16 L/kg.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),[l] / [h·kg],0.08,192013,DB00201,Caffeine
,21476905,volume of distribution,"The clearance of CF was 0.08 ± 0.02 L/h/kg, and the volume of distribution was 0.91 ± 0.16 L/kg.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),[l] / [kg],0.91,192014,DB00201,Caffeine
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.24,192015,DB00201,Caffeine
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.37,192016,DB00201,Caffeine
,21476905,dem,"The demethylation fractions of CF to TB, PX and TP were 0.24, 0.37 and 0.39, respectively.",Measurements of caffeine and plasma metabolite/caffeine ratios as a test for hepatic drug-oxidizing capacity in goats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21476905/),,0.39,192017,DB00201,Caffeine
,32725383,Vss ratio,"Changes in exposure (area under the curve) up to 5.1-fold were observed; however, ratios of Vss changes have a range of 0.70-1.26, with one outlier displaying a Vss ratio of 0.57.",Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32725383/),,0.57,192758,DB00201,Caffeine
,21827488,C(t),"The optimal paraxanthine/caffeine C(t) that correlated with the plasma paraxanthine/caffeine AUC(0-24) ratio in the 24-h abstinence period was 2 and 4h (r=0.88) in plasma, and 4 and 6h in saliva (r=0.70), while it was the saliva 4h time-point in the no abstinence period (r=0.78).","Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827488/),h,2,193226,DB00201,Caffeine
,21827488,C(t),"The optimal paraxanthine/caffeine C(t) that correlated with the plasma paraxanthine/caffeine AUC(0-24) ratio in the 24-h abstinence period was 2 and 4h (r=0.88) in plasma, and 4 and 6h in saliva (r=0.70), while it was the saliva 4h time-point in the no abstinence period (r=0.78).","Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827488/),h,4,193227,DB00201,Caffeine
,21827488,C(t),"The optimal paraxanthine/caffeine C(t) that correlated with the plasma paraxanthine/caffeine AUC(0-24) ratio in the 24-h abstinence period was 2 and 4h (r=0.88) in plasma, and 4 and 6h in saliva (r=0.70), while it was the saliva 4h time-point in the no abstinence period (r=0.78).","Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827488/),h,6,193228,DB00201,Caffeine
,12222750,hydroxylation index,Four PMs were identified with the omeprazole phenotype probe and had a mean +/- SD hydroxylation index of 1.335 +/- 0.271.,Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12222750/),,1.335,196426,DB00201,Caffeine
,3612497,clearances,Caffeine clearances of 1.52-6.71 ml/min/kg were observed and were suggestive of polymorphism with rapid (type I) and slow (type II) metabolizing subpopulations represented.,Caffeine and paraxanthine pharmacokinetics in the rabbit: concentration and product inhibition effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3612497/),[ml] / [kg·min],1.52-6.71,196896,DB00201,Caffeine
,11145772,AUCs,"AUCs were 298.5+/-82.5 mg-h/L (control), 77.1+/-85.2 mg-h/L (superactivated charcoal), and 81.3 +/- 71.8 mg-h/L (superactivated charcoal-cola).",Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145772/),[mg-h] / [l],298.5,196938,DB00201,Caffeine
,11145772,AUCs,"AUCs were 298.5+/-82.5 mg-h/L (control), 77.1+/-85.2 mg-h/L (superactivated charcoal), and 81.3 +/- 71.8 mg-h/L (superactivated charcoal-cola).",Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145772/),[mg-h] / [l],77.1,196939,DB00201,Caffeine
,11145772,AUCs,"AUCs were 298.5+/-82.5 mg-h/L (control), 77.1+/-85.2 mg-h/L (superactivated charcoal), and 81.3 +/- 71.8 mg-h/L (superactivated charcoal-cola).",Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11145772/),[mg-h] / [l],81.3,196940,DB00201,Caffeine
,9447474,clearance,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),[ml] / [min],1.65 to 2.05,197432,DB00201,Caffeine
,9447474,clearance,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),[ml] / [min],1.65 to 2.06,197433,DB00201,Caffeine
,9447474,half-life,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),h,5.3 to 4,197434,DB00201,Caffeine
,9447474,half-life,"Total caffeine clearance increased on average by 24% (from 1.65 to 2.05 ml/min, P = 0.1) 2 days after antipyrine dosing, and 25% (from 1.65 to 2.06 ml/min, P < 0.01) 5 days after the administration of antipyrine, whereas the half-life decreased by around 24% (from 5.3 to 4 h, P = 0.09) after 2 days and 26% (from 5.3 to 3.9 h, P = 0.05) after 5 days.",A pilot study of the effect of antipyrine on caffeine kinetics in six healthy volunteer subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9447474/),h,5.3 to 3.9,197435,DB00201,Caffeine
,12121905,concentration,The concentration in plasma (1.85 +/- 1.60 microg/ml [mean +/- standard deviation; n = 80]) at 1 h following administration of the last dose was not significantly different from that in ELF (2.25 +/- 3.50 microg/ml) or ACs (2.61 +/- 5.01 microg/ml).,"Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121905/),[μg] / [ml],1.85,198099,DB00201,Caffeine
,12121905,concentration,The concentration in plasma (1.85 +/- 1.60 microg/ml [mean +/- standard deviation; n = 80]) at 1 h following administration of the last dose was not significantly different from that in ELF (2.25 +/- 3.50 microg/ml) or ACs (2.61 +/- 5.01 microg/ml).,"Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121905/),[μg] / [ml],2.25,198100,DB00201,Caffeine
,12121905,concentration,The concentration in plasma (1.85 +/- 1.60 microg/ml [mean +/- standard deviation; n = 80]) at 1 h following administration of the last dose was not significantly different from that in ELF (2.25 +/- 3.50 microg/ml) or ACs (2.61 +/- 5.01 microg/ml).,"Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12121905/),[μg] / [ml],2.61,198101,DB00201,Caffeine
,1875916,signal to noise ratio,"The limit of detection, defined as the injected quantity of caffeine giving rise to a signal to noise ratio of 2, is 40 pg, corresponding to a plasma concentration of 1 ng/ml.","Rapid and sensitive gas-chromatographic determination of caffeine in blood plasma, saliva, and xanthine beverages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1875916/),,2,198594,DB00201,Caffeine
,19734672,area under the plasma EGCG concentration-time curve (AUC),"As for the results, in plasma taken after ingestion of a beverage containing 95 mg of EGCG alone, the area under the plasma EGCG concentration-time curve (AUC) was 857 ngxh/ml.",Effects of co-administration of tea epigallocatechin-3-gallate (EGCG) and caffeine on absorption and metabolism of EGCG in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19734672/),[h·ng] / [ml],857,199941,DB00201,Caffeine
,19734672,AUC,"A higher AUC (1,370 ngxh/ml) was observed when subjects ingested a beverage containing EGCG (95 mg) and a low amount of CAF (40 mg).",Effects of co-administration of tea epigallocatechin-3-gallate (EGCG) and caffeine on absorption and metabolism of EGCG in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19734672/),[h·ng] / [ml],"1,370",199942,DB00201,Caffeine
,19734672,AUC,"In the case of ingestion of a beverage containing EGCG (95 mg) and a high amount of CAF (180 mg), the AUC tended to be somewhat higher (1,165 ngxh/ml), but not significantly so, compared with the beverage with EGCG alone.",Effects of co-administration of tea epigallocatechin-3-gallate (EGCG) and caffeine on absorption and metabolism of EGCG in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19734672/),[h·ng] / [ml],"1,165",199943,DB00201,Caffeine
,8090799,AUCs,There were two- to threefold higher locomotor activity AUCs(4 h) with oral caffeine at three dose levels compared to the activity AUCs(4 h) for IP doses.,Tolerance to oral and IP caffeine: locomotor activity and pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8090799/),h,4,201630,DB00201,Caffeine
,30990904,m/,"GL-V9 and caffeine (internal standard) were monitored by positive electrospray triple quadrupole mass spectrometer and quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 410.20 → 126.10 (GL-V9) and 195.10 → 138.00 (IS: caffeine), respectively.","Determination of GL-V9, a derivative of wogonin, in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after oral and pulmonary administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30990904/),,410.20,202193,DB00201,Caffeine
,30990904,m/,"GL-V9 and caffeine (internal standard) were monitored by positive electrospray triple quadrupole mass spectrometer and quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 410.20 → 126.10 (GL-V9) and 195.10 → 138.00 (IS: caffeine), respectively.","Determination of GL-V9, a derivative of wogonin, in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after oral and pulmonary administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30990904/),,126,202194,DB00201,Caffeine
,30990904,m/,"GL-V9 and caffeine (internal standard) were monitored by positive electrospray triple quadrupole mass spectrometer and quantified using multiple reaction monitoring (MRM) mode with the transitions of m/z 410.20 → 126.10 (GL-V9) and 195.10 → 138.00 (IS: caffeine), respectively.","Determination of GL-V9, a derivative of wogonin, in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after oral and pulmonary administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30990904/),,195.10,202195,DB00201,Caffeine
,30990904,extraction recovery,Good linearity was obtained over the range of 2-1000 ng/mL (R2 > 0.99) and the extraction recovery was 101.91 ± 11.34%.,"Determination of GL-V9, a derivative of wogonin, in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study after oral and pulmonary administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30990904/),%,101.91,202196,DB00201,Caffeine
,3193494,elimination half-life,Three serum caffeine levels were analyzed and an abnormally long elimination half-life of approximately 16 hours was calculated from the results.,Caffeine overdose in an adolescent male. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3193494/),h,16,202604,DB00201,Caffeine
,7661457,elimination half-life,"Harmonic mean elimination half-life was 3.8 (range, 2.6 to 6.9) hours, and total clearance was 0.118 (range, 0.090 to 0.197) L/kg/h.",Pharmacokinetics of caffeine in lactating dairy cows. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661457/),h,3.8,204492,DB00201,Caffeine
,7661457,total clearance,"Harmonic mean elimination half-life was 3.8 (range, 2.6 to 6.9) hours, and total clearance was 0.118 (range, 0.090 to 0.197) L/kg/h.",Pharmacokinetics of caffeine in lactating dairy cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661457/),[l] / [h·kg],0.118,204493,DB00201,Caffeine
,3407246,absorption rate constant KA,"Compared with controls (n = 15), a significantly slowed caffeine absorption was found in gastric stasis (n = 8) by means of a lower absorption rate constant KA (0.018 +/- 0.007 vs. 0.122 +/- 0.110 min-1 in controls) and a prolonged peak time tmax (160 +/- 77 vs. 46 +/- 19 min).",Effect of altered gastric emptying on caffeine absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),1/[min],0.018,206856,DB00201,Caffeine
,3407246,absorption rate constant KA,"Compared with controls (n = 15), a significantly slowed caffeine absorption was found in gastric stasis (n = 8) by means of a lower absorption rate constant KA (0.018 +/- 0.007 vs. 0.122 +/- 0.110 min-1 in controls) and a prolonged peak time tmax (160 +/- 77 vs. 46 +/- 19 min).",Effect of altered gastric emptying on caffeine absorption. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),1/[min],0.122,206857,DB00201,Caffeine
,3407246,peak time tmax,"Compared with controls (n = 15), a significantly slowed caffeine absorption was found in gastric stasis (n = 8) by means of a lower absorption rate constant KA (0.018 +/- 0.007 vs. 0.122 +/- 0.110 min-1 in controls) and a prolonged peak time tmax (160 +/- 77 vs. 46 +/- 19 min).",Effect of altered gastric emptying on caffeine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),min,160,206858,DB00201,Caffeine
,3407246,peak time tmax,"Compared with controls (n = 15), a significantly slowed caffeine absorption was found in gastric stasis (n = 8) by means of a lower absorption rate constant KA (0.018 +/- 0.007 vs. 0.122 +/- 0.110 min-1 in controls) and a prolonged peak time tmax (160 +/- 77 vs. 46 +/- 19 min).",Effect of altered gastric emptying on caffeine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),min,46,206859,DB00201,Caffeine
,3407246,KA,"Similar results were obtained after a fibre-free and a fibre-rich liquid test meal, respectively (n = 8 and n = 8, respectively; KA 0.035 +/- 0.01 and 0.035 +/- 0.023 min-1, respectively; tmax 91 +/- 24 and 93 +/- 23 min, respectively vs. KA 0.10 +/- 0.06 min-1 and tmax 50 +/- 14 min in controls; n = 7).",Effect of altered gastric emptying on caffeine absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),1/[min],0.035,206860,DB00201,Caffeine
,3407246,KA,"Similar results were obtained after a fibre-free and a fibre-rich liquid test meal, respectively (n = 8 and n = 8, respectively; KA 0.035 +/- 0.01 and 0.035 +/- 0.023 min-1, respectively; tmax 91 +/- 24 and 93 +/- 23 min, respectively vs. KA 0.10 +/- 0.06 min-1 and tmax 50 +/- 14 min in controls; n = 7).",Effect of altered gastric emptying on caffeine absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),1/[min],0.035,206861,DB00201,Caffeine
,3407246,tmax,"Similar results were obtained after a fibre-free and a fibre-rich liquid test meal, respectively (n = 8 and n = 8, respectively; KA 0.035 +/- 0.01 and 0.035 +/- 0.023 min-1, respectively; tmax 91 +/- 24 and 93 +/- 23 min, respectively vs. KA 0.10 +/- 0.06 min-1 and tmax 50 +/- 14 min in controls; n = 7).",Effect of altered gastric emptying on caffeine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),min,91,206862,DB00201,Caffeine
,3407246,tmax,"Similar results were obtained after a fibre-free and a fibre-rich liquid test meal, respectively (n = 8 and n = 8, respectively; KA 0.035 +/- 0.01 and 0.035 +/- 0.023 min-1, respectively; tmax 91 +/- 24 and 93 +/- 23 min, respectively vs. KA 0.10 +/- 0.06 min-1 and tmax 50 +/- 14 min in controls; n = 7).",Effect of altered gastric emptying on caffeine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),min,93,206863,DB00201,Caffeine
,3407246,KA,"Similar results were obtained after a fibre-free and a fibre-rich liquid test meal, respectively (n = 8 and n = 8, respectively; KA 0.035 +/- 0.01 and 0.035 +/- 0.023 min-1, respectively; tmax 91 +/- 24 and 93 +/- 23 min, respectively vs. KA 0.10 +/- 0.06 min-1 and tmax 50 +/- 14 min in controls; n = 7).",Effect of altered gastric emptying on caffeine absorption. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),1/[min],0.10,206864,DB00201,Caffeine
,3407246,tmax,"Similar results were obtained after a fibre-free and a fibre-rich liquid test meal, respectively (n = 8 and n = 8, respectively; KA 0.035 +/- 0.01 and 0.035 +/- 0.023 min-1, respectively; tmax 91 +/- 24 and 93 +/- 23 min, respectively vs. KA 0.10 +/- 0.06 min-1 and tmax 50 +/- 14 min in controls; n = 7).",Effect of altered gastric emptying on caffeine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),min,50,206865,DB00201,Caffeine
,3407246,peak concentration cmax,"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[μg] / [ml],5.9,206866,DB00201,Caffeine
,3407246,peak concentration cmax,"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[μg] / [ml],8.8,206867,DB00201,Caffeine
,3407246,peak concentration cmax,"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[μg] / [ml],17.7,206868,DB00201,Caffeine
,3407246,area under the serum concentration-time curve x elimination rate constant (AUC x KE),"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[mg] / [l],8.9,206869,DB00201,Caffeine
,3407246,area under the serum concentration-time curve x elimination rate constant (AUC x KE),"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[mg] / [l],10.8,206870,DB00201,Caffeine
,3407246,area under the serum concentration-time curve x elimination rate constant (AUC x KE),"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[μg] / [ml],17.7,206871,DB00201,Caffeine
,3407246,area under the serum concentration-time curve x elimination rate constant (AUC x KE),"The significantly lower average of the peak concentration cmax and of the area under the serum concentration-time curve x elimination rate constant (AUC x KE) in gastric stasis (5.9 +/- 1.8 micrograms/ml and 8.9 +/- 3.2 mg/l, respectively) and after B II partial gastrectomy (8.8 +/- 2.6 micrograms/ml and 10.8 +/- 3.0 mg/l, respectively) compared with controls (17.7 +/- 9.4 micrograms/ml and 20.8 +/- 10.7 mg/l respectively) probably reflect reduced bioavailability, which is apparently unchanged after a liquid test meal.",Effect of altered gastric emptying on caffeine absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3407246/),[mg] / [l],20.8,206872,DB00201,Caffeine
,2396307,detection limit,The detection limit was 6 nM.,Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396307/),nM,6,207226,DB00201,Caffeine
,2396307,detection limit,A Beckman ODS column was used and the detection limit was 5 nM.,Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396307/),nM,5,207227,DB00201,Caffeine
,16371327,Peak plasma concentrations,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),μM,50,207769,DB00201,Caffeine
,16371327,half-lives for elimination,"Peak plasma concentrations after normal consumption are usually around 50 microM, and half-lives for elimination range between 2.5-10 h.","Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16371327/),h,2.5-10,207770,DB00201,Caffeine
,2069371,maximum caffeine concentrations,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[μg] / [ml],4.35,208657,DB00201,Caffeine
,2069371,maximum caffeine concentrations,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[μg] / [ml],4.07,208658,DB00201,Caffeine
,2069371,areas under the concentration-time curve from time zero to 24 h at steady state,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[h·μg] / [ml],30.3,208659,DB00201,Caffeine
,2069371,areas under the concentration-time curve from time zero to 24 h at steady state,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),[h·μg] / [ml],29.7,208660,DB00201,Caffeine
,2069371,elimination half-lives,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),h,4.8,208661,DB00201,Caffeine
,2069371,elimination half-lives,"For the placebo versus lomefloxacin-containing treatments, maximum caffeine concentrations in plasma (4.35 +/- 0.63 versus 4.07 +/- 0.56 micrograms/ml), areas under the concentration-time curve from time zero to 24 h at steady state (30.3 +/- 6.9 versus 29.7 +/- 6.6 micrograms.h/ml), and elimination half-lives of caffeine (4.8 +/- 1.1 versus 4.8 +/- 1.2 h) were not significantly different.",Lack of interaction between lomefloxacin and caffeine in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2069371/),h,4.8,208662,DB00201,Caffeine
,17725176,renal clearance,"Coadministration of probenecid resulted in a 34% reduction of the renal clearance of 1-MX (mean +/- SD 190 +/- 42 versus 290 +/- 83 ml min(-1), 95% CI on difference 0.2, 200, p = 0.04) with a 41% reduction in its estimated non-glomerular clearance.",Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725176/),[ml] / [min],190,208670,DB00201,Caffeine
,17725176,renal clearance,"Coadministration of probenecid resulted in a 34% reduction of the renal clearance of 1-MX (mean +/- SD 190 +/- 42 versus 290 +/- 83 ml min(-1), 95% CI on difference 0.2, 200, p = 0.04) with a 41% reduction in its estimated non-glomerular clearance.",Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17725176/),[ml] / [min],290,208671,DB00201,Caffeine
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,2,209255,DB00201,Caffeine
,8530713,systemic bioavailability,Oral estrogens have minimal systemic bioavailability (2% to 10%) due to gut and liver (first-pass) metabolism.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),%,10,209256,DB00201,Caffeine
,8530713,terminal half lives,The terminal half lives for the different estrogen compounds (after oral or intravenous administration) vary from 1-12 hours.,Pharmacokinetic and pharmacologic variation between different estrogen products. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8530713/),h,1-12,209257,DB00201,Caffeine
,4084271,t 1/2,It was found a significant prolongation of caffeine elimination in pregnancy (t 1/2 = 9.4 +/- 0.6 h) with a correlation between duration of pregnancy and elimination half-life of caffeine (v = 0.72).,[Determination of caffeine and metamizole elimination in pregnancy and after delivery as an in vivo method for characterization of various cytochrome p-450 dependent biotransformation reactions]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4084271/),h,9.4,209284,DB00201,Caffeine
less,12734608,fraction excreted unchanged in urine,The fraction excreted unchanged in urine was less than 0.2% for clomethiazole and less than 0.4% for NLA-715.,Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12734608/),%,0.2,209479,DB00201,Caffeine
less,12734608,fraction excreted unchanged in urine,The fraction excreted unchanged in urine was less than 0.2% for clomethiazole and less than 0.4% for NLA-715.,Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12734608/),%,0.4,209480,DB00201,Caffeine
,12734608,Plasma clearance,Plasma clearance of clomethiazole in subjects with mildly impaired liver function was not statistically different from that of healthy controls (40 l/h vs 44 l/h).,Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12734608/),[l] / [h],40,209481,DB00201,Caffeine
,12734608,Plasma clearance,Plasma clearance of clomethiazole in subjects with mildly impaired liver function was not statistically different from that of healthy controls (40 l/h vs 44 l/h).,Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12734608/),[l] / [h],44,209482,DB00201,Caffeine
,4029248,elimination half-life,"OCS subjects had a prolonged elimination half-life of caffeine, (mean 7.88 h vs 5.37 h in the controls).",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),h,7.88,209644,DB00201,Caffeine
,4029248,elimination half-life,"OCS subjects had a prolonged elimination half-life of caffeine, (mean 7.88 h vs 5.37 h in the controls).",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),h,5.37,209645,DB00201,Caffeine
,4029248,plasma clearance,"This was the result of marked impairment of the plasma clearance of caffeine (1.05 vs 1.75 ml/min/kg, respectively) with no change in apparent volume of distribution (0.685 in OCS vs 0.7501/kg in the control group).",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),[ml] / [kg·min],1.05,209646,DB00201,Caffeine
,4029248,plasma clearance,"This was the result of marked impairment of the plasma clearance of caffeine (1.05 vs 1.75 ml/min/kg, respectively) with no change in apparent volume of distribution (0.685 in OCS vs 0.7501/kg in the control group).",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),[ml] / [kg·min],1.75,209647,DB00201,Caffeine
,4029248,apparent volume of distribution,"This was the result of marked impairment of the plasma clearance of caffeine (1.05 vs 1.75 ml/min/kg, respectively) with no change in apparent volume of distribution (0.685 in OCS vs 0.7501/kg in the control group).",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),1/[kg],0.685,209648,DB00201,Caffeine
,4029248,apparent volume of distribution,"This was the result of marked impairment of the plasma clearance of caffeine (1.05 vs 1.75 ml/min/kg, respectively) with no change in apparent volume of distribution (0.685 in OCS vs 0.7501/kg in the control group).",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),1/[kg],0.7501,209649,DB00201,Caffeine
,4029248,peak plasma caffeine concentration,"The absorption parameters determined were peak plasma caffeine concentration (3.99 vs 4.09 micrograms/ml) and time to peak concentration after drug administration (1.52 vs 0.79), which was moderately prolonged in OCS users.",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),[μg] / [ml],3.99,209650,DB00201,Caffeine
,4029248,peak plasma caffeine concentration,"The absorption parameters determined were peak plasma caffeine concentration (3.99 vs 4.09 micrograms/ml) and time to peak concentration after drug administration (1.52 vs 0.79), which was moderately prolonged in OCS users.",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),[μg] / [ml],4.09,209651,DB00201,Caffeine
,4029248,time to peak concentration,"The absorption parameters determined were peak plasma caffeine concentration (3.99 vs 4.09 micrograms/ml) and time to peak concentration after drug administration (1.52 vs 0.79), which was moderately prolonged in OCS users.",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),,1.52,209652,DB00201,Caffeine
,4029248,time to peak concentration,"The absorption parameters determined were peak plasma caffeine concentration (3.99 vs 4.09 micrograms/ml) and time to peak concentration after drug administration (1.52 vs 0.79), which was moderately prolonged in OCS users.",Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4029248/),,0.79,209653,DB00201,Caffeine
,16164886,Heart rate,"Heart rate was increased from baseline at 6 hours compared with placebo (16.7 beats per minute with Xenadrine EFX, P = 0.011; 11.4 beats per minute with Advantra Z, P = 0.031).",Hemodynamic effects of ephedra-free weight-loss supplements in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16164886/),[beats] / [min],16.7,209970,DB00201,Caffeine
,16164886,Heart rate,"Heart rate was increased from baseline at 6 hours compared with placebo (16.7 beats per minute with Xenadrine EFX, P = 0.011; 11.4 beats per minute with Advantra Z, P = 0.031).",Hemodynamic effects of ephedra-free weight-loss supplements in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16164886/),[beats] / [min],11.4,209971,DB00201,Caffeine
,16164886,t(max),"Dose-adjusted synephrine pharmacokinetics were similar between treatments with t(max) = 90 min, t(1/2) = 3.0 hours, V/F = 16347 L, and CL/F = 88.9 L/min for Xenadrine EFX.",Hemodynamic effects of ephedra-free weight-loss supplements in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16164886/),min,90,209972,DB00201,Caffeine
,16164886,t(1/2),"Dose-adjusted synephrine pharmacokinetics were similar between treatments with t(max) = 90 min, t(1/2) = 3.0 hours, V/F = 16347 L, and CL/F = 88.9 L/min for Xenadrine EFX.",Hemodynamic effects of ephedra-free weight-loss supplements in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16164886/),h,3.0,209973,DB00201,Caffeine
,16164886,V/F,"Dose-adjusted synephrine pharmacokinetics were similar between treatments with t(max) = 90 min, t(1/2) = 3.0 hours, V/F = 16347 L, and CL/F = 88.9 L/min for Xenadrine EFX.",Hemodynamic effects of ephedra-free weight-loss supplements in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16164886/),l,16347,209974,DB00201,Caffeine
,16164886,CL/F,"Dose-adjusted synephrine pharmacokinetics were similar between treatments with t(max) = 90 min, t(1/2) = 3.0 hours, V/F = 16347 L, and CL/F = 88.9 L/min for Xenadrine EFX.",Hemodynamic effects of ephedra-free weight-loss supplements in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16164886/),[l] / [min],88.9,209975,DB00201,Caffeine
,430317,d,"Mean (+/- SE) AV d, t 1/2, ke1, and clearance following a single intravenous dose were 0.916 +/- 0.070 1/kg, 102.9 +/- 17.9 hours, 0.009 +/- 0.001/hours and 8.9 +/- 1.5 ml/kg/hour, respectively.",Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),[1] / [kg],0.916,210153,DB00201,Caffeine
,430317,ke1,"Mean (+/- SE) AV d, t 1/2, ke1, and clearance following a single intravenous dose were 0.916 +/- 0.070 1/kg, 102.9 +/- 17.9 hours, 0.009 +/- 0.001/hours and 8.9 +/- 1.5 ml/kg/hour, respectively.",Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),1/[h],0.009,210154,DB00201,Caffeine
,430317,clearance,"Mean (+/- SE) AV d, t 1/2, ke1, and clearance following a single intravenous dose were 0.916 +/- 0.070 1/kg, 102.9 +/- 17.9 hours, 0.009 +/- 0.001/hours and 8.9 +/- 1.5 ml/kg/hour, respectively.",Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),[ml] / [h·kg],8.9,210155,DB00201,Caffeine
,430317,Cpss,Cpss of caffeine in infants given a high empirical dose (11.2 +/- 1.5 mg/kg/day) ranged from 22.5 to 84.2 mg/l (mean = 45.3) whereas a dose schedule based on kinetic data (2.5 mg/kg/day) yielded plasma concentrations ranging from 7.4 to 19.4 mg/l (mean = 13.7).,Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),[mg] / [l],22.5 to 84.2,210156,DB00201,Caffeine
,430317,Cpss,Cpss of caffeine in infants given a high empirical dose (11.2 +/- 1.5 mg/kg/day) ranged from 22.5 to 84.2 mg/l (mean = 45.3) whereas a dose schedule based on kinetic data (2.5 mg/kg/day) yielded plasma concentrations ranging from 7.4 to 19.4 mg/l (mean = 13.7).,Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),[mg] / [l],45.3,210157,DB00201,Caffeine
,430317,plasma concentrations,Cpss of caffeine in infants given a high empirical dose (11.2 +/- 1.5 mg/kg/day) ranged from 22.5 to 84.2 mg/l (mean = 45.3) whereas a dose schedule based on kinetic data (2.5 mg/kg/day) yielded plasma concentrations ranging from 7.4 to 19.4 mg/l (mean = 13.7).,Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),[mg] / [l],7.4 to 19.4,210158,DB00201,Caffeine
,430317,plasma concentrations,Cpss of caffeine in infants given a high empirical dose (11.2 +/- 1.5 mg/kg/day) ranged from 22.5 to 84.2 mg/l (mean = 45.3) whereas a dose schedule based on kinetic data (2.5 mg/kg/day) yielded plasma concentrations ranging from 7.4 to 19.4 mg/l (mean = 13.7).,Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/430317/),[mg] / [l],13.7,210159,DB00201,Caffeine
,2060565,half-life,Exercise raised the maximal plasma caffeine concentrations (R: 7.28: E: 10.45) and reduced both the half-life (R 3.99 h: E 2.29 h) and the volume of distribution (R 37 l: E 20.9 l).,Effects of moderate exercise on the pharmacokinetics of caffeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060565/),h,3.99,210850,DB00201,Caffeine
,2060565,half-life,Exercise raised the maximal plasma caffeine concentrations (R: 7.28: E: 10.45) and reduced both the half-life (R 3.99 h: E 2.29 h) and the volume of distribution (R 37 l: E 20.9 l).,Effects of moderate exercise on the pharmacokinetics of caffeine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060565/),h,2.29,210851,DB00201,Caffeine
,2060565,volume of distribution,Exercise raised the maximal plasma caffeine concentrations (R: 7.28: E: 10.45) and reduced both the half-life (R 3.99 h: E 2.29 h) and the volume of distribution (R 37 l: E 20.9 l).,Effects of moderate exercise on the pharmacokinetics of caffeine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060565/),l,37,210852,DB00201,Caffeine
,2060565,volume of distribution,Exercise raised the maximal plasma caffeine concentrations (R: 7.28: E: 10.45) and reduced both the half-life (R 3.99 h: E 2.29 h) and the volume of distribution (R 37 l: E 20.9 l).,Effects of moderate exercise on the pharmacokinetics of caffeine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2060565/),l,20.9,210853,DB00201,Caffeine
,7094974,Clb,"Mean (+/- SE; range) Clb was extremely slow - 8.5 ml/kg/h (+/- 0.4; 5.8-12.2), t1/2 was prolonged - 65.0 h (+/- 3.7; 48.2-87.5 h) and Vd was 0.781/kg(+/- 0.04; 0.47-1.01).",Pharmacokinetic aspects of caffeine in premature infants with apnoea. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094974/),[ml] / [h·kg],8.5,212299,DB00201,Caffeine
,7094974,t1/2,"Mean (+/- SE; range) Clb was extremely slow - 8.5 ml/kg/h (+/- 0.4; 5.8-12.2), t1/2 was prolonged - 65.0 h (+/- 3.7; 48.2-87.5 h) and Vd was 0.781/kg(+/- 0.04; 0.47-1.01).",Pharmacokinetic aspects of caffeine in premature infants with apnoea. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094974/),h,65.0,212300,DB00201,Caffeine
,7094974,Vd,"Mean (+/- SE; range) Clb was extremely slow - 8.5 ml/kg/h (+/- 0.4; 5.8-12.2), t1/2 was prolonged - 65.0 h (+/- 3.7; 48.2-87.5 h) and Vd was 0.781/kg(+/- 0.04; 0.47-1.01).",Pharmacokinetic aspects of caffeine in premature infants with apnoea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094974/),1/[kg],0.781,212301,DB00201,Caffeine
,26008214,Cmax,"Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[ml] / [h],72.1,214088,DB00201,Caffeine
,26008214,Cmax,"Cmax ranged from 72.1 (10 ml/h; 0.02 mg, IV) to 101,163 pg/ml (100 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [ml],"101,163",214089,DB00201,Caffeine
,26008214,Tmax,Tmax ranged between 15 (2 mg) and 210 min (10 mg).,Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,15,214090,DB00201,Caffeine
,26008214,Tmax,Tmax ranged between 15 (2 mg) and 210 min (10 mg).,Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,210,214091,DB00201,Caffeine
,26008214,T1/2,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,28,214092,DB00201,Caffeine
,26008214,T1/2,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,126,214093,DB00201,Caffeine
,26008214,AUC,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [min·ml],5400,214094,DB00201,Caffeine
,26008214,AUC,"T1/2 ranged from 28 (0.005 mg, IV) to 126 min (4 mg, oral), whereas AUC ranged between 5400 (0.005 mg, IV) and 6.56 × 10(10) pg/ml × min (1 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[pg] / [min·ml],6.56 × 10(10),214095,DB00201,Caffeine
,26008214,Cl,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[l] / [min],0.97,214096,DB00201,Caffeine
,26008214,Cl,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),[l] / [min],132.50,214097,DB00201,Caffeine
,26008214,VD,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),l,35,214098,DB00201,Caffeine
,26008214,VD,"Cl ranged from 0.97 (0.005 mg, IV) to 132.50 L/min (6 mg, oral), whereas VD ranged between 35 (0.005 mg, IV) and 1602 L (4 mg, oral).",Clinical pharmacokinetics of melatonin: a systematic review. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),l,1602,214099,DB00201,Caffeine
,26008214,Bioavailability,Bioavailability of oral melatonin ranged from 9 to 33%.,Clinical pharmacokinetics of melatonin: a systematic review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),%,9 to 33,214100,DB00201,Caffeine
,26008214,Tmax,"Despite methodological differences between the included studies, Tmax was approximately 50 min following oral immediate-release formulations of melatonin.",Clinical pharmacokinetics of melatonin: a systematic review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,50,214101,DB00201,Caffeine
,26008214,T1/2,T1/2 was 45 min in both administration routes.,Clinical pharmacokinetics of melatonin: a systematic review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),min,45,214102,DB00201,Caffeine
,26008214,Bioavailability,Bioavailability of oral melatonin was approximately 15%.,Clinical pharmacokinetics of melatonin: a systematic review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26008214/),%,15,214103,DB00201,Caffeine
,1939407,half-life (t1/2),"The mean value for the half-life (t1/2) was 9.46 +/- 4.32 h, the volume of distribution was 0.55 +/- 0.13 l/kg, and the plasma clearance (Cl) was 0.85 +/- 0.44 ml/min/kg.",Pharmacokinetics of intravenous caffeine in critically ill patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1939407/),h,9.46,214104,DB00201,Caffeine
,1939407,volume of distribution,"The mean value for the half-life (t1/2) was 9.46 +/- 4.32 h, the volume of distribution was 0.55 +/- 0.13 l/kg, and the plasma clearance (Cl) was 0.85 +/- 0.44 ml/min/kg.",Pharmacokinetics of intravenous caffeine in critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1939407/),[l] / [kg],0.55,214105,DB00201,Caffeine
,1939407,plasma clearance (Cl),"The mean value for the half-life (t1/2) was 9.46 +/- 4.32 h, the volume of distribution was 0.55 +/- 0.13 l/kg, and the plasma clearance (Cl) was 0.85 +/- 0.44 ml/min/kg.",Pharmacokinetics of intravenous caffeine in critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1939407/),[ml] / [kg·min],0.85,214106,DB00201,Caffeine
,11356089,total plasma clearance,After starvation the total plasma clearance of caffeine decreased (about 20 per cent).,The effect of short-term starvation or water deprivation on caffeine pharmacokinetics in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11356089/),%,20,216032,DB00201,Caffeine
,11356089,total plasma clearance,The total plasma clearance of caffeine decreased (about 30 per cent).,The effect of short-term starvation or water deprivation on caffeine pharmacokinetics in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11356089/),%,30,216033,DB00201,Caffeine
,17294509,flow rate,"Mobile phase consisting of methanol and distilled water was used at a flow rate of 1.0 mL/min for the effective separation of cis-, trans-resveratrol and caffeine (IS).",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),[ml] / [min],1.0,216530,DB00201,Caffeine
,17294509,Nominal retention times,"Nominal retention times of cis-, trans-resveratrol and IS were 3.2, 4.3 and 6.1 min, respectively.",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),min,3.2,216531,DB00201,Caffeine
,17294509,Nominal retention times,"Nominal retention times of cis-, trans-resveratrol and IS were 3.2, 4.3 and 6.1 min, respectively.",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),min,4.3,216532,DB00201,Caffeine
,17294509,Nominal retention times,"Nominal retention times of cis-, trans-resveratrol and IS were 3.2, 4.3 and 6.1 min, respectively.",Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),min,6.1,216533,DB00201,Caffeine
more,17294509,absolute recovery,The absolute recovery of both isomers was more than 85%.,Stereospecific determination of cis- and trans-resveratrol in rat plasma by HPLC: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17294509/),%,85,216534,DB00201,Caffeine
,10877011,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[μg] / [ml],0.9,217781,DB00201,Caffeine
,10877011,maximum plasma concentration (Cmax),"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[μg] / [ml],1.4,217782,DB00201,Caffeine
,10877011,area under the plasma concentration time curve ratio,"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.5,217783,DB00201,Caffeine
,10877011,area under the plasma concentration time curve ratio,"The maximum plasma concentration (Cmax) of paraxanthine was significantly lower (P < 0.05) in malaria (0.9 +/- 0.4 microg/ ml) than in healthy controls (1.4 +/- 0.5 microg/ml), and the paraxanthine:caffeine area under the plasma concentration time curve ratio, an index of cytochrome P450 (CYP)IA2 activity was significantly lower (P < 0.05) in malaria patients (0.5 +/- 0.1) than in healthy controls (0.3 +/- 0.2).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.3,217784,DB00201,Caffeine
,10877011,elimination half-life,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],7.1,217785,DB00201,Caffeine
,10877011,area under the plasma concentration time curve,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],7.1,217786,DB00201,Caffeine
,10877011,area under the plasma concentration time curve,"The elimination half-life of theophylline was longer in malaria, while the area under the plasma concentration time curve of theobromine was significantly higher (P < 0.05) in malaria (7.1 +/- 3.4 microg ml(-1) h) than in healthy adults (4.1 +/- 2.2 microg ml(-1) h).",The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),[h·μg] / [ml],4.1,217787,DB00201,Caffeine
,10877011,saliva:plasma concentrations ratio,Excellent correlations were found between saliva and plasma concentrations of caffeine (r2 = 0.98) with a mean saliva:plasma concentrations ratio of 0.7 +/- 0.1.,The effects of acute falciparum malaria on the disposition of caffeine and the comparison of saliva and plasma-derived pharmacokinetic parameters in adult Nigerians. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877011/),,0.7,217788,DB00201,Caffeine
,8894505,Terminal-phase elimination half-lives,Terminal-phase elimination half-lives were 8.9 hr in sheep and 8.1 hr in cattle.,Systemic clearance and demethylation of caffeine in sheep and cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894505/),h,8.9,220569,DB00201,Caffeine
,8894505,Terminal-phase elimination half-lives,Terminal-phase elimination half-lives were 8.9 hr in sheep and 8.1 hr in cattle.,Systemic clearance and demethylation of caffeine in sheep and cattle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8894505/),h,8.1,220570,DB00201,Caffeine
,2791443,Clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],6.01 x 10(-2),222364,DB00201,Caffeine
,2791443,clearance,"Clearance for passive smokers was 6.01 x 10(-2) L/hr.kg and for nonsmokers, clearance was 4.09 x 10(-2) L/hr.kg (p less than 0.025).",Effects of passive smoking on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),[l] / [h·kg],4.09 x 10(-2),222365,DB00201,Caffeine
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,6.93,222366,DB00201,Caffeine
,2791443,Terminal elimination half-life,Terminal elimination half-life for passive smokers was 6.93 hours versus 8.69 hours for nonsmokers (p less than 0.05).,Effects of passive smoking on theophylline clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,8.69,222367,DB00201,Caffeine
,2791443,mean residence time,The mean residence time for passive smokers was 9.89 hours.,Effects of passive smoking on theophylline clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,9.89,222368,DB00201,Caffeine
,2791443,mean residence time,"For nonsmokers, the mean residence time was 13.11 hours (p less than 0.05).",Effects of passive smoking on theophylline clearance. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2791443/),h,13.11,222369,DB00201,Caffeine
,20663043,inhibition constant (K(i)),"Aqueous extract of Danshen (125-2000 microg/ml) competitively inhibited human and rat liver microsomal CYP1A2 activity with inhibition constant (K(i)) values at 190 and 360 microg/ml, respectively.",Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663043/),[μg] / [ml],190,222713,DB00201,Caffeine
,20663043,inhibition constant (K(i)),"Aqueous extract of Danshen (125-2000 microg/ml) competitively inhibited human and rat liver microsomal CYP1A2 activity with inhibition constant (K(i)) values at 190 and 360 microg/ml, respectively.",Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20663043/),[μg] / [ml],360,222714,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224505,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,152.3,224506,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,195.1,224507,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,138.3,224508,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,275.2,224509,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,230.3,224510,DB00201,Caffeine
,19338139,m/,"Following methanol-induced protein precipitation, the analytes were separated using a mobile phase comprised of methanol:water (0.5% formic acid) = 20:80 (v/v) on a commercially available column (150 mm x 2.1 mm I.D., 5 microm) and analyzed by electrospray ionization tandem mass spectrometry in the selected reaction monitoring (SRM) mode with the precursor to product ion transitions m/z 152.3-->110.2 for PAR, 152.3-->135.3 for ATH, 195.1-->138.3 for CAF, 275.2-->230.3 for CPM and 264.2-->58.2 for TMH.","Rapid simultaneous determination of paracetamol, amantadine hydrochloride, caffeine and chlorpheniramine maleate in human plasma by liquid chromatography/tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19338139/),,264.2,224511,DB00201,Caffeine
,22695883,recoveries,The recoveries ranged from 67.5% to 98.5%.,"UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22695883/),%,67.5,224839,DB00201,Caffeine
,22695883,recoveries,The recoveries ranged from 67.5% to 98.5%.,"UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22695883/),%,98.5,224840,DB00201,Caffeine
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],107,226379,DB00201,Caffeine
,8807660,total clearance,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21,226380,DB00201,Caffeine
,8807660,half-life,"During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h.",A fluvoxamine-caffeine interaction study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),h,5 to 31,226381,DB00201,Caffeine
,8807660,clearance,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],46 to 9,226382,DB00201,Caffeine
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],21 to 9,226383,DB00201,Caffeine
,8807660,clearances,"The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively.",A fluvoxamine-caffeine interaction study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8807660/),[ml] / [min],14 to 6,226384,DB00201,Caffeine
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.281,227308,DB00201,Caffeine
,2170254,apparent clearance,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [h·kg],0.455,227309,DB00201,Caffeine
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],0.520,227310,DB00201,Caffeine
,2170254,apparent volume of distribution,CAF apparent clearance and apparent volume of distribution were lower in H(-) rats than in controls: 0.281 +/- 0.072 vs 0.455 +/- 0.165 l/kg/h (-38%; P less than 0.05) and 0.520 +/- 0.239 vs 1.28 +/- 0.266 l/kg (-59%; P less than 0.01) respectively.,Effect of hypophysectomy on caffeine elimination in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),[l] / [kg],1.28,227311,DB00201,Caffeine
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,1.33,227312,DB00201,Caffeine
,2170254,half-life,CAF half-life was lower in H(-) rats than in controls: 1.33 +/- 0.621 vs 2.12 +/- 0.676 h (-37%; P less than 0.01).,Effect of hypophysectomy on caffeine elimination in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2170254/),h,2.12,227313,DB00201,Caffeine
,33116005,elimination half-life,"The mean values for elimination half-life and oral clearance estimated in the 10 patients were 124.6 ± 44.6 h and 2.26 ± 0.73 mL/min/1.73 m2, respectively.",Pharmacokinetic Variability of Caffeine in Routinely Treated Preterm Infants: Preliminary Considerations on Developmental Changes of Systemic Clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33116005/),h,124.6,227467,DB00201,Caffeine
,33116005,oral clearance,"The mean values for elimination half-life and oral clearance estimated in the 10 patients were 124.6 ± 44.6 h and 2.26 ± 0.73 mL/min/1.73 m2, respectively.",Pharmacokinetic Variability of Caffeine in Routinely Treated Preterm Infants: Preliminary Considerations on Developmental Changes of Systemic Clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33116005/),[ml] / [1.73·m2·min],2.26,227468,DB00201,Caffeine
,7445577,half life,"2. The elimination of caffeine from the serum and tissues examined (liver, kidney, brain, muscle) showed an exponential course with a half life of 40-60 minutes and was completed after 4 to 5 hours.",[Pharmacokinetics of caffeine in mice and its modification by ethanol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445577/),min,40-60,228555,DB00201,Caffeine
,7445577,half life,3. By giving ethanol the elimination of caffeine was significantly decreased and its half life increased to 160-240 minutes.,[Pharmacokinetics of caffeine in mice and its modification by ethanol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445577/),min,160-240,228556,DB00201,Caffeine
,17474141,flow rate,"The DIB-derivatives of MDMA, MDA and the internal standard, 1-methyl-3-phenylpropylamine (MPPA), were isocratically separated on an ODS column using a mixture of 50 mm phosphate buffer (pH 7.0)-acetonitrile-methanol-2-propanol (50:45:5:2, v/v/v/v %) as an eluent at a flow rate of 1.5 mL/min.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ml] / [min],1.5,228860,DB00201,Caffeine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],1.2,228861,DB00201,Caffeine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),,4.2,228862,DB00201,Caffeine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],1.3,228863,DB00201,Caffeine
,17474141,detection limits,"The detection limits of MDA and MDMA were 1.2 and 4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively.",Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17474141/),[ng] / [ml],4.8,228864,DB00201,Caffeine
,22264564,LODs,"The LODs and LOQs were 0.9-6.0 and 2.50-16.0 ng/ml, respectively; the recoveries of three levels of quality control samples were from 86.7% to 102%; the intra-day and inter-day precisions were less than 3% and 9%, separately; and the RSDs of compound stability were all lower than 10% within 24h after sample preparation.",An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264564/),[ng] / [ml],0.9-6.0,229291,DB00201,Caffeine
,22264564,LOQs,"The LODs and LOQs were 0.9-6.0 and 2.50-16.0 ng/ml, respectively; the recoveries of three levels of quality control samples were from 86.7% to 102%; the intra-day and inter-day precisions were less than 3% and 9%, separately; and the RSDs of compound stability were all lower than 10% within 24h after sample preparation.",An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264564/),[ng] / [ml],2.50-16.0,229292,DB00201,Caffeine
,22264564,recoveries,"The LODs and LOQs were 0.9-6.0 and 2.50-16.0 ng/ml, respectively; the recoveries of three levels of quality control samples were from 86.7% to 102%; the intra-day and inter-day precisions were less than 3% and 9%, separately; and the RSDs of compound stability were all lower than 10% within 24h after sample preparation.",An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264564/),%,86.7,229293,DB00201,Caffeine
,22264564,recoveries,"The LODs and LOQs were 0.9-6.0 and 2.50-16.0 ng/ml, respectively; the recoveries of three levels of quality control samples were from 86.7% to 102%; the intra-day and inter-day precisions were less than 3% and 9%, separately; and the RSDs of compound stability were all lower than 10% within 24h after sample preparation.",An HPLC-ESI-MS method for simultaneous determination of fourteen metabolites of promethazine and caffeine and its application to pharmacokinetic study of the combination therapy against motion sickness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264564/),%,102,229294,DB00201,Caffeine
,23724689,flow rate,"The chromatographic conditions were as follows: Phenomenex Luna C18 (4.6 mm x 250 mm, 5 microm) at 25 degrees C, a mixture of methanol-water (25: 75) as the mobile phase, at the flow rate of 1.0 mL x min(-1) and the detection wavelength of 290 nm.",[Determination of theacrine in rat plasma by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),[ml] / [min],1.0,229545,DB00201,Caffeine
,23724689,extraction recoveries,"The average extraction recoveries of theacrine were 90.3% -95.8% at concentrations of 0.5, 5.0, 50 mg x L(-1).",[Determination of theacrine in rat plasma by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),%,90.3,229546,DB00201,Caffeine
,23724689,extraction recoveries,"The average extraction recoveries of theacrine were 90.3% -95.8% at concentrations of 0.5, 5.0, 50 mg x L(-1).",[Determination of theacrine in rat plasma by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),%,95,229547,DB00201,Caffeine
,23724689,C(max),"The main pharmacokinetic parameters after ig. administration of theacrine at concentration of 30 mg x kg(-1) were as follow: C(max) (35.45 +/- 30 2.68) mg x L(-1), t(max) (0.51 +/- 0.13) h, t1/2 (3.13 +/- 1.37) h, AUC(0-infinity) (2.65.39 +/- 94.71) mg x L(-1) x h.",[Determination of theacrine in rat plasma by RP-HPLC]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),[mg] / [l],35.45,229548,DB00201,Caffeine
,23724689,t(max),"The main pharmacokinetic parameters after ig. administration of theacrine at concentration of 30 mg x kg(-1) were as follow: C(max) (35.45 +/- 30 2.68) mg x L(-1), t(max) (0.51 +/- 0.13) h, t1/2 (3.13 +/- 1.37) h, AUC(0-infinity) (2.65.39 +/- 94.71) mg x L(-1) x h.",[Determination of theacrine in rat plasma by RP-HPLC]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),h,0.51,229549,DB00201,Caffeine
,23724689,t1/2,"The main pharmacokinetic parameters after ig. administration of theacrine at concentration of 30 mg x kg(-1) were as follow: C(max) (35.45 +/- 30 2.68) mg x L(-1), t(max) (0.51 +/- 0.13) h, t1/2 (3.13 +/- 1.37) h, AUC(0-infinity) (2.65.39 +/- 94.71) mg x L(-1) x h.",[Determination of theacrine in rat plasma by RP-HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),h,3.13,229550,DB00201,Caffeine
,23724689,AUC(0-infinity),"The main pharmacokinetic parameters after ig. administration of theacrine at concentration of 30 mg x kg(-1) were as follow: C(max) (35.45 +/- 30 2.68) mg x L(-1), t(max) (0.51 +/- 0.13) h, t1/2 (3.13 +/- 1.37) h, AUC(0-infinity) (2.65.39 +/- 94.71) mg x L(-1) x h.",[Determination of theacrine in rat plasma by RP-HPLC]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724689/),[h·mg] / [l],2.65.39,229551,DB00201,Caffeine
,33951339,tmax,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,1.5,232747,DB00201,Caffeine
,33951339,tmax,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,3.0,232748,DB00201,Caffeine
,33951339,t1/2,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,5.,232749,DB00201,Caffeine
,33951339,t1/2,"When caffeine was administered with steady-state CBD, caffeine exposure increased by 15% for Cmax and 95% for AUC0-∞ , tmax increased from 1.5 to 3.0 hours, and t1/2 increased from 5.4 to 10.9 hours compared with caffeine administered with placebo.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,10,232750,DB00201,Caffeine
,33951339,tmax,"Under the same conditions, paraxanthine exposure decreased by 22% for Cmax and increased by 18% for AUC0-∞ , tmax increased from 8.0 to 14.0 hours, and t1/2 increased from 7.2 to 13.7 hours.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,8,232751,DB00201,Caffeine
,33951339,t1/2,"Under the same conditions, paraxanthine exposure decreased by 22% for Cmax and increased by 18% for AUC0-∞ , tmax increased from 8.0 to 14.0 hours, and t1/2 increased from 7.2 to 13.7 hours.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,7.2,232752,DB00201,Caffeine
,33951339,t1/2,"Under the same conditions, paraxanthine exposure decreased by 22% for Cmax and increased by 18% for AUC0-∞ , tmax increased from 8.0 to 14.0 hours, and t1/2 increased from 7.2 to 13.7 hours.","A Phase 1 Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Trial to Investigate the Effect of Cannabidiol on the CYP1A2 Probe Caffeine in Healthy Subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33951339/),h,13,232753,DB00201,Caffeine
,31694152,oxygen consumption,"The 22 h oxygen consumption and EE were significantly higher with MFC than PL (1582 ± 143, 1535 ± 154 kcal/day, respectively, p = 0.003, trial difference of 46.4 ± 57.8 kcal/day).","Acute Ingestion of a Mixed Flavonoid and Caffeine Supplement Increases Energy Expenditure and Fat Oxidation in Adult Women: A Randomized, Crossover Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31694152/),[kcal] / [d],1582,233209,DB00201,Caffeine
,31694152,EE,"The 22 h oxygen consumption and EE were significantly higher with MFC than PL (1582 ± 143, 1535 ± 154 kcal/day, respectively, p = 0.003, trial difference of 46.4 ± 57.8 kcal/day).","Acute Ingestion of a Mixed Flavonoid and Caffeine Supplement Increases Energy Expenditure and Fat Oxidation in Adult Women: A Randomized, Crossover Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31694152/),[kcal] / [d],1535,233210,DB00201,Caffeine
,31694152,FATox,"FATox trended higher for MFC when evaluated using GLM (99.2 ± 14.0, 92.4 ± 14.4 g/22 h, p = 0.054).","Acute Ingestion of a Mixed Flavonoid and Caffeine Supplement Increases Energy Expenditure and Fat Oxidation in Adult Women: A Randomized, Crossover Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31694152/),[g] / [22·h],99.2,233211,DB00201,Caffeine
,31694152,FATox,"FATox trended higher for MFC when evaluated using GLM (99.2 ± 14.0, 92.4 ± 14.4 g/22 h, p = 0.054).","Acute Ingestion of a Mixed Flavonoid and Caffeine Supplement Increases Energy Expenditure and Fat Oxidation in Adult Women: A Randomized, Crossover Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31694152/),[g] / [22·h],92.4,233212,DB00201,Caffeine
,7185911,overall blood elimination half-life,"The overall blood elimination half-life of radioactivity in pregnant rats treated by gavage was 2.6 h, and the half-life of caffeine in blood was 1.7 h.",Blood levels of caffeine and results of fetal examination after oral administration of caffeine to pregnant rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185911/),h,2.6,233280,DB00201,Caffeine
,7185911,half-life,"The overall blood elimination half-life of radioactivity in pregnant rats treated by gavage was 2.6 h, and the half-life of caffeine in blood was 1.7 h.",Blood levels of caffeine and results of fetal examination after oral administration of caffeine to pregnant rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7185911/),h,1.7,233281,DB00201,Caffeine
,7741785,area under the serum concentration-time curves (AUC),The geometric mean of the area under the serum concentration-time curves (AUC) of 4-MAA for the test formulation was 87.61 (57.58-133.30) micrograms.h/ml and was similar to that for the reference formulation (86.83; 53.86-139.92 micrograms.h/ml).,Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741785/),[h·μg] / [ml],87.61,233392,DB00201,Caffeine
,7741785,area under the serum concentration-time curves (AUC),The geometric mean of the area under the serum concentration-time curves (AUC) of 4-MAA for the test formulation was 87.61 (57.58-133.30) micrograms.h/ml and was similar to that for the reference formulation (86.83; 53.86-139.92 micrograms.h/ml).,Comparative bioavailability of two oral metamizole formulations. Influence of the acetylation phenotype. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7741785/),[h·μg] / [ml],86.83,233393,DB00201,Caffeine
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],242,233774,DB00201,Caffeine
,10634135,AUC,"Ketoconazole and rifampin pretreatment significantly changed AUC values of ALP (mean AUC values in microg/l h: ALP = 242.2, ALP + ketoconazole = 426.2, ALP + rifampin = 28.4, ANOVA F = 17.7, P < 0.001).",Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10634135/),[μg] / [h·l],42,233775,DB00201,Caffeine
,8738763,volume of distribution,A final analysis using all 80 patients found clearance (L/day) = 0.14 x weight (kg) + 0.0024 x postnatal age (days) (+/- 20%) and volume of distribution = 0.82 L (+/- 24%).,Population pharmacokinetics of caffeine in neonates and young infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8738763/),l,0.82,234113,DB00201,Caffeine
,3808800,half-lives,"Four breast-fed infants had measurements of significantly longer caffeine half-lives compared with 12 formula-fed infants (76 +/- 13 hours v 21 +/- 28 hours and 54 +/- 9 hours v 16 +/- 13 hours at 47 to 50 weeks and 51 to 54 weeks postconceptional age, respectively), as well as significantly higher trough blood levels (three- to five-fold) after 46 weeks' postconceptional age.",Delay in caffeine elimination in breast-fed infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3808800/),h,76,235133,DB00201,Caffeine
,3808800,half-lives,"Four breast-fed infants had measurements of significantly longer caffeine half-lives compared with 12 formula-fed infants (76 +/- 13 hours v 21 +/- 28 hours and 54 +/- 9 hours v 16 +/- 13 hours at 47 to 50 weeks and 51 to 54 weeks postconceptional age, respectively), as well as significantly higher trough blood levels (three- to five-fold) after 46 weeks' postconceptional age.",Delay in caffeine elimination in breast-fed infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3808800/),h,21,235134,DB00201,Caffeine
,3808800,half-lives,"Four breast-fed infants had measurements of significantly longer caffeine half-lives compared with 12 formula-fed infants (76 +/- 13 hours v 21 +/- 28 hours and 54 +/- 9 hours v 16 +/- 13 hours at 47 to 50 weeks and 51 to 54 weeks postconceptional age, respectively), as well as significantly higher trough blood levels (three- to five-fold) after 46 weeks' postconceptional age.",Delay in caffeine elimination in breast-fed infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3808800/),h,54,235135,DB00201,Caffeine
,3808800,half-lives,"Four breast-fed infants had measurements of significantly longer caffeine half-lives compared with 12 formula-fed infants (76 +/- 13 hours v 21 +/- 28 hours and 54 +/- 9 hours v 16 +/- 13 hours at 47 to 50 weeks and 51 to 54 weeks postconceptional age, respectively), as well as significantly higher trough blood levels (three- to five-fold) after 46 weeks' postconceptional age.",Delay in caffeine elimination in breast-fed infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3808800/),h,16,235136,DB00201,Caffeine
,3808800,half-life,The fifth breast-fed infant accumulated caffeine secondary to a steep increase in caffeine half-life from 102 hours at 44 weeks to 372 hours at 51 weeks.,Delay in caffeine elimination in breast-fed infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3808800/),h,102,235137,DB00201,Caffeine
,3808800,half-life,The fifth breast-fed infant accumulated caffeine secondary to a steep increase in caffeine half-life from 102 hours at 44 weeks to 372 hours at 51 weeks.,Delay in caffeine elimination in breast-fed infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3808800/),h,372,235138,DB00201,Caffeine
,23871018,total run time,Each sample was run at 0.5 mL/min for a total run time of 7 min/sample.,Simultaneous quantification of caffeine and its three primary metabolites in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23871018/),[min] / [sample],7,235555,DB00201,Caffeine
,19403289,K(i),"Inhibition kinetics studies showed the K(i) values were in the order: dihydrotanshinone (3.64 microM), cryptotanshinone (4.07 microM), tanshinone I (22.6 microM) and tanshinone IIA (23.8 microM), furafylline (35.8 microM), a CYP1A2 inhibitor.",Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19403289/),μM,3.64,236775,DB00201,Caffeine
,19403289,K(i),"Inhibition kinetics studies showed the K(i) values were in the order: dihydrotanshinone (3.64 microM), cryptotanshinone (4.07 microM), tanshinone I (22.6 microM) and tanshinone IIA (23.8 microM), furafylline (35.8 microM), a CYP1A2 inhibitor.",Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19403289/),μM,4.07,236776,DB00201,Caffeine
,19403289,K(i),"Inhibition kinetics studies showed the K(i) values were in the order: dihydrotanshinone (3.64 microM), cryptotanshinone (4.07 microM), tanshinone I (22.6 microM) and tanshinone IIA (23.8 microM), furafylline (35.8 microM), a CYP1A2 inhibitor.",Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19403289/),μM,22.6,236777,DB00201,Caffeine
,19403289,K(i),"Inhibition kinetics studies showed the K(i) values were in the order: dihydrotanshinone (3.64 microM), cryptotanshinone (4.07 microM), tanshinone I (22.6 microM) and tanshinone IIA (23.8 microM), furafylline (35.8 microM), a CYP1A2 inhibitor.",Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19403289/),μM,23.8,236778,DB00201,Caffeine
,19403289,K(i),"Inhibition kinetics studies showed the K(i) values were in the order: dihydrotanshinone (3.64 microM), cryptotanshinone (4.07 microM), tanshinone I (22.6 microM) and tanshinone IIA (23.8 microM), furafylline (35.8 microM), a CYP1A2 inhibitor.",Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19403289/),μM,35.8,236779,DB00201,Caffeine
,19403289,Ki,"The Ki of Danshen extract (mainly tanshinones) was 72 microg/ml. Acute Danshen extract treatment (50-200mg/kg, i.p.) decreased metabolism of caffeine to paraxanthine, with overall decrease in caffeine clearance (14-22%); increase in AUC (11-25%) and plasma T(1/2) (12-16%).",Effects of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on rat CYP1A2 expression and metabolism of model CYP1A2 probe substrates. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19403289/),[μg] / [ml],72,236780,DB00201,Caffeine
,30897305,tmax,"Taken after a meal, ibuprofen in the FDC reached tmax earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and Cmax was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate.","Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30897305/),h,1.25,238723,DB00201,Caffeine
,30897305,tmax,"Taken after a meal, ibuprofen in the FDC reached tmax earlier than ibuprofen lysinate (median 1.25 vs 1.63 hours), and Cmax was approximately 13% higher, with comparable AUC, suggesting that the profile of ibuprofen was in favor of the FDC compared with ibuprofen lysinate.","Pharmacokinetic Properties of Ibuprofen (IBU) From the Fixed-Dose Combination IBU/Caffeine (400/100 mg; FDC) in Comparison With 400 mg IBU as Acid or Lysinate Under Fasted and Fed Conditions-Data From 2 Single-Center, Single-Dose, Randomized Crossover Studies in Healthy Volunteers. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30897305/),h,1.63,238724,DB00201,Caffeine
,7589033,half-life (t1/2,"In comparison to SEA, ALT resulted in a significant decrease in a caffeine half-life (t1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g.l-1.min-1), and increased clearance (117 vs 86 ml.min-1.70 kg-1).",Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),h,4.7,239109,DB00201,Caffeine
,7589033,half-life (t1/2,"In comparison to SEA, ALT resulted in a significant decrease in a caffeine half-life (t1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g.l-1.min-1), and increased clearance (117 vs 86 ml.min-1.70 kg-1).",Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),h,6.7,239110,DB00201,Caffeine
,7589033,area under the curve,"In comparison to SEA, ALT resulted in a significant decrease in a caffeine half-life (t1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g.l-1.min-1), and increased clearance (117 vs 86 ml.min-1.70 kg-1).",Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[g] / [l·min],2.5,239111,DB00201,Caffeine
,7589033,area under the curve,"In comparison to SEA, ALT resulted in a significant decrease in a caffeine half-life (t1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g.l-1.min-1), and increased clearance (117 vs 86 ml.min-1.70 kg-1).",Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[g] / [l·min],3.7,239112,DB00201,Caffeine
,7589033,clearance,"In comparison to SEA, ALT resulted in a significant decrease in a caffeine half-life (t1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g.l-1.min-1), and increased clearance (117 vs 86 ml.min-1.70 kg-1).",Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[ml] / [70·kg·min],117,239113,DB00201,Caffeine
,7589033,clearance,"In comparison to SEA, ALT resulted in a significant decrease in a caffeine half-life (t1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g.l-1.min-1), and increased clearance (117 vs 86 ml.min-1.70 kg-1).",Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[ml] / [70·kg·min],86,239114,DB00201,Caffeine
,7589033,area under the curve,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[mg] / [l·min],85,239115,DB00201,Caffeine
,7589033,area under the curve,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[mg] / [l·min],207,239116,DB00201,Caffeine
,7589033,volume of distribution,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),l,5.2,239117,DB00201,Caffeine
,7589033,volume of distribution,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),l,2.4,239118,DB00201,Caffeine
,7589033,volume of distribution,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[ml] / [min],532,239119,DB00201,Caffeine
,7589033,volume of distribution,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[ml] / [min],234,239120,DB00201,Caffeine
,7589033,clearance,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),l,2.4,239121,DB00201,Caffeine
,7589033,clearance,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[ml] / [min],532,239122,DB00201,Caffeine
,7589033,clearance,In ALT the area under the curve the ICG significantly decreased (85 vs 207 mg.l-1.min-1) and the volume of distribution and clearance increased (5.2 vs 2.4 l and 532 vs 234 ml.min-1 respectively) compared to SEA.,Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589033/),[ml] / [min],234,239123,DB00201,Caffeine
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.83,239192,DB00201,Caffeine
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.45,239193,DB00201,Caffeine
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.70,239194,DB00201,Caffeine
,34213088,M/P ratio,"Predicted M/P ratio for acetaminophen, alprazolam, caffeine, and digoxin were 0.83 ± 0.01, 0.45 ± 0.05, 0.70 ± 0.04, and 0.76 ± 0.02, respectively.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,0.76,239195,DB00201,Caffeine
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,4.0,239196,DB00201,Caffeine
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,6.7,239197,DB00201,Caffeine
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,9.9,239198,DB00201,Caffeine
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,86,239199,DB00201,Caffeine
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),%,2.1,239200,DB00201,Caffeine
,34213088,relative infant dose,"Assuming a daily milk intake of 150 ml, the predicted relative infant dose (%) for these compounds were 4.0, 6.7, 9.9, and 86, respectively, which correspond to a daily ingestion of 2.0 ± 0.5 mg, 3.7 ± 1.2 µg, 2.1 ± 1.0 mg, and 32 ± 4.0 µg by an infant of 5 kg bodyweight.","Prediction of drug concentrations in milk during breastfeeding, integrating predictive algorithms within a physiologically-based pharmacokinetic model. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34213088/),,32,239201,DB00201,Caffeine
,2729942,half-life,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),h,5.2,240577,DB00201,Caffeine
,2729942,half-life,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),h,8.2,240578,DB00201,Caffeine
,2729942,area under the caffeine concentration-time curve,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[h·μg] / [ml],16.3,240579,DB00201,Caffeine
,2729942,area under the caffeine concentration-time curve,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[h·μg] / [ml],25.9,240580,DB00201,Caffeine
,2729942,total body clearance,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[ml] / [1.73·m2·min],106,240581,DB00201,Caffeine
,2729942,total body clearance,Ciprofloxacin significantly increased the half-life of caffeine (from 5.2 +/- 1.2 to 8.2 +/- 2.5 h) and the area under the caffeine concentration-time curve (from 16.3 +/- 6.6 to 25.9 +/- 7.8 micrograms.h/ml) while decreasing the total body clearance (from 106 +/- 41.6 to 58.2 +/- 28.8 ml/min per 1.73 m2).,Interaction between oral ciprofloxacin and caffeine in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729942/),[ml] / [1.73·m2·min],58.2,240582,DB00201,Caffeine
,20669017,apparent volume of distribution [Vd(ss)],"CA showed rapid absorption, first-order elimination with biexponential decay, rapid intercompartmental transfer, wide distribution in almost the entire body water (apparent volume of distribution [Vd(ss)] 0.45 l/kg), terminal elimination half-life (t(1/2) (β)) 4.08 h, and systemic clearance (Cl) 0.75 ml/min/kg; there were no important differences between parameters determined in plasma or in other organs (liver and gills).",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[l] / [kg],0.45,242773,DB00201,Caffeine
,20669017,terminal elimination half-life (t(1/2) (β)),"CA showed rapid absorption, first-order elimination with biexponential decay, rapid intercompartmental transfer, wide distribution in almost the entire body water (apparent volume of distribution [Vd(ss)] 0.45 l/kg), terminal elimination half-life (t(1/2) (β)) 4.08 h, and systemic clearance (Cl) 0.75 ml/min/kg; there were no important differences between parameters determined in plasma or in other organs (liver and gills).",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),h,4.08,242774,DB00201,Caffeine
,20669017,systemic clearance (Cl),"CA showed rapid absorption, first-order elimination with biexponential decay, rapid intercompartmental transfer, wide distribution in almost the entire body water (apparent volume of distribution [Vd(ss)] 0.45 l/kg), terminal elimination half-life (t(1/2) (β)) 4.08 h, and systemic clearance (Cl) 0.75 ml/min/kg; there were no important differences between parameters determined in plasma or in other organs (liver and gills).",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[ml] / [kg·min],0.75,242775,DB00201,Caffeine
,20669017,V(max),"PX was rapidly formed in liver, showing saturable-kinetic properties in this organ, with V(max) 8.11 μg/g h and K(m) 12.58 μg/g.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[μg] / [g·h],8.11,242776,DB00201,Caffeine
,20669017,K(m),"PX was rapidly formed in liver, showing saturable-kinetic properties in this organ, with V(max) 8.11 μg/g h and K(m) 12.58 μg/g.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[μg] / [g],12.58,242777,DB00201,Caffeine
,20669017,half-life (t(1/2 el)),"The terminal elimination linear process was similar between matrices, with a half-life (t(1/2 el)) 2.12 h, Vd(ss) 0.35 l/kg, and Cl 1.24 ml/min/kg.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),h,2.12,242778,DB00201,Caffeine
,20669017,Vd(ss),"The terminal elimination linear process was similar between matrices, with a half-life (t(1/2 el)) 2.12 h, Vd(ss) 0.35 l/kg, and Cl 1.24 ml/min/kg.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[l] / [kg],0.35,242779,DB00201,Caffeine
,20669017,Cl,"The terminal elimination linear process was similar between matrices, with a half-life (t(1/2 el)) 2.12 h, Vd(ss) 0.35 l/kg, and Cl 1.24 ml/min/kg.",Disposition kinetics of caffeine and paraxanthine in Nile tilapia (Oreochromis niloticus): characterization of the main metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20669017/),[ml] / [kg·min],1.24,242780,DB00201,Caffeine
,7768256,V,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),l,49.9,243692,DB00201,Caffeine
,7768256,V,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),l,34.3,243693,DB00201,Caffeine
,7768256,t1/2,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),h,15.5,243694,DB00201,Caffeine
,7768256,t1/2,"Antipyrine apparent volume of distribution (V) and elimination half-life (t1/2) were significantly greater in the obese than in the lean group (V 49.9 vs 34.3 l respectively; t1/2 15.5 vs 12.0 h respectively), but its clearance rate (CL0) values were similar.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),h,12.0,243695,DB00201,Caffeine
,7768256,V,V corrected for total body weight was significantly reduced in group A than in group B (0.45 vs 0.55 l.kg-1 respectively).,Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),[l] / [kg],0.45,243696,DB00201,Caffeine
,7768256,V,V corrected for total body weight was significantly reduced in group A than in group B (0.45 vs 0.55 l.kg-1 respectively).,Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),[l] / [kg],0.55,243697,DB00201,Caffeine
,7768256,V,"In group C, weight reduction was associated with a significant decrease in antipyrine V (from 51.8 to 47.5 l) and t1/2 (from 15.1 to 12.7 h), and a non-significant increase in antipyrine CL0.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),l,51.8 to 47.5,243698,DB00201,Caffeine
,7768256,t1/2,"In group C, weight reduction was associated with a significant decrease in antipyrine V (from 51.8 to 47.5 l) and t1/2 (from 15.1 to 12.7 h), and a non-significant increase in antipyrine CL0.",Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768256/),h,15.1 to 12.7,243699,DB00201,Caffeine
,8244516,plasma renin activity,Caffeine did not alter either baseline blood pressure or the blood pressure response to Ang II but did increase baseline plasma renin activity from 0.72 +/- 0.09 to 1.42 +/- 0.26 ng angiotensin I/mL per hour (P = .01).,Caffeine attenuates the renal vascular response to angiotensin II infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8244516/),an·ng,0.72,244579,DB00201,Caffeine
,8244516,plasma renin activity,Caffeine did not alter either baseline blood pressure or the blood pressure response to Ang II but did increase baseline plasma renin activity from 0.72 +/- 0.09 to 1.42 +/- 0.26 ng angiotensin I/mL per hour (P = .01).,Caffeine attenuates the renal vascular response to angiotensin II infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8244516/),an·ng,1.42,244580,DB00201,Caffeine
,10924397,elimination half-life (t(1/2)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),h,31.4,244859,DB00201,Caffeine
,10924397,steady state volume of distribution (V(SS)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[l] / [kg],0.62,244860,DB00201,Caffeine
,10924397,total body clearance (Cl(T)),"The elimination half-life (t(1/2)) was 31.4 (21.2 to 58.9) hours, the steady state volume of distribution (V(SS)) was 0.62 (0.51 to 0.74) litre kg(-1)and the total body clearance (Cl(T)) was 14.7 (8.70 to 19.7) ml kg(-1)per hour.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],14.7,244861,DB00201,Caffeine
,10924397,Renal clearance,Renal clearance estimated in two camels was 0.62 and 0.34 ml kg(-1)per hour.,"The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],0.62,244862,DB00201,Caffeine
,10924397,Renal clearance,Renal clearance estimated in two camels was 0.62 and 0.34 ml kg(-1)per hour.,"The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),[ml] / [h·kg],0.34,244863,DB00201,Caffeine
,10924397,plasma protein binding,"In vitro plasma protein binding (mean +/-SEM, n = 10) to a concentration of 2 and 8 microg ml(-1)was 36.0 +/- 0.24 and 39.2 +/- 0.36 per cent respectively.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),%,36.0,244864,DB00201,Caffeine
,10924397,plasma protein binding,"In vitro plasma protein binding (mean +/-SEM, n = 10) to a concentration of 2 and 8 microg ml(-1)was 36.0 +/- 0.24 and 39.2 +/- 0.36 per cent respectively.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),%,39.2,244865,DB00201,Caffeine
,10924397,terminal elimination half-life,"The terminal elimination half-life of the former, estimated in two camels, was 70.","The pharmacokinetics, metabolism and urinary detection time of caffeine in camels. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10924397/),,70,244866,DB00201,Caffeine
,7944016,elimination half-life (t1/2),"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),h,6.39,245268,DB00201,Caffeine
,7944016,volume of distribution at steady state,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),[ml] / [kg],685.3,245269,DB00201,Caffeine
,7944016,total body clearance,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),[ml] / [kg·min],1.31,245270,DB00201,Caffeine
,7944016,absorption t1/2,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),h,1.02,245271,DB00201,Caffeine
,7944016,oral elimination t1/2,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),h,6.53,245272,DB00201,Caffeine
,7944016,lag time after oral administration,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),h,0.0614,245273,DB00201,Caffeine
,7944016,highest measured concentration,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),[μg] / [ml],5.29,245274,DB00201,Caffeine
,7944016,time to peak concentration,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),h,2.74,245275,DB00201,Caffeine
,7944016,bioavailability,"Analysis of the drug concentration-time data indicated IV elimination half-life (t1/2) of 6.39 +/- 1.87 hours, volume of distribution at steady state of 685.3 +/- 132.2 ml/kg, total body clearance of 1.31 +/- 0.38 ml/min/kg, absorption t1/2 of 1.02 +/- 0.68 hour, oral elimination t1/2 of 6.53 +/- 2.72 hours, lag time after oral administration of 0.0614 +/- 0.0661 hour, highest measured concentration of 5.29 +/- 1.17 micrograms/ml, time to peak concentration of 2.74 +/- 1.30 hours, and bioavailability of 99.4 +/- 19.4%.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),%,99.4,245276,DB00201,Caffeine
,7944016,t1/2 of distribution,"On the basis of data from the 6 dogs that best fit a 2-compartment model, t1/2 of distribution was 0.58 +/- 0.72 hour.",Application of an enzyme-multiplied immunoassay technique for determination of caffeine elimination kinetics as a test of liver function in clinically normal dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7944016/),h,0.58,245277,DB00201,Caffeine
,25897037,areas under the enrichment-time curve,"The mean areas under the enrichment-time curve before and after nutritional rehabilitation were 0.539±0.320 and 0.620±0.322 atom per cent excess minute, respectively.",Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25897037/),%·atom·cess·e·min,0.539,245529,DB00201,Caffeine
,25897037,areas under the enrichment-time curve,"The mean areas under the enrichment-time curve before and after nutritional rehabilitation were 0.539±0.320 and 0.620±0.322 atom per cent excess minute, respectively.",Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25897037/),%·atom·cess·e·min,0.620,245530,DB00201,Caffeine
,25897037,CPDR,"The mean CPDR in the exhaled carbon dioxide of the underweight children over a period of 2 h was 7.56±4.01% and 7.95±3.68% before and after nutritional rehabilitation, respectively, and there was no significant difference in the mean values (p=0.603).",Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25897037/),%,7.56,245531,DB00201,Caffeine
,25897037,CPDR,"The mean CPDR in the exhaled carbon dioxide of the underweight children over a period of 2 h was 7.56±4.01% and 7.95±3.68% before and after nutritional rehabilitation, respectively, and there was no significant difference in the mean values (p=0.603).",Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25897037/),%,7.95,245532,DB00201,Caffeine
,10850374,volume of distribution,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[l] / [kg],0.937,245772,DB00201,Caffeine
,10850374,elimination rate constant,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),1/[h],0.0249,245773,DB00201,Caffeine
,10850374,elimination half-life,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),h,32.1,245774,DB00201,Caffeine
,10850374,total body clearance,"The mean (+/- S.E.M.) volume of distribution, 0.937 +/- 0.232 l/kg, elimination rate constant, 0.0249 +/- 0.0095/h, elimination half-life, 32.1 +/- 12.1 h, and total body clearance, 21.7 +/- 6.18 ml/h/kg, of theophylline in Korean premature neonates were comparable to the values of neonates in other countries.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[ml] / [h·kg],21.7,245775,DB00201,Caffeine
,10850374,elimination half-life,"For caffeine, the mean (+/- S.E.M.) elimination half-life was 95.1 +/- 25.4 h and the elimination rate constant was 0.0079 +/- 0.0024/h.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),h,95.1,245776,DB00201,Caffeine
,10850374,elimination rate constant,"For caffeine, the mean (+/- S.E.M.) elimination half-life was 95.1 +/- 25.4 h and the elimination rate constant was 0.0079 +/- 0.0024/h.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),1/[h],0.0079,245777,DB00201,Caffeine
,10850374,serum concentrations,"The mean (+/- S.E.M.) serum concentrations of theophylline and caffeine on the sixth day after aminophylline infusion were 10.4 +/- 2.28 microg/ml (range, 6.38-13.4 microg/ml) and 2.94 +/- 0.98 microg/ml (range, 1.80-4.44 microg/ml), respectively.",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),[μg] / [ml],2.94,245778,DB00201,Caffeine
,10850374,concentration ratio,"The mean (+/- S.E.M.) caffeine to theophylline concentration ratio on the day after discontinuation of aminophylline infusion was 0.71 +/- 0.23 (range, 0.39-1.03).",Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10850374/),,0.71,245779,DB00201,Caffeine
,23660248,flow rate,Chromatographic separation was performed on an ODS column with gradient elution using methanol-1% formic acid as mobile phase at a flow rate of 0.3mL/min.,A rapid and sensitive LC-MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23660248/),[ml] / [min],0.3,247729,DB00201,Caffeine
,23660248,elimination half-lives (t1/2),"The elimination half-lives (t1/2) were (472.4±66.1), (509.6±97.0) and (486.2±94.6) min after single intravenous administration of 2, 4 and 8mg/kg BBM, respectively.",A rapid and sensitive LC-MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23660248/),min,472.4,247730,DB00201,Caffeine
,23660248,elimination half-lives (t1/2),"The elimination half-lives (t1/2) were (472.4±66.1), (509.6±97.0) and (486.2±94.6) min after single intravenous administration of 2, 4 and 8mg/kg BBM, respectively.",A rapid and sensitive LC-MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23660248/),min,509.6,247731,DB00201,Caffeine
,23660248,elimination half-lives (t1/2),"The elimination half-lives (t1/2) were (472.4±66.1), (509.6±97.0) and (486.2±94.6) min after single intravenous administration of 2, 4 and 8mg/kg BBM, respectively.",A rapid and sensitive LC-MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23660248/),min,486.2,247732,DB00201,Caffeine
,7661835,clearance,"Caffeine clearance significantly (p < 0.05) increased in ALT (96.8 +/- 20.0 ml.min-1) as compared to SEA (53.6 +/- 24.8 ml.min-1), demonstrating that liver function increased in ALT.",Effects of chronic hypoxia on the pharmacokinetics of caffeine and cardio-green in micro swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661835/),[ml] / [min],96.8,250131,DB00201,Caffeine
,7661835,clearance,"Caffeine clearance significantly (p < 0.05) increased in ALT (96.8 +/- 20.0 ml.min-1) as compared to SEA (53.6 +/- 24.8 ml.min-1), demonstrating that liver function increased in ALT.",Effects of chronic hypoxia on the pharmacokinetics of caffeine and cardio-green in micro swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661835/),[ml] / [min],53.6,250132,DB00201,Caffeine
,7661835,clearance,ICG clearance significantly increased in ALT (179.8 +/- 57.4 ml.min-1) as compared to SEA (84.4 +/- 28.9 ml.min-1) indicating that hepatic blood flow (HBF) increased.,Effects of chronic hypoxia on the pharmacokinetics of caffeine and cardio-green in micro swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661835/),[ml] / [min],179.8,250133,DB00201,Caffeine
,7661835,clearance,ICG clearance significantly increased in ALT (179.8 +/- 57.4 ml.min-1) as compared to SEA (84.4 +/- 28.9 ml.min-1) indicating that hepatic blood flow (HBF) increased.,Effects of chronic hypoxia on the pharmacokinetics of caffeine and cardio-green in micro swine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7661835/),[ml] / [min],84.4,250134,DB00201,Caffeine
,8793599,absolute bioavailability,Its absolute bioavailability is 77% and does not change upon multiple dosing.,Pharmacokinetics of pantoprazole in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),%,77,251776,DB00201,Caffeine
,8793599,Cmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[mg] / [l],2.5,251777,DB00201,Caffeine
,8793599,tmax,"Following a single oral dose of 40 mg, Cmax is approximately 2.5 mg/l, with a tmax of 2-3 h.",Pharmacokinetics of pantoprazole in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,2-3,251778,DB00201,Caffeine
,8793599,AUC(0,"The AUC(0,inf.) is approximately 5 mgxh/l.",Pharmacokinetics of pantoprazole in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[h·mg] / [l],5,251779,DB00201,Caffeine
,8793599,total serum clearance,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [h·kg],0.1,251780,DB00201,Caffeine
,8793599,serum elimination half-life,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.1,251781,DB00201,Caffeine
,8793599,apparent volume of distribution,"Pantoprazole is extensively metabolized in the liver, has a total serum clearance of 0.1 l/h/kg, a serum elimination half-life of about 1.1 h, and an apparent volume of distribution of 0.15 l/kg. 98% of pantoprazole is bound to serum proteins.",Pharmacokinetics of pantoprazole in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),[l] / [kg],0.15,251782,DB00201,Caffeine
,8793599,half-life,"In patients with severe liver cirrhosis, the decreased rate of metabolism results in a half-life of 7-9 h.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,7-9,251783,DB00201,Caffeine
,8793599,half-life,"The clearance of pantoprazole is only slightly affected by age, its half-life being approximately 1.25 h in the elderly.",Pharmacokinetics of pantoprazole in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8793599/),h,1.25,251784,DB00201,Caffeine
,7064899,metabolic clearance,The average metabolic clearance was approximately 77 (ml hr-1) kg-1 and the average half-life was approximately 4.6 h for all caffeine administrations.,The effect of vitamin C on the pharmacokinetics of caffeine in elderly men. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7064899/),[ml] / [hr·kg],77,252069,DB00201,Caffeine
,7064899,half-life,The average metabolic clearance was approximately 77 (ml hr-1) kg-1 and the average half-life was approximately 4.6 h for all caffeine administrations.,The effect of vitamin C on the pharmacokinetics of caffeine in elderly men. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7064899/),h,4.6,252070,DB00201,Caffeine
,2859173,fraction bound,The fraction bound (15%) remained constant in the concentration range of 1-100 micrograms/ml.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),%,15,254861,DB00201,Caffeine
,2859173,half-life,"The mean half-life and elimination rate constant were 1 hr and 0.70 hr-1, respectively.","Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),h,1,254862,DB00201,Caffeine
,2859173,elimination rate constant,"The mean half-life and elimination rate constant were 1 hr and 0.70 hr-1, respectively.","Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),1/[h],0.70,254863,DB00201,Caffeine
,2859173,apparent volume of distribution,The average apparent volume of distribution was 1.50 liters/kg and total clearance was 0.90 liter/hr/kg.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[l] / [kg],1.50,254864,DB00201,Caffeine
,2859173,total clearance,The average apparent volume of distribution was 1.50 liters/kg and total clearance was 0.90 liter/hr/kg.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[l] / [h·kg],0.90,254865,DB00201,Caffeine
,2859173,apparent Km,These findings indicate that in the rat paraxanthine is eliminated by a saturable process with an apparent Km of about 31 micrograms/ml and an apparent Vmax of about 0.40 micrograms/ml/min.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[μg] / [ml],31,254866,DB00201,Caffeine
,2859173,apparent Vmax,These findings indicate that in the rat paraxanthine is eliminated by a saturable process with an apparent Km of about 31 micrograms/ml and an apparent Vmax of about 0.40 micrograms/ml/min.,"Pharmacokinetics of paraxanthine, one of the primary metabolites of caffeine, in the rat. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859173/),[μg] / [min·ml],0.40,254867,DB00201,Caffeine
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.71,255499,DB00201,Caffeine
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],15.8,255500,DB00201,Caffeine
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],2.42,255501,DB00201,Caffeine
,30758744,Cmax,"The geometric means of Cmax for ASA, SA and paracetamol were similar in the test (3.71, 15.8 and 2.42 µg/ml, respectively) and reference groups (3.89, 15.8, 2.42 µg/ml, respectively).",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[μg] / [ml],3.89,255502,DB00201,Caffeine
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.86,255503,DB00201,Caffeine
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],60.5,255504,DB00201,Caffeine
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.68,255505,DB00201,Caffeine
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],2.96,255506,DB00201,Caffeine
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],59.1,255507,DB00201,Caffeine
,30758744,AUC0-∞,"The geometric mean of AUC0-∞ for ASA, SA and paracetamol from the test combination was 2.86, 60.5 and 7.68 µg h/ml, respectively, and that for the reference was 2.96, 59.1 and 7.77 µg h/ml, respectively.",Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30758744/),[h·μg] / [ml],7.77,255508,DB00201,Caffeine
,16778712,total area under the plasma concentration-time curve,"Caffeine significantly decreased the plasma concentrations at 6 time points (P<0.05) and total area under the plasma concentration-time curve (156.5+/-51.7 vs. 118.9+/-38.2 ng/h/mL, P<0.01) of FLV.",Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778712/),[ng] / [h·ml],156.5,256167,DB00201,Caffeine
,16778712,total area under the plasma concentration-time curve,"Caffeine significantly decreased the plasma concentrations at 6 time points (P<0.05) and total area under the plasma concentration-time curve (156.5+/-51.7 vs. 118.9+/-38.2 ng/h/mL, P<0.01) of FLV.",Effects of caffeine on the kinetics of fluvoxamine and its major metabolite in plasma after a single oral dose of the drug. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16778712/),[ng] / [h·ml],118.9,256168,DB00201,Caffeine
,10877010,elimination half-life,"However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h).",The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),h,9.2,256242,DB00201,Caffeine
,10877010,elimination half-life,"However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h).",The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),h,13.1,256243,DB00201,Caffeine
,10877010,elimination half-life,"However, the elimination half-life of caffeine was significantly longer in children with malaria (9.2 +/- 3.5 h) (P < 0.01) and kwashiorkor (13.1 +/- 7.9 h) (P < 0.05) than in the healthy controls (3.7 +/- 1.8 h).",The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),h,3.7,256244,DB00201,Caffeine
,10877010,total plasma oral clearance,The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[ml] / [kg·min],4.4,256245,DB00201,Caffeine
,10877010,total plasma oral clearance,The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[ml] / [kg·min],2.0,256246,DB00201,Caffeine
,10877010,total plasma oral clearance,The total plasma oral clearance of caffeine of 4.4 +/- 1.9 ml/min/kg in healthy children was significantly higher (P < 0.01) than in those with kwashiorkor (2.0 +/- 0.9 ml/min/kg) and malaria (1.6 +/- 1.0 ml/min/ kg) (P < 0.05).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[ml] / [·kg·min],1.6,256247,DB00201,Caffeine
,10877010,Cmax,Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[μg] / [ml],1.3,256248,DB00201,Caffeine
,10877010,Cmax,Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[μg] / [ml],0.8,256249,DB00201,Caffeine
,10877010,Cmax,Paraxanthine was the principal metabolite in all the three groups with Cmax significantly higher in healthy children (1.3 +/- 0.3 microg/ml) than in children with malaria (0.8 +/- 0.4 microg/ml) (P < 0.05) and kwashiorkor (0.3 +/- 0.1 microg/ml) (P < 0.0001).,The pharmacokinetics of caffeine in Nigerian children suffering from malaria and kwashiorkor. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10877010/),[μg] / [ml],0.3,256250,DB00201,Caffeine
,1799946,biologic half lives,"The biologic half lives of CAF were 15.5, 18.6, and 16.4 h after administering i.v., i.m. and p.o., respectively.","Pharmacokinetics of caffeine and its metabolites in horses after intravenous, intramuscular or oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1799946/),h,15.5,258670,DB00201,Caffeine
,1799946,biologic half lives,"The biologic half lives of CAF were 15.5, 18.6, and 16.4 h after administering i.v., i.m. and p.o., respectively.","Pharmacokinetics of caffeine and its metabolites in horses after intravenous, intramuscular or oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1799946/),h,18.6,258671,DB00201,Caffeine
,1799946,biologic half lives,"The biologic half lives of CAF were 15.5, 18.6, and 16.4 h after administering i.v., i.m. and p.o., respectively.","Pharmacokinetics of caffeine and its metabolites in horses after intravenous, intramuscular or oral administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1799946/),h,16.4,258672,DB00201,Caffeine
,22459459,area under the plasma concentration-time curve (AUC),The deferiprone plasma concentration showed a rapid absorption and average area under the plasma concentration-time curve (AUC) of deferiprone was 17.0 ± 1.23 h.μg/ml.,Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22459459/),[h·μg] / [ml],17.0,259359,DB00201,Caffeine
,22459459,absorption,Average absorption and elimination half-life values of deferiprone of 24 volunteers were 0.62 ± 0.12 and 2.65 ± 0.43 hours.,Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22459459/),h,0.62,259360,DB00201,Caffeine
,22459459,elimination half-life,Average absorption and elimination half-life values of deferiprone of 24 volunteers were 0.62 ± 0.12 and 2.65 ± 0.43 hours.,Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22459459/),h,2.65,259361,DB00201,Caffeine
,21870106,T(max),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.03,259984,DB00201,Caffeine
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,3.66,259985,DB00201,Caffeine
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.66,259986,DB00201,Caffeine
,21870106,T(1/2),"Compared with the placebo period, the T(max) and T(1/2) of midazolam during BBR administration were prolonged from 3.03 ± 0.27 to 3.66 ± 0.37 h and 0.66 ± 0.08 to 0.99 ± 0.09 h, respectively; the oral clearance of midazolam was decreased 27% (P < 0.05); and the phenotypic indices of 1 h midazolam/1'-hydroxymidazolam increased 59% (P < 0.01).",Repeated administration of berberine inhibits cytochromes P450 in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21870106/),h,0.99,259987,DB00201,Caffeine
,9517369,elimination half-life,"The elimination half-life based upon the serum concentrations 12-48 h after discontinuation of fluvoxamine was 32.1 +/- 11.0 h whereas the half-life based upon the concentrations 3-7 days after discontinuation was significantly shorter, 15.8 +/- 4.2h (means +/- s.d.; P < 0.001).",Non-linear fluvoxamine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517369/),h,32.1,260081,DB00201,Caffeine
,9517369,half-life,"The elimination half-life based upon the serum concentrations 12-48 h after discontinuation of fluvoxamine was 32.1 +/- 11.0 h whereas the half-life based upon the concentrations 3-7 days after discontinuation was significantly shorter, 15.8 +/- 4.2h (means +/- s.d.; P < 0.001).",Non-linear fluvoxamine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9517369/),h,15.8,260082,DB00201,Caffeine
,4027137,apparent volume of distribution,"The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS).",Caffeine disposition in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027137/),l,69.9,260623,DB00201,Caffeine
,4027137,apparent volume of distribution,"The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS).",Caffeine disposition in obesity. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027137/),l,43.6,260624,DB00201,Caffeine
,4027137,oral clearance,"The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS).",Caffeine disposition in obesity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027137/),[ml] / [min],135,260625,DB00201,Caffeine
,4027137,oral clearance,"The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS).",Caffeine disposition in obesity. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027137/),[ml] / [min],112,260626,DB00201,Caffeine
,4027137,elimination half-life,"The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS).",Caffeine disposition in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027137/),h,7.05,260627,DB00201,Caffeine
,4027137,elimination half-life,"The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS).",Caffeine disposition in obesity. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4027137/),h,5.40,260628,DB00201,Caffeine
,11699614,CLoral,"Moreover, there were no significant differences in any of the olanzapine pharmacokinetic parameters between the CYP2D6 PMs and EMs (CLoral=0.246 l h(-1) kg(-1) and 0.203 l h(-1) kg(-1), respectively, P=0.30).",Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699614/),[l] / [h·kg],0.246,261045,DB00201,Caffeine
,11699614,CLoral,"Moreover, there were no significant differences in any of the olanzapine pharmacokinetic parameters between the CYP2D6 PMs and EMs (CLoral=0.246 l h(-1) kg(-1) and 0.203 l h(-1) kg(-1), respectively, P=0.30).",Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699614/),[l] / [h·kg],0.203,261046,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5370,262206,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],5246,262207,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.43,262208,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],2.87,262209,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.23,262210,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],35.11,262211,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],677.9,262212,DB00201,Caffeine
,25862215,C max,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[ng] / [ml],466.9,262213,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,207",262214,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],"56,688",262215,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],34.85,262216,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],37.27,262217,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],92.07,262218,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],93.04,262219,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1428,262220,DB00201,Caffeine
,25862215,AUC0-∞,"Geometric least squares (LS) means (without versus with LDX) for C max (ng/mL) were 5370 versus 5246 for caffeine, 2.43 versus 2.87 for dextromethorphan, 35.23 versus 35.11 for midazolam, and 677.9 versus 466.9 for omeprazole; and for AUC0-∞ (ng · h/mL) were 56,207 versus 56,688 for caffeine, 34.85 versus 37.27 for dextromethorphan, 92.07 versus 93.04 for midazolam, and 1428 versus 1499 for omeprazole.","Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25862215/),[h·ng] / [ml],1499,262221,DB00201,Caffeine
,7836625,half-life,Salivary caffeine peaked at 4.7 umol/mL at 11:30 a.m. and declined with a half-life of 7.3 hours.,Effect of caffeine on circadian excretion of urinary calcium and magnesium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7836625/),h,7.3,263245,DB00201,Caffeine
,6832208,maximum plasma concentration (Cmax),"In addition, the variation in the maximum plasma concentration (Cmax) was low, 10.0 +/- 1.0 micrograms/ml.",The absolute bioavailability of caffeine in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832208/),[μg] / [ml],10.0,265197,DB00201,Caffeine
,6832208,F(%),"The rapid absorption resulted in essentially complete bioavailability of the oral caffeine, F(%) = 108.3 +/- 3.6%.",The absolute bioavailability of caffeine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832208/),%,108.3,265198,DB00201,Caffeine
,6832208,plasma half-lives,"The caffeine plasma half-lives varied from 2.7 to 9.9 h, indicating substantial inter-subject variability in its elimination.",The absolute bioavailability of caffeine in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6832208/),h,2.7 to 9.9,265199,DB00201,Caffeine
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],95.6,267028,DB00201,Caffeine
,11736864,AUClast,"The geometric mean AUClast values (with 95% CI) for MDZ were 95.6 (79.0, 115.7) and 160.4 (133.6, 192.6) microg l(-1) h when given alone and as part of the six drug cocktail, respectively.",An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736864/),[h·μg] / [l],160.4,267029,DB00201,Caffeine
>,30951501,IC50,"Results The H. sabdariffa aqueous extract weakly inhibited the selected CYP isozymes in vitro, with IC50 of >100 μgmL-1 in the order of CYP1A2 > CYP2C8 > CYP2B6 >> CYP2D6 > CYP2C19 > CYP3A4 > CYP2A6 > CYP2C9.",In vitro modulation of cytochrome P450 isozymes and pharmacokinetics of caffeine by extracts of Hibiscus sabdariffa Linn calyx. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30951501/),1/[μgml],100,267295,DB00201,Caffeine
,603798,plasma elimination half life (T1/2),"Mean (+/-SE) plasma elimination half life (T1/2) was 47.5 (+/-5.35) h in 1-day-old puppies, as opposed to 6.66(+/-0.85) h in adult dogs.",Caffeine pharmacokinetics in young and adult dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/603798/),h,47.5,267305,DB00201,Caffeine
,603798,plasma elimination half life (T1/2),"Mean (+/-SE) plasma elimination half life (T1/2) was 47.5 (+/-5.35) h in 1-day-old puppies, as opposed to 6.66(+/-0.85) h in adult dogs.",Caffeine pharmacokinetics in young and adult dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/603798/),h,6.66,267306,DB00201,Caffeine
,603798,volume of distribution,The volume of distribution was greatest (0.94+/- 0.03 liters/kg) and the total body clearance was smaller (2.81 +/- 0.73 liters/kg/min X 10(-4)) in the 1-day-old animals.,Caffeine pharmacokinetics in young and adult dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/603798/),[l] / [kg],0.94,267307,DB00201,Caffeine
,603798,total body clearance,The volume of distribution was greatest (0.94+/- 0.03 liters/kg) and the total body clearance was smaller (2.81 +/- 0.73 liters/kg/min X 10(-4)) in the 1-day-old animals.,Caffeine pharmacokinetics in young and adult dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/603798/),[kg·l·min] / [(10)^4],2.81,267308,DB00201,Caffeine
lower,3763369,absolute bioavailability,"Considering the urinary excretion data, it is concluded that the tablets release their contents completely; the absolute bioavailability, however, calculated from plasma concentrations, is lower than 100%, indicating a first-pass effect.",Bioavailability of paracetamol after oral administration to healthy volunteers. Influence of caffeine on rate and extent of absorption. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3763369/),%,100,267692,DB00201,Caffeine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.6,267752,DB00201,Caffeine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.7,267753,DB00201,Caffeine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,1.9,267754,DB00201,Caffeine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,2.0,267755,DB00201,Caffeine
,28903089,Retention times,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,2.1,267756,DB00201,Caffeine
,28903089,run time,"Retention times for caffeine, M5, M4, PTX and M1 were 1.6, 1.7, 1.9, 2.0 and 2.1min, respectively, with a run time of 5min.","Simultaneous determination of pentoxifylline, metabolites M1 (lisofylline), M4 and M5, and caffeine in plasma and dried blood spots for pharmacokinetic studies in preterm infants and neonates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28903089/),min,5,267757,DB00201,Caffeine
,9125091,maximal concentration (Cmax,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),[mg] / [l],6.13,268307,DB00201,Caffeine
,9125091,Tmax,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),min,55,268308,DB00201,Caffeine
,9125091,half-time of elimination (T1/2,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),min,180,268309,DB00201,Caffeine
,9125091,total clearance (Cl),"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),[ml] / [kg·min],3.41,268310,DB00201,Caffeine
,9125091,volume of distribution (Vd,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),[i] / [kg],0.88,268311,DB00201,Caffeine
,9125091,Cmax,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),[mg] / [l],6.23,268312,DB00201,Caffeine
,9125091,Tmax,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),min,94,268313,DB00201,Caffeine
,9125091,T1/2,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),min,283,268314,DB00201,Caffeine
,9125091,Cl,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),[ml] / [kg·min],1.90,268315,DB00201,Caffeine
,9125091,Vd,"Pharmacokinetic parameters were similar to established literature data on caffeine [Volunteer 1: maximal concentration (Cmax: 6.13 mg.L-1 at Tmax: 55 min, half-time of elimination (T1/2: 180 min, total clearance (Cl): 3.41 ml.min-1.kg-1; volume of distribution (Vd: 0.88 I.kg-1; Volunteer 2: Cmax: 6.23 mg.L-1, Tmax: 94 min, T1/2: 283 min, Cl: 1.90 ml.min-1.kg-1, Vd: 0.77 L.kg-1).",Caffeine pharmacokinetics during hyperbaric hyperoxia in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9125091/),[l] / [kg],0.77,268316,DB00201,Caffeine
,19879084,run time,"After sample preparation by liquid-liquid extraction, the analytes and internal standard (diphenhydramine) were analyzed by reversed-phase HPLC on a Venusil Mp-C(18) column (50mmx4.6mm, 5microm) using formic acid:10mM ammonium acetate:methanol (1:40:60, v/v/v) as mobile phase in a run time of 2.6min.","Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879084/),min,2.6,268828,DB00201,Caffeine
,17952423,C(max),"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],179,270783,DB00201,Caffeine
,17952423,C(max),"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],98,270784,DB00201,Caffeine
,17952423,AUC,"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"17,450",270785,DB00201,Caffeine
,17952423,AUC,"In the case of halofantrine, C(max) decreased from 179 +/- 119 to 98 +/- 32 ng/ml, and the AUC was reduced from 17,450 +/- 4,611 to 11,821 +/- 4,069 ng x h/ml.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"11,821",270786,DB00201,Caffeine
,17952423,C(max),"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],124,270787,DB00201,Caffeine
,17952423,C(max),"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[ng] / [ml],62,270788,DB00201,Caffeine
,17952423,AUC,"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"13,341",270789,DB00201,Caffeine
,17952423,AUC,"C(max) of desbutylhalofantrine decreased from 124 +/- 41 to 62 +/- 23 ng/ml and the AUC from 13,341 +/- 4,749 to 7,359 +/- 3,018 ng x h/ml when kolanut was co-administered.",Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17952423/),[h·ng] / [ml],"7,359",270790,DB00201,Caffeine
,10586393,total clearance,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),[l] / [h·kg],0.143,271384,DB00201,Caffeine
,10586393,renal clearance,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),[l] / [h·kg],0.014,271385,DB00201,Caffeine
,10586393,steady-state volume of distribution,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),[l] / [kg],13.2,271386,DB00201,Caffeine
,10586393,terminal exponential half-life,"Mean (%CV) azimilide parameters were total clearance = 0.143 L/h/kg (38%), renal clearance = 0.014 L/h/kg (35%), steady-state volume of distribution = 13.2 L/kg (23%), and terminal exponential half-life = 78.8 h (44%).",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),h,78.8,271387,DB00201,Caffeine
,10586393,times of maximum blood concentration,"In addition, the rate (Cmax) and extent of absorption (AUC) following oral administration of the capsule dosage form were bioequivalent to the oral solution with means for times of maximum blood concentration of 7.08 and 7.18 hours for the oral solution and capsule, respectively.",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),h,7.08,271388,DB00201,Caffeine
,10586393,times of maximum blood concentration,"In addition, the rate (Cmax) and extent of absorption (AUC) following oral administration of the capsule dosage form were bioequivalent to the oral solution with means for times of maximum blood concentration of 7.08 and 7.18 hours for the oral solution and capsule, respectively.",Azimilide pharmacokinetics following intravenous and oral administration of a solution and capsule formulation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10586393/),h,7.18,271389,DB00201,Caffeine
,11262908,CL,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),[l] / [h],2.39,272375,DB00201,Caffeine
,11262908,t1/2,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),h,90.18,272376,DB00201,Caffeine
,11262908,CL,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),[l] / [h],8.10,272377,DB00201,Caffeine
,11262908,t1/2,"Using a four-point procedure we acquired the following values: patients--CL 2.39 +/- 2.36 l/h, t1/2 = 90.18 +/- 168.44 h; healthy volunteers--CL = 8.10 +/- 4.58 l/h, t1/2 = 8.60 +/- 4.12 h (p < 0.05).",[Use of the paraxanthine/caffeine ratio in the saliva of patients with liver cirrhosis]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11262908/),h,8.60,272378,DB00201,Caffeine
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,118,273139,DB00201,Caffeine
,7200787,relative bioavailabilities,Significant differences of the relative bioavailabilities are shown by Silentan-diazepam (= 118%) and Silentan-DHE-tartrate (= 310%) in comparison with the standard encapsulated preparations.,"[Comparative pharmacokinetics and relative bioavailability of the active principles diazepam, acetylsalicylic acid, caffeine, and dihydroergotamine tartrate in a combination product]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7200787/),%,310,273140,DB00201,Caffeine
,3899452,Bioavailability,Bioavailability is of the order of 5% or less by oral or rectal administration.,Clinical pharmacokinetics of ergotamine in migraine and cluster headache. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899452/),%,5,273707,DB00201,Caffeine
,3899452,elimination of half-life,The elimination of half-life is 2 to 2.5 hours and clearance is about 0.68 L/h/kg.,Clinical pharmacokinetics of ergotamine in migraine and cluster headache. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899452/),h,2 to 2.5,273708,DB00201,Caffeine
,3899452,clearance,The elimination of half-life is 2 to 2.5 hours and clearance is about 0.68 L/h/kg.,Clinical pharmacokinetics of ergotamine in migraine and cluster headache. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899452/),[l] / [h·kg],0.68,273709,DB00201,Caffeine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],52,273907,DB00201,Caffeine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],64,273908,DB00201,Caffeine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],79,273909,DB00201,Caffeine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],90,273910,DB00201,Caffeine
,22258279,abundance,"Estimated hepatic CYP1A2 abundance values were 52, 64, 79, 90, and 94 pmol/mg microsomal protein for subjects smoking 0, 1-5, 6-10, 11-20, and >20 cigarettes/day respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[pM] / [mg],94,273911,DB00201,Caffeine
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],141,273912,DB00201,Caffeine
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],100,273913,DB00201,Caffeine
,22258279,oral clearance,"The validated model was able to recover the smoking-induced increase in oral clearance of PF-2400013; predicted and observed mean (CV%) values in male nonsmokers and smokers were 90 L/h (40%) and 141 L/h (34%) respectively, and 100 L/h (58%) and 131 L/h (33%) respectively.",Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22258279/),[l] / [h],131,273914,DB00201,Caffeine
